image_name
stringlengths 68
68
| type
stringclasses 2
values | gt_table
stringlengths 116
12.6k
|
|---|---|---|
7721254c541eb81d5c2e852a15735d41a64ef0a5a8041451fc85950c0945657f.png
|
complex
|
<table><tr><td></td><td colspan="4">All subjects</td><td colspan="2">Placebo</td><td colspan="2">Donation</td></tr><tr><td></td><td colspan="2">Group</td><td colspan="2">Time</td><td colspan="2">Time</td><td colspan="2">Time</td></tr><tr><td></td><td><i>F</i> value</td><td><i>p</i> value</td><td><i>F</i> value</td><td><i>p</i> value</td><td><i>F</i> value</td><td><i>p</i> value</td><td><i>F</i> value</td><td><i>p</i> value</td></tr><tr><td>Pmax</td><td>0.43</td><td>0.5219</td><td>9.54</td><td><0.0001</td><td>4.13</td><td><0.0001</td><td>6.48</td><td><0.0001</td></tr><tr><td>VO<sub>2</sub>peak</td><td>0.32</td><td>0.5775</td><td>4.31</td><td><0.0001</td><td>0.81</td><td>0.6573</td><td>5.46</td><td><0.0001</td></tr><tr><td>Hb mass</td><td>0.80</td><td>0.3959</td><td>3.82</td><td><0.0001</td><td>0.51</td><td>0.9255</td><td>6.03</td><td><0.0001</td></tr><tr><td>EPO</td><td>0.10</td><td>0.7631</td><td>2.88</td><td>0.0003</td><td>0.76</td><td>0.7181</td><td>2.62</td><td>0.0019</td></tr><tr><td>Lactate 190W</td><td>0.18</td><td>0.6722</td><td>9.10</td><td><0.0001</td><td>8.34</td><td>0.0008</td><td>3.22</td><td><0.0001</td></tr><tr><td>Lactate post</td><td>0.01</td><td>0.9069</td><td>4.12</td><td><0.0001</td><td>1.62</td><td>0.0993</td><td>3.63</td><td><0.0001</td></tr><tr><td>HR max</td><td>0.21</td><td>0.6510</td><td>4.44</td><td><0.0001</td><td>1.75</td><td>0.0699</td><td>3.70</td><td><0.0001</td></tr><tr><td>Oxygen pulse</td><td>0.41</td><td>0.5325</td><td>1.61</td><td>0.0744</td><td>0.61</td><td>0.8459</td><td>3.57</td><td><0.0001</td></tr><tr><td>VE max</td><td>0.09</td><td>0.7675</td><td>3.78</td><td><0.0001</td><td>1.23</td><td>0.2807</td><td>3.15</td><td>0.0002</td></tr><tr><td>Total time</td><td>0.43</td><td>0.5241</td><td>9.61</td><td><0.0001</td><td>4.12</td><td><0.0001</td><td>6.57</td><td><0.0001</td></tr><tr><td>Hematocrit</td><td>12.90</td><td>0.0021</td><td>6.51</td><td><0.0001</td><td>1.56</td><td>0.1168</td><td>12.38</td><td><0.0001</td></tr><tr><td>Hemoglobin</td><td>6.77</td><td>0.0180</td><td>8.48</td><td><0.0001</td><td>1.25</td><td>0.2635</td><td>12.94</td><td><0.0001</td></tr><tr><td>Iron</td><td>0.55</td><td>0.4670</td><td>3.30</td><td>0.0003</td><td>1.69</td><td>0.0811</td><td>2.91</td><td>0.0006</td></tr><tr><td>Ferritin</td><td>8.49</td><td>0.0093</td><td>3.48</td><td><0.0001</td><td>1.12</td><td>0.3589</td><td>6.50</td><td><0.0001</td></tr><tr><td>Transferrin</td><td>1.98</td><td>0.1769</td><td>2.97</td><td>0.0003</td><td>0.96</td><td>0.5055</td><td>3.11</td><td>0.0003</td></tr><tr><td>Transf sat</td><td>1.25</td><td>0.2785</td><td>2.98</td><td>0.0003</td><td>1.62</td><td>0.0976</td><td>3.10</td><td>0.0003</td></tr><tr><td>MCH</td><td>0.03</td><td>0.8603</td><td>6.36</td><td><0.0001</td><td>1.82</td><td>0.0551</td><td>6.61</td><td><0.0001</td></tr><tr><td>MCHC</td><td>0.01</td><td>0.9105</td><td>8.10</td><td><0.0001</td><td>2.64</td><td>0.0045</td><td>6.81</td><td><0.0001</td></tr><tr><td>MCV</td><td>0.03</td><td>0.8689</td><td>4.14</td><td><0.0001</td><td>1.35</td><td>0.2047</td><td>4.26</td><td><0.0001</td></tr><tr><td>MPV</td><td>2.77</td><td>0.1136</td><td>2.47</td><td>0.0028</td><td>1.11</td><td>0.3699</td><td>2.71</td><td>0.0013</td></tr><tr><td>RBC</td><td>6.93</td><td>0.0169</td><td>6.31</td><td><0.0001</td><td>1.18</td><td>0.3122</td><td>11.67</td><td><0.0001</td></tr><tr><td>RDW</td><td>1.05</td><td>0.3181</td><td>10.74</td><td><0.0001</td><td>2.02</td><td>0.0303</td><td>10.70</td><td><0.0001</td></tr><tr><td>WBC</td><td>0.89</td><td>0.3589</td><td>0.86</td><td>0.5990</td><td>0.46</td><td>0.9445</td><td>1.61</td><td>0.0821</td></tr><tr><td>Platelets</td><td>0.09</td><td>0.7639</td><td>3.37</td><td><0.0001</td><td>1.43</td><td>0.1670</td><td>3.14</td><td>0.0002</td></tr></table>
|
5a5c575650d048316cf56bdf6c883c4167d218a95407a07073e59a2692969e91.png
|
complex
|
<table><tr><td></td><td></td><td colspan="2">Number of resting follicles (%)</td><td colspan="2">Number of primary follicles (%)</td><td colspan="2">Number of secondary follicles (%)</td></tr><tr><td>Group</td><td>Total number of follicles</td><td>Total</td><td>Intact</td><td>Total</td><td>Intact</td><td>Total</td><td>Intact</td></tr><tr><td>Unfrozen</td><td>249</td><td>203 (81.5 %)</td><td>203 (100 %)</td><td>39 (15.7 %)</td><td>38 (97.4 %)</td><td>7 (2.8 %)</td><td>7 (100 %)</td></tr><tr><td>Vitrification</td><td>482</td><td>467*** (96.9 %)</td><td>392*** (84 %)</td><td>11** (2.3 %)</td><td>9 (81.8 %)</td><td>4* (0.8 %)</td><td>2 (50 %)</td></tr><tr><td>Slow-freezing</td><td>374</td><td>365*** (97.6 %)</td><td>293*** (80.3 %)</td><td>9** (2.4 %)</td><td>9 (100 %)</td><td>0* (0 %)</td><td>_</td></tr></table>
|
7c99ef38c018db2f6815f0a766d6e550bfb2369f560f976f9f05475ad366c831.png
|
complex
|
<table><tr><td></td><td>Average annual costs</td><td>References</td></tr><tr><td colspan="3">Health care costs (per episode/year)</td></tr><tr><td> Myocardial infarction</td><td>$18627</td><td>Bergenheim et al., 2012 [12]</td></tr><tr><td> Heart failure</td><td>$14118</td><td>Bergenheim et al., 2012 [12]</td></tr><tr><td> Stroke</td><td>$7939</td><td>Bergenheim et al., 2012 [12]</td></tr><tr><td> Hypoglycemia events requiring medical assistance</td><td>$199</td><td>Bergenheim et al., 2012 [12]</td></tr><tr><td> Severe hypoglycemia event</td><td>$146</td><td>Bergenheim et al., 2012 [12]</td></tr><tr><td> Weight gain</td><td>$289</td><td>Bergenheim et al., 2012 [12]</td></tr><tr><td colspan="3">Drug cost (per patient/year)</td></tr><tr><td> Metformin, generic drug</td><td>$24</td><td>NADAC (January 2015) [22]</td></tr><tr><td> Dipeptidyl peptidase-4 inhibitor, brand</td><td>$3500 ($3401; $3599)</td><td>NADAC (January 2015) [22]</td></tr><tr><td> Sulfonylurea (glipizide), generic</td><td>$16</td><td>NADAC (January 2015) [22]</td></tr><tr><td> Insulin glargine, brand</td><td>$3646</td><td>NADAC (January 2015) [22]</td></tr></table>
|
65774c26679bfc5425069c62db335b90d28beb3fd43c6a64b9232a265b9e2f12.png
|
complex
|
<table><tr><td rowspan="2">Nutrients</td><td rowspan="2">Incomes (€) per Person per Month</td><td colspan="5">Primary</td><td colspan="5">Secondary</td><td colspan="5">Undergraduate</td><td colspan="5">Postgraduate</td></tr><tr><td>Mean</td><td>SE <sup>5</sup></td><td>Difference with >2700 € <sup>2</sup></td><td>Relative Difference (%) <sup>3</sup></td><td><i>p</i></td><td>Mean</td><td>SE <sup>5</sup></td><td>Difference with >2700 € <sup>2</sup></td><td>Relative Difference (%) <sup>3</sup></td><td><i>p</i></td><td>Mean</td><td>SE <sup>5</sup></td><td>Difference with >2700 € <sup>2</sup></td><td>Relative Difference (%) <sup>3</sup></td><td><i>p</i></td><td>Mean</td><td>SE <sup>5</sup></td><td>Difference with >2700 € <sup>2</sup></td><td>Relative Difference (%) <sup>3</sup></td><td><i>p</i></td></tr><tr><td rowspan="4">Magnesium</td><td><1200</td><td>350.7</td><td>13.1</td><td>51.6</td><td>12.8%</td><td>0.0003</td><td>357.7</td><td>3.3</td><td>29.8</td><td>7.7%</td><td><0.0001</td><td>382.6</td><td>4.6</td><td>10.8</td><td>2.8%</td><td>0.0038</td><td>388.0</td><td>5.8</td><td>16.7</td><td>4.1%</td><td><0.0001</td></tr><tr><td>1200–1800</td><td>366.7</td><td>11.5</td><td>35.6</td><td>8.9%</td><td></td><td>368.1</td><td>2.8</td><td>19.4</td><td>5.0%</td><td></td><td>379.5</td><td>3.9</td><td>14.0</td><td>3.6%</td><td></td><td>391.1</td><td>5.1</td><td>13.6</td><td>3.4%</td><td></td></tr><tr><td>1800–2700</td><td>363.3</td><td>12.7</td><td>38.9</td><td>9.7%</td><td></td><td>383.8</td><td>3.0</td><td>3.7</td><td>0.9%</td><td></td><td>389.4</td><td>4.1</td><td>4.1</td><td>1.0%</td><td></td><td>390.7</td><td>4.8</td><td>14.0</td><td>3.5%</td><td></td></tr><tr><td>>2700</td><td>402.3</td><td>14.4</td><td>0.0</td><td>0.0%</td><td></td><td>387.5</td><td>3.6</td><td>0.0</td><td>0.0%</td><td></td><td>393.5</td><td>4.3</td><td>0.0</td><td>0.0%</td><td></td><td>404.7</td><td>4.6</td><td>0.0</td><td>0.0%</td><td></td></tr><tr><td rowspan="4">Potassium</td><td><1200</td><td>3147.4</td><td>87.3</td><td>217.2</td><td>6.5%</td><td>0.009</td><td>3239.8</td><td>22.0</td><td>175.5</td><td>5.1%</td><td><0.0001</td><td>3370.9</td><td>31.1</td><td>61.9</td><td>1.8%</td><td>0.001</td><td>3358.2</td><td>19.7</td><td>113.0</td><td>3.3%</td><td>0.0005</td></tr><tr><td>1200–1800</td><td>3173.9</td><td>76.4</td><td>190.7</td><td>5.7%</td><td></td><td>3330.5</td><td>18.3</td><td>84.9</td><td>2.5%</td><td></td><td>3346.4</td><td>26.4</td><td>86.4</td><td>2.5%</td><td></td><td>3396.0</td><td>18.4</td><td>75.2</td><td>2.2%</td><td></td></tr><tr><td>1800–2700</td><td>3198.6</td><td>84.6</td><td>166.0</td><td>4.9%</td><td></td><td>3381.8</td><td>20.1</td><td>33.5</td><td>1.0%</td><td></td><td>3442.0</td><td>27.5</td><td>−9.2</td><td>−0.3%</td><td></td><td>3421.9</td><td>18.2</td><td>49.2</td><td>1.4%</td><td></td></tr><tr><td>>2700</td><td>3364.6</td><td>96.1</td><td>0.0</td><td>0.0%</td><td></td><td>3415.3</td><td>24.1</td><td>0.0</td><td>0.0%</td><td></td><td>3432.8</td><td>28.9</td><td>0.0</td><td>0.0%</td><td></td><td>3471.2</td><td>17.6</td><td>0.0</td><td>0.0%</td><td></td></tr><tr><td rowspan="4">Folate</td><td><1200</td><td>339.6</td><td>14.3</td><td>11.9</td><td>3.4%</td><td>0.04</td><td>341.1</td><td>3.2</td><td>29.4</td><td>7.9%</td><td><0.0001</td><td>362.7</td><td>4.9</td><td>12.7</td><td>3.4%</td><td>0.009</td><td>369.0</td><td>6.4</td><td>9.0</td><td>2.4%</td><td>0.006</td></tr><tr><td>1200–1800</td><td>333.5</td><td>12.5</td><td>18.0</td><td>5.1%</td><td></td><td>355.3</td><td>2.9</td><td>15.3</td><td>4.1%</td><td></td><td>363.5</td><td>4.2</td><td>12.0</td><td>3.2%</td><td></td><td>365.4</td><td>5.6</td><td>12.6</td><td>3.3%</td><td></td></tr><tr><td>1800–2700 €</td><td>352.9</td><td>13.8</td><td>−1.3</td><td>−0.4%</td><td></td><td>358.7</td><td>3.2</td><td>11.8</td><td>3.2%</td><td></td><td>372.7</td><td>4.3</td><td>2.7</td><td>0.7%</td><td></td><td>366.8</td><td>5.3</td><td>11.2</td><td>3.0%</td><td></td></tr><tr><td>>2700</td><td>351.5</td><td>15.7</td><td>0.0</td><td>0.0%</td><td></td><td>370.5</td><td>3.9</td><td>0.0</td><td>0.0%</td><td></td><td>375.4</td><td>4.6</td><td>0.0</td><td>0.0%</td><td></td><td>378.1</td><td>5.1</td><td>0.0</td><td>0.0%</td><td></td></tr><tr><td rowspan="4">Beta-carotene</td><td><1200</td><td>3207.5</td><td>335.1</td><td>261.5</td><td>7.5%</td><td>0.2</td><td>3176.0</td><td>84.9</td><td>462.4</td><td>12.7%</td><td>0.002</td><td>3676.4</td><td>128.9</td><td>−2.9</td><td>−0.1%</td><td>0.04</td><td>3621.7</td><td>156.1</td><td>128.7</td><td>3.4%</td><td>0.07</td></tr><tr><td>1200–1800</td><td>3059.7</td><td>293.2</td><td>409.3</td><td>11.8%</td><td></td><td>3407.9</td><td>70.7</td><td>230.5</td><td>6.3%</td><td></td><td>3495.7</td><td>109.6</td><td>177.9</td><td>4.8%</td><td></td><td>3584.6</td><td>136.6</td><td>165.8</td><td>4.4%</td><td></td></tr><tr><td>1800–2700</td><td>3371.1</td><td>324.4</td><td>97.9</td><td>2.8%</td><td></td><td>3563.3</td><td>77.6</td><td>75.1</td><td>2.1%</td><td></td><td>3705.5</td><td>114.0</td><td>−32.0</td><td>−0.9%</td><td></td><td>3648.8</td><td>128.9</td><td>101.6</td><td>2.7%</td><td></td></tr><tr><td>>2700</td><td>3469.0</td><td>368.6</td><td>0.0</td><td>0.0%</td><td></td><td>3638.4</td><td>99.8</td><td>0.0</td><td>0.0%</td><td></td><td>3673.6</td><td>119.9</td><td>0.0</td><td>0.0%</td><td></td><td>3750.4</td><td>123.1</td><td>0.0</td><td>0.0%</td><td></td></tr><tr><td rowspan="4">Proteins</td><td><1200</td><td>95.5</td><td>2.3</td><td>2.1</td><td>2.1%</td><td>0.008</td><td>94.3</td><td>0.6</td><td>0.2</td><td>0.3%</td><td>0.4</td><td>94.5</td><td>0.8</td><td>−0.1</td><td>−0.1%</td><td>0.9</td><td>91.8</td><td>1.0</td><td>1.5</td><td>1.6%</td><td>0.05</td></tr><tr><td>1200–1800</td><td>90.0</td><td>2.0</td><td>7.6</td><td>7.8%</td><td></td><td>95.5</td><td>0.5</td><td>−1.0</td><td>−1.0%</td><td></td><td>94.4</td><td>0.7</td><td>0.0</td><td>0.0%</td><td></td><td>92.2</td><td>0.8</td><td>1.1</td><td>1.2%</td><td></td></tr><tr><td>1800–2700</td><td>92.3</td><td>2.2</td><td>5.3</td><td>5.4%</td><td></td><td>94.9</td><td>0.5</td><td>−0.4</td><td>−0.4%</td><td></td><td>95.1</td><td>0.7</td><td>−0.6</td><td>−0.7%</td><td></td><td>92.3</td><td>0.8</td><td>0.9</td><td>1.0%</td><td></td></tr><tr><td>>2700</td><td>97.6</td><td>2.5</td><td>0.0</td><td>0.0%</td><td></td><td>94.6</td><td>0.6</td><td>0.0</td><td>0.0%</td><td></td><td>94.4</td><td>0.7</td><td>0.0</td><td>0.0%</td><td></td><td>93.3</td><td>0.8</td><td>0.0</td><td>0.0%</td><td></td></tr><tr><td rowspan="4">Fibre</td><td><1200</td><td>21.3</td><td>0.8</td><td>−0.6</td><td>−2.7%</td><td>0.03</td><td>20.9</td><td>0.2</td><td>1.4</td><td>6.3%</td><td>0.0001</td><td>22.8</td><td>0.3</td><td>−0.3</td><td>−1.5%</td><td>0.2</td><td>23.8</td><td>0.4</td><td>−0.6</td><td>−2.5%</td><td>0.5</td></tr><tr><td>1200–1800</td><td>20.7</td><td>0.7</td><td>0.1</td><td>0.3%</td><td></td><td>21.5</td><td>0.2</td><td>0.8</td><td>3.7%</td><td></td><td>22.1</td><td>0.3</td><td>0.4</td><td>1.6%</td><td></td><td>23.2</td><td>0.4</td><td>0.1</td><td>0.3%</td><td></td></tr><tr><td>1800–2700</td><td>21.0</td><td>0.8</td><td>−0.3</td><td>−1.2%</td><td></td><td>22.1</td><td>0.2</td><td>0.2</td><td>0.8%</td><td></td><td>22.6</td><td>0.3</td><td>−0.1</td><td>−0.4%</td><td></td><td>23.2</td><td>0.3</td><td>0.0</td><td>0.0%</td><td></td></tr><tr><td>>2700</td><td>20.7</td><td>0.9</td><td>0.0</td><td>0.0%</td><td></td><td>22.3</td><td>0.3</td><td>0.0</td><td>0.0%</td><td></td><td>22.5</td><td>0.3</td><td>0.0</td><td>0.0%</td><td></td><td>23.2</td><td>0.3</td><td>0.0</td><td>0.0%</td><td></td></tr></table>
|
d389760a0860d6a7d2c8864a37e8cec738d54f9e322c239816db9b28d161b5b1.png
|
simple
|
<table><tr><td>Items</td><td>Mean</td><td>SD</td><td>Median</td><td>Min</td><td>Max</td><td>Skew</td><td>Kurtosis</td></tr><tr><td>1</td><td>0.89</td><td>0.49</td><td>1</td><td>0</td><td>2</td><td>−0.23</td><td>0.79</td></tr><tr><td>2</td><td>0.39</td><td>0.54</td><td>0</td><td>0</td><td>2</td><td>0.97</td><td>−0.14</td></tr><tr><td>3</td><td>0.25</td><td>0.49</td><td>0</td><td>0</td><td>2</td><td>1.76</td><td>2.26</td></tr><tr><td>4</td><td>0.26</td><td>0.50</td><td>0</td><td>0</td><td>2</td><td>1.70</td><td>2.02</td></tr><tr><td>5</td><td>0.71</td><td>0.55</td><td>1</td><td>0</td><td>2</td><td>−0.01</td><td>−0.55</td></tr><tr><td>6</td><td>0.74</td><td>0.53</td><td>1</td><td>0</td><td>2</td><td>−0.16</td><td>−0.38</td></tr><tr><td>7</td><td>0.51</td><td>0.53</td><td>0</td><td>0</td><td>2</td><td>0.33</td><td>−1.16</td></tr><tr><td>8</td><td>0.61</td><td>0.56</td><td>1</td><td>0</td><td>2</td><td>0.23</td><td>−0.82</td></tr><tr><td>9</td><td>0.35</td><td>0.54</td><td>0</td><td>0</td><td>2</td><td>1.17</td><td>0.34</td></tr><tr><td>10</td><td>0.31</td><td>0.51</td><td>0</td><td>0</td><td>2</td><td>1.32</td><td>0.71</td></tr><tr><td>11</td><td>0.16</td><td>0.43</td><td>0</td><td>0</td><td>2</td><td>2.71</td><td>6.86</td></tr><tr><td>12</td><td>0.58</td><td>0.61</td><td>1</td><td>0</td><td>2</td><td>0.54</td><td>−0.63</td></tr><tr><td>13</td><td>0.89</td><td>0.50</td><td>1</td><td>0</td><td>2</td><td>−0.22</td><td>0.76</td></tr><tr><td>14</td><td>0.44</td><td>0.58</td><td>0</td><td>0</td><td>2</td><td>0.91</td><td>−0.17</td></tr><tr><td>15</td><td>0.48</td><td>0.55</td><td>0</td><td>0</td><td>2</td><td>0.59</td><td>−0.75</td></tr><tr><td>16</td><td>0.29</td><td>0.49</td><td>0</td><td>0</td><td>2</td><td>1.35</td><td>0.76</td></tr><tr><td>17</td><td>0.46</td><td>0.59</td><td>0</td><td>0</td><td>2</td><td>0.85</td><td>−0.27</td></tr><tr><td>18</td><td>0.21</td><td>0.42</td><td>0</td><td>0</td><td>2</td><td>1.66</td><td>1.41</td></tr><tr><td>19</td><td>0.09</td><td>0.33</td><td>0</td><td>0</td><td>2</td><td>4.02</td><td>16.63</td></tr><tr><td>20</td><td>0.37</td><td>0.53</td><td>0</td><td>0</td><td>2</td><td>0.99</td><td>−0.14</td></tr><tr><td>21</td><td>1.00</td><td>0.61</td><td>1</td><td>0</td><td>2</td><td>0</td><td>−0.32</td></tr><tr><td>22</td><td>0.34</td><td>0.53</td><td>0</td><td>0</td><td>2</td><td>1.22</td><td>0.47</td></tr><tr><td>23</td><td>0.52</td><td>0.62</td><td>0</td><td>0</td><td>2</td><td>0.79</td><td>−0.39</td></tr><tr><td>24</td><td>0.73</td><td>0.57</td><td>1</td><td>0</td><td>2</td><td>0.08</td><td>−0.51</td></tr><tr><td>25</td><td>0.26</td><td>0.50</td><td>0</td><td>0</td><td>2</td><td>1.71</td><td>2.06</td></tr><tr><td>26</td><td>0.54</td><td>0.61</td><td>0</td><td>0</td><td>2</td><td>0.66</td><td>−0.52</td></tr><tr><td>27</td><td>0.16</td><td>0.40</td><td>0</td><td>0</td><td>2</td><td>2.44</td><td>5.43</td></tr><tr><td>28</td><td>0.35</td><td>0.53</td><td>0</td><td>0</td><td>2</td><td>1.18</td><td>0.38</td></tr></table>
|
1d4fec610555fab29b3eca8ef0cc8fa8b3d4e457d4f2307350dc663dd88f591c.png
|
simple
|
<table><tr><td></td><td><i>N=</i>55</td></tr><tr><td>Motor score</td><td></td></tr><tr><td> Voluntary movement score [0–20]</td><td>6.33 (5.71)</td></tr><tr><td> Stiffness [0–8]</td><td>2.20 (2.14)</td></tr><tr><td> Chorea [0–16]</td><td>5.19 (4.51)</td></tr><tr><td> Precise movement [0–8]</td><td>4.06 (2.46)</td></tr><tr><td>Behavioural score</td><td></td></tr><tr><td> Depression anxiety [0–20]</td><td>9.12 (5.01)</td></tr><tr><td> Temper [0–8]</td><td>2.81 (2.18)</td></tr><tr><td> Psychotic disorder [0–12]</td><td>1.35 (2.16)</td></tr><tr><td> Cognition [0–12]</td><td>3.52 (2.97)</td></tr><tr><td>Functional score</td><td></td></tr><tr><td> Functional score [0–7]</td><td>3.06 (2.53)</td></tr></table>
|
400b50155e44e7033977d7a0e589b7e8665b312215a7fc986dd67f51ab4518ab.png
|
simple
|
<table><tr><td>Characteristic</td><td><i>N</i></td></tr><tr><td>Gender</td><td> </td></tr><tr><td> Male/female </td><td>33/90</td></tr><tr><td>Age </td><td> </td></tr><tr><td> 21 to 30 y</td><td>22</td></tr><tr><td> 31 to 40 y</td><td>36</td></tr><tr><td> 41 to 50 y</td><td>30</td></tr><tr><td> >50 y</td><td>35</td></tr><tr><td>Years in practice</td><td> </td></tr><tr><td> <5 y</td><td>19</td></tr><tr><td> 5 to 10 y</td><td>21</td></tr><tr><td> 11 to 20 y</td><td>34</td></tr><tr><td> >20 y</td><td>49</td></tr><tr><td>Average number of clients with nonsurgicalknee osteoarthritis treated per year</td><td> </td></tr><tr><td> 1 to 20</td><td>43</td></tr><tr><td> 21 to 40</td><td>42</td></tr><tr><td> >40</td><td>38</td></tr></table>
|
1737004d9086890b79abb277bd7cbcf77189be5ac372bdf9db79531acf6c3c33.png
|
simple
|
<table><tr><td>Diagnostic miR(s)</td><td>Disease Setting</td><td>Description</td><td>Reference(s)</td></tr><tr><td>miR-20a, miR-24, miR-25, miR-145, miR-152, miR-199-5p, miR-221, miR-222, miR-223, miR-320</td><td>Lung Cancer</td><td>10 microRNAs were found to have significantly different expression levels in NSCLC serum samples compared with the control serum samples.</td><td>[24]</td></tr><tr><td>miR-10b, miR-155, miR-195, miR34a</td><td>Breast Cancer</td><td>Increased expression of miR-10b, miR-155, and miR-195 and decreased miR-34a was associated with disease.</td><td>[25]</td></tr><tr><td>miR-221</td><td>Ovarian Cancer, Melanoma, Lymphoma</td><td>Increase expression in several different cancers compared to control serum samples.</td><td>[27,28,29]</td></tr><tr><td>miR-141, miR-16, miR-92a, miR-92b, miR-103, miR-107, miR-197, miR-34b, miR-328, miR-485-3p, miR-486-5p, miR-574-3p, miR-636, miR-640, miR-766, and miR-885-5p.</td><td>Prostate</td><td>Levels of these microRNAs were found to be higher in the serum of patients compared to controls.</td><td>[21,26]</td></tr></table>
|
c736baaf01bc27007cf680600e7337135ddd9d9e3727a91d3146b588fb9f9ea4.png
|
complex
|
<table><tr><td>Rank</td><td>GAN</td><td>[3]</td><td colspan="2">Rank</td><td>Gene description</td></tr><tr><td></td><td></td><td></td><td>S2N</td><td>SVM-RFE</td><td></td></tr><tr><td>1</td><td>M27891</td><td>•</td><td>1</td><td>2</td><td>cystatin C (<i>CST3</i>)</td></tr><tr><td>2</td><td>M28130</td><td>•</td><td>25</td><td>3</td><td>interleukin 8 (<i>IL8</i>)</td></tr><tr><td>3</td><td>M84526</td><td>•</td><td>5</td><td>1</td><td>D component of complement (adipsin) (<i>DF</i>)</td></tr><tr><td>4</td><td>M19507</td><td></td><td>131</td><td>7</td><td>myeloperoxidase (<i>MPO</i>)</td></tr><tr><td>5</td><td>Y00787</td><td>•</td><td>23</td><td>4</td><td>interleukin-8 precursor</td></tr><tr><td>6</td><td>M11722</td><td></td><td>71</td><td>41</td><td>deoxynucleotidyltransferase, terminal (<i>DNTT</i>)</td></tr><tr><td>7</td><td>X95735</td><td>•</td><td>2</td><td>11</td><td>zyxin (<i>ZYX</i>)</td></tr><tr><td>8</td><td>D88422</td><td></td><td>3</td><td>8</td><td>cystatin A (<i>CSTA</i>)</td></tr><tr><td>9</td><td>M27783</td><td></td><td>15</td><td>5</td><td>elastase 2, neutrophil (<i>ELA2</i>)</td></tr><tr><td>10</td><td>M96326</td><td>•</td><td>75</td><td>10</td><td>azurocidin 1 (<i>AZU1</i>)</td></tr></table>
|
18e5c9a792cac2084bcc8c9fedf4cdb5e30e20347834078b6756c1b724b69527.png
|
simple
|
<table><tr><td></td><td>SLD (<i>n</i> = 20)</td><td>HAD (<i>n</i> = 20)</td></tr><tr><td>Body weight (g)</td><td></td><td></td></tr><tr><td>initial</td><td>198 ± 4</td><td>200 ± 5</td></tr><tr><td>1 week</td><td>257 ± 6</td><td>247 ± 6</td></tr><tr><td>6 weeks</td><td>450 ± 10</td><td>438 ± 10</td></tr><tr><td>70 days</td><td>525 ± 12</td><td>498 ± 12</td></tr><tr><td>Food intake (g/kg b.w./day)</td><td></td><td></td></tr><tr><td>1st week</td><td>116 ± 4</td><td>122 ± 4</td></tr><tr><td>6th week</td><td>74 ± 1</td><td>73 ± 1</td></tr><tr><td>last week</td><td>64 ± 2</td><td>66 ± 1</td></tr></table>
|
1c1ca57ae724ee07d46563d63397583c79fb2407c9461e686dc914300ef01383.png
|
complex
|
<table><tr><td></td><td rowspan="2">Expression</td><td colspan="3">MAWBP</td></tr><tr><td>Protein</td><td>Positive (%)</td><td>Negative (%)</td><td><i>P-</i>value</td></tr><tr><td>TGF-beta</td><td>Positive</td><td>43/216 (19.9)</td><td>59/216 (27.3)</td><td><0.001</td></tr><tr><td></td><td>Negative</td><td>13/216 (6.0)</td><td>101/216 (46.8)</td><td></td></tr><tr><td>E-cadherin</td><td>Positive</td><td>31/208 (14.9</td><td>58/208 (27.9)</td><td>0.026</td></tr><tr><td></td><td>Negative</td><td>25/208 (15.7)</td><td>94/208 (45.2)</td><td></td></tr><tr><td>PGC</td><td>Positive</td><td>28/223 (12.0)</td><td>57/223 (25.6)</td><td>0.112</td></tr><tr><td></td><td>Negative</td><td>32/223 (14.3)</td><td>106/223 (47.5)</td><td></td></tr></table>
|
353569041ad3b6497afc0d440421046861a44d933ca7e8d6923272f1d5517281.png
|
simple
|
<table><tr><td>Cpd.</td><td>% inhibition (at 6.25 μg/mL)</td><td>Estimation of MIC<sub>90</sub></td><td>LD<sub>50ip</sub> (mg/kg)</td></tr><tr><td>4a</td><td>100</td><td><6.25</td><td>800</td></tr><tr><td>4b</td><td>61</td><td>>6.25</td><td>650</td></tr><tr><td>4c</td><td>91</td><td><6.25</td><td>180</td></tr><tr><td>4d</td><td>65</td><td>>6.25</td><td>710</td></tr><tr><td>4e</td><td>15</td><td>>6.25</td><td>>1000</td></tr><tr><td>4f</td><td>0</td><td>>6.25</td><td>410</td></tr><tr><td>4g</td><td>92</td><td><6.25</td><td>>1000</td></tr><tr><td>4h</td><td>96</td><td><6.25</td><td>750</td></tr><tr><td>4i</td><td>ND</td><td>ND</td><td>280</td></tr></table>
|
f0ef75f96a887b972e3fcf8a5661fcf7aafe7621d974a3fc95c89743054d6940.png
|
simple
|
<table><tr><td>Sex</td><td>Progesterone (ng/ml)</td><td>Corticosterone (ng/ml)</td><td>IGF-I (ng/ml)</td><td>Testosterone (ng/ml)</td><td>Estradiol (ng/ml)</td></tr><tr><td>Female</td><td>2.74 ± 0.44</td><td>67.87 ± 6.26</td><td>43.33 ± 5.66</td><td>1.98 ± 0.21</td><td>6.43 ± 0.31*</td></tr><tr><td>Male</td><td>2.24 ± 1.61</td><td>55.95 ± 13.99</td><td>47.92 ± 12.76</td><td>2.93 ± 0.32*</td><td>5.21 ± 0.26</td></tr></table>
|
28452fe04424b7a85f4ad0642fca8f79b28b48066d7528dd1fe1ae849777ab6c.png
|
complex
|
<table><tr><td>Group</td><td>Description of the group</td><td>Strength</td></tr><tr><td>TM1</td><td>The total number of skills is 2; number of skills of each employee and task is 2.</td><td>The quantum of effort needed in every task is to be equal; each employee has the same contribution of maximum dedication and salary.</td></tr><tr><td>TM2</td><td>The amount of skills is 10; number of employee skills is 5–7; number of skills required in the task is 3-4.</td><td rowspan="2">The functionalities in TM2 and TM3 have the same TPG; the tasks have the same efforts; each employee has maximum dedication and salary.</td></tr><tr><td>TM3</td><td>The amount of skills is 15; number of employee skills is 6-7; number of skills required in the task is 2-3.</td></tr><tr><td>TM4</td><td>The amount of skills is 10; number of employee skills is 2-3; number of skills required in the task is 4-5.</td><td rowspan="2">The functionalities in TM4 and TM5 have the same TPG; the tasks have the same effort and each employee has maximum dedication and salary.</td></tr><tr><td>TM5</td><td>The amount of skills is 5; number of employee skills is 3-4; number of skills required in the task is 2-3.</td></tr></table>
|
bef73fe9b9583b3e5eb965f605f860565b41b9619e6ddf47af4889a0b2caa5e1.png
|
simple
|
<table><tr><td></td><td>All</td><td>Males</td><td>Females</td></tr><tr><td>Age</td><td></td><td></td><td></td></tr><tr><td> 20 - 29 years</td><td>104 (23.6%)</td><td>41 (21.8%)</td><td>63 (25.0%)</td></tr><tr><td> 30 - 39 years</td><td>116 (26.4%)</td><td>44 (23.4%)</td><td>72 (28.6%)</td></tr><tr><td> 40 - 49 years</td><td>129 (29.3%)</td><td>59 (31.4%)</td><td>69 (27.4%)</td></tr><tr><td> ≥50 years</td><td>91 (20.7%)</td><td>44 (23.4%)</td><td>48 (19.0%)</td></tr><tr><td>Number of working years in current position</td><td></td><td></td><td></td></tr><tr><td> 1 to 5 years</td><td>132 (30.0%)</td><td>63 (33.5%)</td><td>69 (27.4%)</td></tr><tr><td> 6 to 10 years</td><td>107 (24.3%)</td><td>47 (25.0%)</td><td>60 (23.8%)</td></tr><tr><td> 11 to 15 years</td><td>94 (21.4%)</td><td>40 (21.3%)</td><td>54 (21.4%)</td></tr><tr><td> 15 years and more</td><td>107 (24.3%)</td><td>38 (20.2%)</td><td>69 (27.4%)</td></tr><tr><td>Number of working hours with computer/day</td><td></td><td></td><td></td></tr><tr><td> 2 to 5 hrs</td><td>107 (24.3%)</td><td>63 (33.5%)</td><td>44 (17.5%)</td></tr><tr><td> 6 to 9 hrs</td><td>248 (56.4%)</td><td>81 (43.1%)</td><td>167 (66.3%)</td></tr><tr><td> > 9 hrs</td><td>85 (19.3%)</td><td>44 (23.4%)</td><td>41 (16.3%)</td></tr></table>
|
4fb4127fa146bf1ace9aec73c4146c2408b37a18678755781a7ec0b5eeb83dba.png
|
simple
|
<table><tr><td>Gender</td><td>Age (years)</td><td>Length of diagnosis of hypothyroidism (years)</td></tr><tr><td>Female</td><td>93</td><td>13</td></tr><tr><td>Female</td><td>80</td><td>10</td></tr><tr><td>Male</td><td>84</td><td>Approx. 8</td></tr><tr><td>Female</td><td>82</td><td>24</td></tr><tr><td>Male</td><td>83</td><td>15</td></tr><tr><td>Female</td><td>88</td><td>9</td></tr><tr><td>Female</td><td>85</td><td>14</td></tr><tr><td>Female</td><td>80</td><td>3</td></tr><tr><td>Female</td><td>83</td><td>14</td></tr><tr><td>Female</td><td>82</td><td>18</td></tr><tr><td>Female</td><td>85</td><td>16</td></tr></table>
|
1631fa74e7b3d91cd6bca4a25fc2b6d72fddbcb86d4d0a23f21a9eb83947b945.png
|
simple
|
<table><tr><td>Abbreviated Trial Name/NCT#</td><td>Phase</td><td>Agent(s)</td><td>Study population</td><td>Expected Primary Endpoint</td></tr><tr><td>NCT01935921</td><td>Ib</td><td>Cetuximab, ipilimumab and IMRT</td><td>stage III-IVaHPV+ OPSCC</td><td>Dose limiting toxicities (DLT)</td></tr><tr><td>RTOG 3504NCT02764593</td><td>III w/phase I lead in</td><td>Nivolumab and cisplatin CRT</td><td>stage III-IV, intermediate to high risk HNSCC</td><td>DLT for phase I</td></tr><tr><td>NCT02777385</td><td>II</td><td>Concurrent vs sequential pembro, cisplatin and IMRT</td><td>stage III-IVbHNSCC</td><td>1 year PFS1 year failure rateAcute toxicity rates</td></tr><tr><td>HN003NCT02775812</td><td>I</td><td>Adjuvant pembro, cisplatin and IMRT</td><td>high risk stage III-IV HSNCC</td><td>DLT</td></tr><tr><td>NCT02641093</td><td>II</td><td>Adjuvant pembro, cisplatin and IMRT</td><td>high risk stage III-IV HSNCC</td><td>Treatment related adverse events (TRAE)Disease free survival (DFS)</td></tr></table>
|
15c8fba76546355d7e0b96d58b7c2b297bfd3368059e9dcf3f0dcfb0932975bb.png
|
complex
|
<table><tr><td></td><td></td><td colspan="4"></td><td colspan="2">Decay class</td><td colspan="4"></td></tr><tr><td></td><td></td><td colspan="4">Quaking aspen</td><td colspan="2"></td><td colspan="4">Douglas-fir</td></tr><tr><td>Component</td><td>Comparison</td><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td></tr><tr><td>Top and branches</td><td>1</td><td>0.8</td><td>6.7</td><td>11.8</td><td>8.7</td><td>8.4</td><td>9.7</td><td>16.7</td><td>37.7</td><td>4.0</td><td>33.8</td></tr><tr><td></td><td>2</td><td>1.2</td><td>17.2</td><td>23.2</td><td>21.4</td><td>21.8</td><td>10.6</td><td>59.9</td><td>82.2</td><td>9.7</td><td>59.6</td></tr><tr><td>Bole</td><td>1</td><td>2.6</td><td>21.5</td><td>39.2</td><td>30.0</td><td>29.4</td><td>60.1</td><td>104.7</td><td>237.9</td><td>13.6</td><td>215.7</td></tr><tr><td></td><td>2</td><td>3.8</td><td>25.2</td><td>44.0</td><td>36.5</td><td>37.3</td><td>65.8</td><td>130.0</td><td>268.2</td><td>16.5</td><td>239.6</td></tr><tr><td>Stump</td><td>1</td><td>0.1</td><td>1.1</td><td>2.0</td><td>1.5</td><td>1.5</td><td>2.2</td><td>3.6</td><td>7.6</td><td>0.7</td><td>6.4</td></tr><tr><td></td><td>2</td><td>0.2</td><td>1.3</td><td>2.3</td><td>1.8</td><td>1.8</td><td>2.4</td><td>4.5</td><td>8.6</td><td>0.8</td><td>7.1</td></tr><tr><td>Belowground</td><td>1</td><td>0.7</td><td>5.7</td><td>10.3</td><td>7.8</td><td>7.6</td><td>16.2</td><td>28.0</td><td>63.4</td><td>3.5</td><td>57.1</td></tr><tr><td></td><td>2</td><td>1.0</td><td>7.5</td><td>13.7</td><td>13.2</td><td>14.7</td><td>17.7</td><td>41.4</td><td>88.1</td><td>6.0</td><td>82.1</td></tr></table>
|
be5d4717e82e405f544cb54200ece7baf1c0232c58e7214b1d05f0b9d8c5531c.png
|
complex
|
<table><tr><td></td><td colspan="2">Intervention</td><td colspan="2">Control</td></tr><tr><td>All costs</td><td>USD</td><td>% total costs</td><td>USD</td><td>% total costs</td></tr><tr><td><i>Personnel</i></td><td><i>87 926</i></td><td><i>58.4</i></td><td><i>56 632</i></td><td><i>60.5</i></td></tr><tr><td> CHWs (salaries and incentives)</td><td>10 332</td><td>6.9</td><td>3 982</td><td>4.3</td></tr><tr><td> Field supervision and medical staff</td><td>28 193</td><td>18.7</td><td>17 194</td><td>18.4</td></tr><tr><td> Management and technical staff</td><td>45 656</td><td>30.3</td><td>32 536</td><td>34.7</td></tr><tr><td> Support staff (logistics, finance, administrative)</td><td>3 746</td><td>2.5</td><td>2 921</td><td>3.1</td></tr><tr><td><i>Programme costs</i></td><td><i>35 648</i></td><td><i>23.7</i></td><td><i>20 848</i></td><td><i>22.3</i></td></tr><tr><td> Office and programme materials</td><td>1 756</td><td>1.2</td><td>1 324</td><td>1.4</td></tr><tr><td> RUTF (supply)</td><td>17 795</td><td>11.8</td><td>5 648</td><td>6.0</td></tr><tr><td> Training costs (trainer, location, supplies)</td><td>9 248</td><td>6.1</td><td>7 407</td><td>7.9</td></tr><tr><td> Supervision and monitoring</td><td>6 849</td><td>4.6</td><td>6 469</td><td>6.9</td></tr><tr><td><i>Logistics</i></td><td><i>20 732</i></td><td><i>13.8</i></td><td><i>12 953</i></td><td><i>13.8</i></td></tr><tr><td> Rent and utilities</td><td>8 927</td><td>5.9</td><td>2 767</td><td>3.0</td></tr><tr><td> Transport (car rental, maintenance and fuel)</td><td>10 025</td><td>6.7</td><td>9 621</td><td>10.3</td></tr><tr><td> RUTF transport and storage</td><td>1 780</td><td>1.2</td><td>565</td><td>0.6</td></tr><tr><td><i>Community contributions</i></td><td><i>6 218</i></td><td><i>4.1</i></td><td><i>3 208</i></td><td><i>3.4</i></td></tr><tr><td> Costs to households</td><td>4 807</td><td>3.2</td><td>3 191</td><td>3.4</td></tr><tr><td> Opportunity costs for community leaders</td><td>35</td><td>0.0</td><td>17</td><td>0.0</td></tr><tr><td> Community-level rent</td><td>1 376</td><td>0.9</td><td>0</td><td>0.0</td></tr><tr><td><i>Total</i></td><td><i>150 523</i></td><td><i>100.0</i></td><td><i>93 641</i></td><td><i>100.0</i></td></tr><tr><td>Cost to government</td><td>11 881</td><td>7.9</td><td>5 341</td><td>5.7</td></tr><tr><td>Cost to partners</td><td>132 425</td><td>88.0</td><td>85 093</td><td>90.9</td></tr><tr><td>Cost to community</td><td>6 218</td><td>4.1</td><td>3 208</td><td>3.4</td></tr></table>
|
22dff048d81b405f5e34b601c880fc5403ba5120068a95278a89f0ff0dfcebc4.png
|
complex
|
<table><tr><td rowspan="2">Variables</td><td rowspan="2">No. of <i>E. coli</i> tested</td><td>C No. (%)<sup>a</sup></td><td>OT No. (%)<sup>a</sup></td><td>SXT No. (%)<sup>a</sup></td><td colspan="2">PB No. (%)<sup>b</sup></td><td colspan="3">N No. (%)<sup>c</sup></td></tr><tr><td>S</td><td>S</td><td>S</td><td>S</td><td>R</td><td>S</td><td>I</td><td>R</td></tr><tr><td colspan="10">Food handlers and source</td></tr><tr><td> Meat handlers at butcher</td><td>8</td><td>8 (100)</td><td>8 (100)</td><td>8 (100)</td><td>7 (87.5)</td><td>1 (12.5)</td><td>–</td><td>2 (25)</td><td>6 (75)</td></tr><tr><td> Milk seller at open market</td><td>9</td><td>9 (100)</td><td>9 (100)</td><td>9 (100)</td><td>9 (100)</td><td>–</td><td>2 (22.2)</td><td>–</td><td>7 (77.8)</td></tr><tr><td> Milk seller at dairy station</td><td>2</td><td>2 (100)</td><td>2 (100)</td><td>2 (100)</td><td>2 (100)</td><td>–</td><td>–</td><td>–</td><td>2 (100)</td></tr><tr><td> Bread and the related food handler at cafeteria</td><td>10</td><td>10 (100)</td><td>10 (100)</td><td>10 (100)</td><td>10 (100)</td><td>–</td><td>–</td><td>–</td><td>10 (100)</td></tr><tr><td> Fruit and vegetables handlers at supermarket</td><td>14</td><td>14 (100)</td><td>14 (100)</td><td>14 (100)</td><td>14 (100)</td><td>–</td><td>–</td><td>3 (21.4)</td><td>11 (78.6)</td></tr><tr><td colspan="10">Currency</td></tr><tr><td> Birr 1</td><td>9</td><td>9 (100)</td><td>9 (100)</td><td>9 (100)</td><td>9 (100)</td><td>–</td><td>–</td><td>–</td><td>9 (100)</td></tr><tr><td> Birr 5</td><td>10</td><td>10 (100)</td><td>10 (100)</td><td>10 (100)</td><td>9 (90)</td><td>1 (10.0)</td><td>1 (10.0)</td><td>2 (20.0)</td><td>7 (70.0)</td></tr><tr><td> Birr 10</td><td>9</td><td>9 (100)</td><td>9 (100)</td><td>9 (100)</td><td>9 (100)</td><td>–</td><td>1 (11.1)</td><td>–</td><td>8 (88.9)</td></tr><tr><td> Birr 50</td><td>8</td><td>8 (100)</td><td>8 (100)</td><td>8 (100)</td><td>8 (100)</td><td>–</td><td>–</td><td>3 (37.5)</td><td>5 (62.5)</td></tr><tr><td> Birr 100</td><td>7</td><td>7 (100)</td><td>7 (100)</td><td>7 (100)</td><td>7 (100)</td><td>–</td><td>–</td><td>–</td><td>7 (100)</td></tr><tr><td>Total</td><td>43</td><td>43 (100)</td><td>43 (100)</td><td>43 (100)</td><td>42 (97.7)</td><td>1 (2.3)</td><td>2 (4.7)</td><td>5 (11.6)</td><td>36 (83.7)</td></tr></table>
|
3982122a3879126e73abeef7d1e6be52728995d39cc742e71ceef57bab17ad23.png
|
complex
|
<table><tr><td></td><td>Kegg pathway</td><td>Number of genes</td><td>Fold enrichment</td><td>p value<sup>*</sup></td></tr><tr><td rowspan="5">UP</td><td>Steroid biosynthesis (cholesterol biosynthesis)</td><td>7</td><td>23.8</td><td>1.6E-07</td></tr><tr><td>Insulin signaling pathway</td><td>7</td><td>3.1</td><td>2.3E-02</td></tr><tr><td>Adipocytokine signaling pathway</td><td>5</td><td>5</td><td>1.6E-02</td></tr><tr><td>MAPK signaling pathway</td><td>9</td><td>2.5</td><td>2.4E-02</td></tr><tr><td>Glycolysis / Gluconeogenesis</td><td>4</td><td>4.5</td><td>5E-02</td></tr><tr><td>DOWN</td><td>Steroid biosynthesis (cholesterol biosynthesis)</td><td>4</td><td>27.8</td><td>3.3E-04</td></tr><tr><td></td><td>Tight junction</td><td>6</td><td>5.3</td><td>4.6E-03</td></tr></table>
|
ecde5feebf764c57601c340a0ba98bbedf94d6bf6b1d12f57999562a2f2be722.png
|
simple
|
<table><tr><td>Details</td><td>HR-12 (current study)</td><td>93–11 [2]</td><td>IR-64 [3]</td><td>Kasalath [4]</td><td>Nipponbare [1]</td></tr><tr><td>Subspecies</td><td><i>indica</i></td><td><i>indica</i></td><td><i>indica</i></td><td><i>aus</i></td><td><i>japonica</i></td></tr><tr><td>Sequence depth</td><td>73x (Illumina) and 20x (PacBio)</td><td>4.2x (Sanger) and 36x (Illumina)</td><td>110x (Illumina)</td><td>6x (Roche 454) and 148X (Illumina)</td><td>6x (Sanger), 62x (Illumina) and 2.57x (Roche 454)</td></tr><tr><td>Sequencing technologies</td><td>Illumina and PacBio</td><td>Sanger and Illumina</td><td>Illumina</td><td>Illumina and Roche 454</td><td>Sanger, Illumina and Roche 454</td></tr><tr><td>Genome assembler(s)</td><td>MaSuRCA and PBJelly</td><td>RePS and SOAPDenovo</td><td>ALLPATHS-LG</td><td>Celera Assembler and String Graph Assembler</td><td>TIGR Assembler</td></tr><tr><td>Genome size (Mb)</td><td>389.77 (389.60)</td><td>374.55 (359.41)</td><td>345.9 (321.2)</td><td>401.14 (328.25)</td><td>374.47 (374.31)</td></tr><tr><td>No. of N's (Mb)</td><td>0.17</td><td>15.14</td><td>24.7</td><td>72.89</td><td>0.17</td></tr><tr><td>Total no. of contigs/scaffolds</td><td>59,692</td><td>50,231</td><td>26,160</td><td>51,550</td><td>NA</td></tr><tr><td>a. Anchored contigs/scaffolds</td><td>43,781</td><td>35,415</td><td>NA</td><td>36,932</td><td>NA</td></tr><tr><td>b. Unanchored contigs/scaffolds</td><td>15,911</td><td>14,816</td><td>NA</td><td>14,618</td><td>NA</td></tr><tr><td>N50 (Kb)</td><td>28.5</td><td>6.69</td><td>22.2</td><td>13.73</td><td>NA</td></tr><tr><td>No. of genes</td><td>56,284</td><td>40,464</td><td>37,758</td><td>53,662</td><td>55,986</td></tr><tr><td>CEG mapping (%)</td><td>94.35</td><td>95.97</td><td>94.35</td><td>95.97</td><td>95.97</td></tr></table>
|
d4d0bfe6a5000584fcd5f1a1d79b93d2ef41867bd4076632c3ba18787c06c7f3.png
|
simple
|
<table><tr><td>Location</td><td>Posture</td><td>Interpretation</td></tr><tr><td>None</td><td>None</td><td>No heat imprint found in frame. Due to the lack of heat imprint in frame, neither location nor posture can be identified.</td></tr><tr><td>Bed</td><td>Sitting Laying</td><td>The individual is either sitting up in bed or laying in bed. The heat imprint is within bed boundaries.</td></tr><tr><td>Bedrail</td><td>Sitting Laying</td><td>The individual is either sitting on the bed with legs partly outside bed, laying in the bed on the bedrail, or sitting on the floor with parts of the upper body, e.g., arms, in the bed. The latter is interpreted as laying on the bedrail. Laying on bedrail is considered hazardous.</td></tr><tr><td>Floor</td><td>Standing Sitting Laying</td><td>The person is either standing on the floor, sitting on the floor, or laying on the floor</td></tr></table>
|
8bea36337a24c39f165a250684cb610845c32ad54ce4d4b045ed7376f8e06402.png
|
complex
|
<table><tr><td>Groups</td><td>Day post-challenge</td><td> </td><td> </td><td> </td></tr><tr><td> </td><td>7</td><td>17</td><td>21</td><td>28</td></tr><tr><td colspan="5">PCV2 in serum</td></tr><tr><td>Vaccinated group</td><td>3 of 5</td><td>3 of 5</td><td>2 of 5</td><td>0 of 5</td></tr><tr><td>Control group</td><td>5 of 5</td><td>5 of 5</td><td>5 of 5</td><td>5 of 5</td></tr><tr><td colspan="5">Viral load in positive pigs</td></tr><tr><td>Vaccinated group</td><td>7.69 ± 0.11</td><td>7.67 ± 0.22</td><td>7.76 ± 0.26</td><td>0.00 ± 0.00</td></tr><tr><td>Control group</td><td>8.31 ± 0.40</td><td>8.41 ± 0.91</td><td>8.77 ± 0.55</td><td>7.72 ± 0.55</td></tr></table>
|
799f63d152d839f0cfefc132aea713f4053dfbbe84e8440a240b2ee133bf4584.png
|
complex
|
<table><tr><td><i>Manufacturer</i></td><td><i>Model</i></td><td><i>AEC System</i></td><td><i>Number of Times Tested</i></td></tr><tr><td>GE</td><td>Discovery 670<sup>a</sup></td><td rowspan="6">AutomA 3D (AutomA & SmartmA)</td><td>2</td></tr><tr><td>GE</td><td>Discovery 670 Pro<sup>a</sup></td><td>1</td></tr><tr><td>GE</td><td>Discovery 690<sup>a</sup></td><td>8</td></tr><tr><td>GE</td><td>Discovery 710<sup>a</sup></td><td>1</td></tr><tr><td>GE</td><td>LightSpeed Ultra</td><td>5</td></tr><tr><td>GE</td><td>VCT</td><td>5</td></tr><tr><td>Philips</td><td>Gemini TF<sup>a</sup></td><td>DoseRight 2.0</td><td>8</td></tr><tr><td>Siemens</td><td>Definition (Dual Source)</td><td></td><td>6 (12)</td></tr><tr><td>Siemens</td><td>Definition AS</td><td></td><td>8</td></tr><tr><td>Siemens</td><td>Definition AS+</td><td></td><td>3</td></tr><tr><td>Siemens</td><td>Definition AS+</td><td></td><td>1</td></tr><tr><td>Siemens</td><td>Definition Edge</td><td></td><td>1</td></tr><tr><td>Siemens</td><td>Emotion 16</td><td></td><td>2</td></tr><tr><td>Siemens</td><td>Sensation 16</td><td></td><td>7</td></tr><tr><td>Siemens</td><td>Sensation 16</td><td>CARE Dose 4D</td><td>5</td></tr><tr><td>Siemens</td><td>Sensation 64</td><td></td><td>6</td></tr><tr><td>Siemens</td><td>Sensation 64</td><td></td><td>7</td></tr><tr><td>Siemens</td><td>Sensation 64</td><td></td><td>6</td></tr><tr><td>Siemens</td><td>Sensation Open<sup>b</sup></td><td></td><td>8</td></tr><tr><td>Siemens</td><td>Sensation Open<sup>b</sup></td><td></td><td>6</td></tr><tr><td>Siemens</td><td>Sensation Open<sup>b</sup></td><td></td><td>7</td></tr><tr><td>Siemens</td><td>Symbia T<sup>a</sup></td><td></td><td>2</td></tr><tr><td>Toshiba</td><td>Aquilion CXL</td><td>SURE Exposure 3D</td><td>4</td></tr></table>
|
efdf728546d1e1011dd0392e128a6c9dedf499c175bd745fcf99f13c914d553d.png
|
complex
|
<table><tr><td> </td><td>Prostatitis</td><td>BPH</td><td>PIN</td><td>PC stage I</td><td>PC stage II</td><td>PC stage III</td><td>PC stage IV</td></tr><tr><td> </td><td>N=342</td><td>N=282</td><td>N=138</td><td>N=332</td><td>N=220</td><td>N=48</td><td>N=16</td></tr><tr><td><i>Albumin</i></td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Mean</td><td>4</td><td>3.98</td><td>4.09</td><td>4.04</td><td>4</td><td>3.95</td><td>3.9</td></tr><tr><td><i>SD</i></td><td>0.38</td><td>0.37</td><td>0.37</td><td>0.38</td><td>0.42</td><td>0.39</td><td>0.42</td></tr><tr><td colspan="8"><i>HGB</i> *</td></tr><tr><td>Mean</td><td>14.27</td><td>14.24</td><td>14.3</td><td>14.17</td><td>13.7</td><td>12.59</td><td>12.84</td></tr><tr><td>SD</td><td>1.54</td><td>1.76</td><td>1.68</td><td>1.66</td><td>1.87</td><td>2.2</td><td>14.08</td></tr><tr><td colspan="8"><i>RBC</i></td></tr><tr><td>Mean</td><td>4.67</td><td>4.65</td><td>4.76</td><td>4.69</td><td>4.63</td><td>4.58</td><td>4.5</td></tr><tr><td>SD</td><td>0.46</td><td>0.52</td><td>0.52</td><td>0.5</td><td>0.57</td><td>0.44</td><td>0.67</td></tr><tr><td colspan="8"><i>Creatinine</i></td></tr><tr><td>Mean</td><td>1.25</td><td>1.16</td><td>1.2</td><td>1.16</td><td>1.15</td><td>1.14</td><td>1.13</td></tr><tr><td>SD</td><td>0.7</td><td>0.32</td><td>0.35</td><td>0.56</td><td>0.34</td><td>0.39</td><td>0.2</td></tr><tr><td colspan="8"><i>PSA*</i></td></tr><tr><td>Mean</td><td>8.06</td><td>7.99</td><td>7.67</td><td>9.7</td><td>14.12</td><td>21.85</td><td>44.03</td></tr><tr><td>SD</td><td>6.74</td><td>11.2</td><td>4.58</td><td>11.66</td><td>29.27</td><td>30.21</td><td>48.71</td></tr><tr><td colspan="8"><i>MCV</i></td></tr><tr><td>Mean</td><td>90.78</td><td>91.13</td><td>90.09</td><td>91.17</td><td>90.98</td><td>90.23</td><td>92.24</td></tr><tr><td>SD</td><td>4.65</td><td>5.35</td><td>5.79</td><td>5.05</td><td>6.11</td><td>4.18</td><td>4.99</td></tr><tr><td colspan="8"><i>Bilirubin</i></td></tr><tr><td>Mean</td><td>0.66</td><td>0.65</td><td>0.6</td><td>0.66</td><td>0.67</td><td>0.65</td><td>0.6</td></tr><tr><td>SD</td><td>0.4</td><td>0.3</td><td>0.25</td><td>0.35</td><td>0.35</td><td>0.34</td><td>0.3</td></tr><tr><td colspan="8"><i>BUN*</i></td></tr><tr><td>Mean</td><td>17.98</td><td>17.6</td><td>17.23</td><td>16.53</td><td>17.4</td><td>16</td><td>15.97</td></tr><tr><td>SD</td><td>6.93</td><td>7.9</td><td>6.5</td><td>6.56</td><td>6.73</td><td>6.74</td><td>4.54</td></tr><tr><td colspan="8"><i>Platlet</i></td></tr><tr><td>Mean</td><td>230.45</td><td>227.63</td><td>240.81</td><td>226.54</td><td>232.5</td><td>234.3</td><td>235.44</td></tr><tr><td>SD</td><td>59.16</td><td>61.56</td><td>84.31</td><td>62.26</td><td>69.25</td><td>68.07</td><td>50.76</td></tr><tr><td colspan="8"><i>WBC</i></td></tr><tr><td>Mean</td><td>7.24</td><td>7.11</td><td>7.42</td><td>7.19</td><td>7.13</td><td>10.41</td><td>7.37</td></tr><tr><td>SD</td><td>2.11</td><td>2.17</td><td>3.24</td><td>2.42</td><td>2.08</td><td>17.78</td><td>1.84</td></tr><tr><td colspan="8"><i>Folate</i></td></tr><tr><td>Mean</td><td>12.93</td><td>12.56</td><td>12.31</td><td>13.37</td><td>11.92</td><td>10.71</td><td>10.03</td></tr><tr><td>SD</td><td>5.44</td><td>5.78</td><td>5.29</td><td>5.25</td><td>5.43</td><td>5.44</td><td>4.99</td></tr><tr><td colspan="8"><i>LDH</i></td></tr><tr><td>Mean</td><td>426.91</td><td>424.78</td><td>371.84</td><td>404.6</td><td>406.41</td><td>392.11</td><td>393.33</td></tr><tr><td>SD</td><td>375.09</td><td>144.84</td><td>185.54</td><td>155.38</td><td>158.19</td><td>170.98</td><td>73.76</td></tr></table>
|
5b2f2e58663bf0b2f3c50a07970775ce64b906b54d3f9964e386d7c7137241dc.png
|
simple
|
<table><tr><td></td><td>16-L</td><td>16-O</td><td>32-L</td><td>32-O</td><td>32-LT</td><td>32-OT</td></tr><tr><td></td><td>(n = 8)</td><td>(n = 8)</td><td>(n = 8)</td><td>(n = 8)</td><td>(n = 7)</td><td>(n = 8)</td></tr><tr><td>Body Weight (g)</td><td>383.8 ± 8.9</td><td>468.8 ± 10.6 **</td><td>460.8 ± 7.6</td><td>563.2 ± 15.2<sup>††</sup></td><td>465.0 ± 14.9</td><td>521.4 ± 21.5</td></tr><tr><td>HbA1c (%)</td><td>3.04 ± 0.07</td><td>3.18 ± 0.06</td><td>3.17 ± 0.07</td><td>4.45 ± 0.26<sup>††</sup></td><td>3.09 ± 0.13</td><td>3.52 ± 0.07<sup>#</sup></td></tr><tr><td>Serum Insulin (ng/ml)</td><td>1.5 ± 2.3</td><td>2.4 ± 0.8</td><td>1.7 ± 0.9</td><td>3.3 ± 1.1</td><td>1.6 ± 0.6</td><td>1.8 ± 0.2</td></tr><tr><td>Plasma glucose in OGTT (mg/dl)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> pre</td><td>86.6 ± 2.2</td><td>100.9 ± 4.1*</td><td>106.3 ± 3.7</td><td>122.3 ± 5.1<sup>†</sup></td><td>95.8 ± 2.0</td><td>98.8 ± 3.9<sup>#</sup></td></tr><tr><td> 60 min</td><td>131.1 ± 4.1</td><td>157.1 ± 14.4</td><td>142.5 ± 4.1</td><td>310.7 ± 5.0<sup>††</sup></td><td>134.9 ± 1.7</td><td>225.6 ± 6.9<sup>##</sup></td></tr><tr><td> 120 min</td><td>102.6 ± 4.1</td><td>100.9 ± 1.9</td><td>101.9 ± 1.9</td><td>161.5 ± 4.8<sup>††</sup></td><td>95.1 ± 3.1</td><td>98.9 ± 4.3<sup>##</sup></td></tr></table>
|
0b7ea8b800a624e90e5b4bf257231105d314269447583e741486fa5b2a73b8a3.png
|
complex
|
<table><tr><td>Code</td><td>Communication items</td><td colspan="3">Inpatient</td><td colspan="3">Outpatient</td></tr><tr><td> </td><td> </td><td>Explaining</td><td>Breaking bad news</td><td>Discussing with a family</td><td>Explaining a diagnosis</td><td>Managing time</td><td>Managing a difficult consultation</td></tr><tr><td>1</td><td>Announcing the duration of the consultation</td><td> </td><td> </td><td> </td><td> </td><td>x</td><td> </td></tr><tr><td>2</td><td>Establishing initial rapport</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td></tr><tr><td>3</td><td>Setting the medical agenda</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td></tr><tr><td>4</td><td>Introducing each other</td><td> </td><td> </td><td>x</td><td> </td><td> </td><td> </td></tr><tr><td>5</td><td>Negotiating the agenda</td><td> </td><td> </td><td>x</td><td>x</td><td>x</td><td>x</td></tr><tr><td>6</td><td>Announcing</td><td> </td><td>x</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>7</td><td>Exploring patient’s perspectives</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td></tr><tr><td>8</td><td>Exploring patient’s understanding of what has happened</td><td> </td><td> </td><td> </td><td> </td><td> </td><td>x</td></tr><tr><td>9</td><td>Summarizing the context</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td></tr><tr><td>10</td><td>Informing</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td></tr><tr><td>11</td><td>Clarifying roles, rules</td><td> </td><td> </td><td>x</td><td> </td><td> </td><td> </td></tr><tr><td>12</td><td>Using clear language/no jargon</td><td>x</td><td>x</td><td>x</td><td>x</td><td> </td><td>x</td></tr><tr><td>13</td><td>Chunking and checking (by open-ended questioning, reflecting, silence)</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td></tr><tr><td>14</td><td>Empathy/legitimating</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td></tr><tr><td>15</td><td>Making information circulate between participants</td><td> </td><td> </td><td>x</td><td> </td><td> </td><td> </td></tr><tr><td>16</td><td>Being supportive</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td></tr><tr><td>17</td><td>Summarizing</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td></tr><tr><td>18</td><td>Planning the future</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td></tr><tr><td>19</td><td>Remaining calm</td><td> </td><td> </td><td>x</td><td> </td><td> </td><td>x</td></tr><tr><td>20</td><td>Checking patient’s understanding at the end</td><td>x</td><td>x</td><td>x</td><td>x</td><td> </td><td> </td></tr><tr><td>21</td><td>Non verbal</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td></tr><tr><td>22</td><td>Defining the limits</td><td> </td><td> </td><td>x</td><td> </td><td> </td><td>x</td></tr><tr><td>23</td><td>Negotiating a common solution with the patient</td><td> </td><td> </td><td>x</td><td> </td><td> </td><td>x</td></tr><tr><td>24</td><td>Maintaining the frame</td><td> </td><td> </td><td> </td><td> </td><td>x</td><td>x</td></tr><tr><td>25</td><td>Acknowledging the problem</td><td> </td><td> </td><td> </td><td> </td><td> </td><td>x</td></tr><tr><td>26</td><td>Apologizing</td><td> </td><td> </td><td> </td><td> </td><td> </td><td>x</td></tr></table>
|
8c1caf9ddc5d4cca1642d4a9e8e3e2575db90769cfff8eaea60554535c91466f.png
|
complex
|
<table><tr><td rowspan="2">Histopathology</td><td>Pediatrics</td><td>Adults</td><td>All patients</td></tr><tr><td colspan="3">n (%)</td></tr><tr><td>Pineal region tumors</td><td>4 (10)</td><td>2 (5)</td><td>6 (14)</td></tr><tr><td>Colloid cyst</td><td>-</td><td>6 (14)</td><td>6 (14)</td></tr><tr><td>Pilocytic astrocytoma</td><td>3 (10)</td><td>2 (5)</td><td>5 (12)</td></tr><tr><td>Central neurocytoma</td><td>1 (2)</td><td>4 (10)</td><td>5 (12)</td></tr><tr><td>Glioblastoma</td><td>1 (2)</td><td>3 (7)</td><td>4 (10)</td></tr><tr><td>Atypical teratoid rhabdoid tumor</td><td>3 (7)</td><td>-</td><td>3 (7)</td></tr><tr><td>Ependymoma</td><td>-</td><td>2 (5)</td><td>2 (5)</td></tr><tr><td>Meningioma</td><td>-</td><td>2 (5)</td><td>2 (5)</td></tr><tr><td>Lymphoma</td><td>-</td><td>1 (2)</td><td>1 (2)</td></tr><tr><td>Choroid plexus papilloma</td><td>1 (2)</td><td>-</td><td>1 (2)</td></tr><tr><td>Anaplastic ependymoma</td><td>1 (2)</td><td>-</td><td>1 (2)</td></tr><tr><td>Anaplastic astrocytoma</td><td>1 (2)</td><td>-</td><td>1 (2)</td></tr><tr><td>Mature teratoma</td><td>1 (2)</td><td>-</td><td>1 (2)</td></tr><tr><td>Anaplastic oligodendroglioma</td><td>-</td><td>1 (2)</td><td>1 (2)</td></tr><tr><td>Craniopharyngioma</td><td>-</td><td>1 (2)</td><td>1 (2)</td></tr><tr><td>Glioneuronal tumor</td><td>1 (2)</td><td>-</td><td>1 (2)</td></tr><tr><td>Langerhans cell histiocytosis</td><td>1 (2)</td><td>-</td><td>1 (2)</td></tr><tr><td>Total</td><td>18</td><td>24</td><td>42</td></tr></table>
|
3b6703e9457a654b6a5ffe37dfb35db09f75e7682181761ff707174fe8160d28.png
|
simple
|
<table><tr><td>Visual area</td><td>Raw <i>N</i> PV</td><td>Corrected <i>N</i> PV</td><td>Raw <i>N</i> dual-labeled</td><td>Corrected <i>N</i> dual-labeled</td><td>% dually-labeled</td></tr><tr><td>V1</td><td>293</td><td>205</td><td>235</td><td>164</td><td>80</td></tr><tr><td>MT</td><td>293</td><td>205</td><td>218</td><td>153</td><td>75</td></tr></table>
|
d772bf761858d418c4b0ee3b77c1ed817be88745fcef74de09718eb13df98813.png
|
simple
|
<table><tr><td>Variable</td><td>Total of patients or mean value</td></tr><tr><td>Gender</td><td> </td></tr><tr><td> Female </td><td>624 (41,8%)</td></tr><tr><td> Male </td><td>868 (58,2%)</td></tr><tr><td>Gestational age (weeks)</td><td> </td></tr><tr><td> 28</td><td>18 (1,2%)</td></tr><tr><td> [28–32[</td><td>85 (5,7%)</td></tr><tr><td> [32–34[</td><td>93 (6,2%)</td></tr><tr><td> [34–37[</td><td>364 (24,4%)</td></tr><tr><td> ≥37</td><td>932 (62,5%)</td></tr><tr><td>Birth weight (g)</td><td> </td></tr><tr><td> <750</td><td>12 (0,8%)</td></tr><tr><td> [750–1000[</td><td>14 (0,9%)</td></tr><tr><td> [1000–1500[</td><td>72 (4,8%)</td></tr><tr><td> [1500–2500[</td><td>464 (31,1%)</td></tr><tr><td> [2500–4000[</td><td>881 (59,1%)</td></tr><tr><td> ≥4000</td><td>49 (3,3%)</td></tr><tr><td>Mode of delivery</td><td> </td></tr><tr><td> Cesarean section</td><td>721 (48,3%)</td></tr><tr><td> Vaginal delivery</td><td>771 (51,7%)</td></tr><tr><td>Mechanical ventilation</td><td> </td></tr><tr><td> Invasive</td><td>52 (3,5%)</td></tr><tr><td> Noninvasive</td><td>45 (3,0%)</td></tr><tr><td> Both modalities</td><td>151 (10,1%)</td></tr><tr><td>Phototherapy</td><td>675 (45,2%)</td></tr><tr><td>Parenteral nutrition</td><td>221 (14,8%)</td></tr></table>
|
6699754b0af133944fe80dc0187b38418d3de0f4da60b49255eb2787dd587950.png
|
simple
|
<table><tr><td></td><td><i>Total (£)</i></td></tr><tr><td><i>Trial Website:</i></td><td></td></tr><tr><td>Implementation of the consent process and the randomization and group assignment system</td><td>470</td></tr><tr><td>Implementation of the primary and secondary outcome questionnaires, including the code</td><td>1,410</td></tr><tr><td>Basic e-mail reminders system and follow-up questionnaires system</td><td>1,645</td></tr><tr><td><i>Control Website:</i></td><td></td></tr><tr><td>Implementation of the control site (estimated about 15-20 pages of information)</td><td>1,645</td></tr><tr><td>Intervention Website:</td><td></td></tr><tr><td>Implementation of the three modules, based on restructuring some old content and adding more new content provided by research team</td><td>5,875</td></tr><tr><td>SUB TOTAL:</td><td>11,045</td></tr><tr><td>Technical consultancy & project management</td><td>7,050</td></tr><tr><td>AGREED SPEND AT OUTSET:</td><td>18,095</td></tr><tr><td>VAT @ 17.5%</td><td>3,167</td></tr><tr><td>TOTAL</td><td>21,262</td></tr></table>
|
20cbe3917514b3b192d61498d72bf149d2aaba16f0893c7c6821edbf41113af4.png
|
complex
|
<table><tr><td></td><td colspan="2"><i>Acinetobacter baumanii</i> (<i>N</i> = 59)</td><td colspan="2"><i>Escherichia coli</i> (<i>N</i> = 92)</td><td colspan="2"><i>Klebsiella pneumoniae</i> (<i>N</i> = 92)</td><td colspan="2"><i>Pseudomonas aeruginosa</i> (<i>N</i> = 26)</td><td colspan="2">Non-typhoidal <i>Salmonella</i> (<i>N</i> = 20)</td></tr><tr><td>Antimicrobial</td><td>No isolates tested</td><td>No (%) Susceptible</td><td>No isolates tested</td><td>No (%) Susceptible</td><td>No isolates tested</td><td><i>N</i> (%) Susceptible</td><td>No isolates tested</td><td>N (%) Susceptible</td><td>No isolates tested</td><td><i>N</i> (%) Susceptible</td></tr><tr><td>Ampicillin</td><td>–</td><td>–</td><td>91</td><td>9 (9.9)</td><td>92</td><td>–</td><td>–</td><td>–</td><td>20</td><td>19 (95)</td></tr><tr><td>Co-amoxyclav<sup>a</sup></td><td>–</td><td>–</td><td>89</td><td>43 (48.3)</td><td>91</td><td>27 (29.7)</td><td>–</td><td>–</td><td>1</td><td>1 (100)</td></tr><tr><td>Ceftriaxone</td><td>–</td><td>–</td><td>90</td><td>59 (65.6)</td><td>88</td><td>20 (22.7)</td><td>–</td><td>–</td><td>20</td><td>20 (100)</td></tr><tr><td>Ceftazidime</td><td>59</td><td>24 (40.7)</td><td>91</td><td>60 (65.9)</td><td>91</td><td>20 (22)</td><td>26</td><td>23 (88.5)</td><td>1</td><td>1 (100)</td></tr><tr><td>Ciprofloxacin</td><td>59</td><td>45 (76.3)</td><td>87</td><td>70 (80.5)</td><td>85</td><td>52 (61.2)</td><td>26</td><td>15 (57.7)</td><td>19</td><td>18 (94.7)</td></tr><tr><td>Piperacillin-tazobactam</td><td>58</td><td>10 (17.2)</td><td>6<sup>$</sup></td><td>5 (83.3)</td><td>49<sup>$</sup></td><td>34 (69.4)</td><td>7<sup>$</sup></td><td>1 (14.3)</td><td>1<sup>$</sup></td><td>1 (100)</td></tr><tr><td>Gentamicin</td><td>59</td><td>27 (45.8)</td><td>91</td><td>64 (70.3)</td><td>89</td><td>25 (28.1)</td><td>25</td><td>15 (60)</td><td>–</td><td>–</td></tr><tr><td>Amikacin</td><td>58</td><td>26 (44.8)</td><td>92</td><td>77 (83.7)</td><td>91</td><td>70 (76.9)</td><td>26</td><td>16 (61.5)</td><td>–</td><td>–</td></tr><tr><td>Meropenem</td><td>56</td><td>26 (46.4)</td><td>92</td><td>92 (100)</td><td>92</td><td>92 (100)</td><td>26</td><td>22 (84.6)</td><td>20</td><td>20 (100)</td></tr><tr><td>Imipenem</td><td>49</td><td>27 (55.1)</td><td>90</td><td>90 (100)</td><td>90</td><td>90 (100)</td><td>26</td><td>21 (80.8)</td><td>20</td><td>20 (100)</td></tr><tr><td>Ertapenem</td><td></td><td></td><td>92</td><td>92 (100)</td><td>91</td><td>91 (100)</td><td>–</td><td>–</td><td>20</td><td>20 (100)</td></tr><tr><td>Colistin</td><td>59</td><td>59 (100)</td><td>90</td><td>90 (100)</td><td>89</td><td>89 (100)</td><td>26</td><td>23 (88.5)</td><td>–</td><td>–</td></tr></table>
|
3624fa3cdff3989e8b0bc997a4ab590bb177d012fcf56c3c683aa2b770e71a26.png
|
simple
|
<table><tr><td>Parameter</td><td>HR point estimate</td><td>95% CI</td><td>p-value</td></tr><tr><td><i>Continuous variables</i></td><td></td><td></td><td></td></tr><tr><td>Age (years)<sup>*</sup></td><td>1.05</td><td>0.81-1.37</td><td>0.722</td></tr><tr><td>Gleason score</td><td>0.82</td><td>0.71-0.96</td><td>0.012</td></tr><tr><td>PSA<sup>#</sup></td><td>1.00</td><td>0.89-1.13</td><td>0.001</td></tr><tr><td><i>Linear interaction term with time</i>°</td><td>1.03</td><td>1.01-1.06</td><td></td></tr><tr><td>ALP<sup>#</sup></td><td>1.07</td><td>0.99-1.16</td><td>0.074</td></tr><tr><td>LDH<sup>#</sup></td><td>1.22</td><td>1.02-1.46</td><td>0.027</td></tr><tr><td><i>Categorical variables</i></td><td></td><td></td><td></td></tr><tr><td>Staging at diagnosis</td><td></td><td></td><td></td></tr><tr><td> M0</td><td>1</td><td></td><td></td></tr><tr><td> M1</td><td>0.92</td><td>0.59-1.45</td><td>0.733</td></tr><tr><td>Metastatic sites</td><td></td><td></td><td></td></tr><tr><td> Bone only</td><td>1</td><td></td><td></td></tr><tr><td> Other</td><td>0.80</td><td>0.40-1.59</td><td>0.526</td></tr></table>
|
57aece16864fb8ee80352ca611c163e3d7564032e457cf31e45ef62e193dc44f.png
|
simple
|
<table><tr><td>Statement</td><td>Online simulator superior</td><td>Equivalent</td><td>Atlas or lecture superior</td><td>Unsure</td></tr><tr><td>Learning tympanic membrane anatomy</td><td>45.5%</td><td>45.5%</td><td>0.0%</td><td>9.1%</td></tr><tr><td>Learning external auditory canal anatomy</td><td>63.6%</td><td>36.4%</td><td>0.0%</td><td>0.0%</td></tr><tr><td>Learning otoscopy technique</td><td>63.6%</td><td>27.3%</td><td>0.0%</td><td>9.1%</td></tr><tr><td>Availability of training technique</td><td>54.5%</td><td>9.1%</td><td>27.3%</td><td>9.1%</td></tr></table>
|
2171fcdf2cb2e4b49d2243b4b91aa7ce082bf40a5d93aba6bdba77e56369fee0.png
|
simple
|
<table><tr><td>LncRNA name</td><td>Target</td><td>Cell type</td><td>Organism/system</td></tr><tr><td>FAL1</td><td>p21</td><td>Cancer cells</td><td>Human/<i>in vitro</i></td></tr><tr><td>BANCR</td><td>p21</td><td>Colorectal cancer cells</td><td>Human/<i>in vitro</i></td></tr><tr><td>LINCRNA-p21</td><td>p21</td><td>Mouse embryonic fibroblasts</td><td>Mouse/<i>in vivo</i> and <i>in vitro</i></td></tr><tr><td>MALAT1</td><td>p53</td><td>Human osteosarcoma cells</td><td>Human/<i>in vitro</i></td></tr><tr><td>7SL</td><td>p53</td><td>HeLa cells</td><td>Human/<i>in vitro</i></td></tr><tr><td>VAD</td><td>INK4 locus/p16INK4a</td><td>hTERT-immortalized WI38 human fibroblasts</td><td>Human/<i>in vitro</i></td></tr><tr><td>ANRIL</td><td>INK4 locus/p16INK4a</td><td>WI38 cell line</td><td>Human/<i>in vitro</i></td></tr><tr><td>MIR31HG</td><td>INK4 locus/p16INK4a</td><td>Immortalized human diploid fibroblasts, TIG3-hTERT</td><td>Human/<i>in vitro</i></td></tr><tr><td>UCA1</td><td>p16INK4a mRNA</td><td>Mouse primary cells</td><td>Mouse/<i>in vitro</i></td></tr><tr><td>SAL-RNA</td><td>p53</td><td>WI38 cell line (old versus young)</td><td>Human/<i>in vitro</i></td></tr><tr><td>SALNR</td><td>NF-90 localization</td><td>Human fibroblast cells</td><td>Human/<i>in vitro</i></td></tr><tr><td>TERRA</td><td>Telomere length</td><td>Mammalian cells and medulloblastoma</td><td></td></tr><tr><td>ASNCMTRNA2</td><td>hsa-miR-4485</td><td>Human endothelial cells</td><td>Human/<i>in vitro</i></td></tr><tr><td>HOTAIR</td><td>E3 ubiquitin ligase and PRC2</td><td>Ovarian cancer cells and HeLa cells</td><td>Human/<i>in vitro</i></td></tr><tr><td>PANDA</td><td>PRC1 and PRC2 recruitment</td><td>Primary human diploid fibroblast strains, BJ (neonatal foreskin), and WI38 (fetal lung)</td><td>Human/<i>in vitro</i></td></tr></table>
|
350d40af7161463f0978853191c8d276c1235ec92f24a5cc97e320321b9ffd8e.png
|
complex
|
<table><tr><td></td><td></td><td colspan="4">Proportion of reps. meeting:</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">Linkage threshold</td><td colspan="2">Association threshold (avg. no. SNPs analyzed)<sup>c</sup></td><td colspan="2">Avg. no. cases analyzed</td><td colspan="2">Overall power</td></tr><tr><td></td><td></td><td>Stringent<sup>a</sup></td><td>Loose<sup>b</sup></td><td>Stringent</td><td>Loose</td><td>Stringent</td><td>Loose</td><td>Stringent</td><td>Loose</td></tr><tr><td>9 (186)</td><td>A</td><td>0</td><td>0.14</td><td>0 (n/a)</td><td>0 (144)</td><td>1500</td><td>1500</td><td>0</td><td>0</td></tr><tr><td></td><td>B</td><td>0</td><td>0.14</td><td>0 (n/a)</td><td>0 (144)</td><td>983</td><td>987</td><td>0</td><td>0</td></tr><tr><td></td><td>C</td><td>0.13</td><td>0.64</td><td>0.23 (48)</td><td>0.25 (145)</td><td>127</td><td>136</td><td>0.03</td><td>0.16</td></tr><tr><td></td><td>D</td><td>0.83</td><td>0.96</td><td>0.01 (48)</td><td>0 (147)</td><td>1500</td><td>1500</td><td>0.01</td><td>0</td></tr><tr><td></td><td>E</td><td>0.2</td><td>0.65</td><td>0.30 (48)</td><td>0.20 (148)</td><td>129</td><td>121</td><td>0.06</td><td>0.13</td></tr><tr><td>11 (389)</td><td>A</td><td>0.06</td><td>0.24</td><td>1 (52)</td><td>1 (147)</td><td>1500</td><td>1500</td><td>0.06</td><td>0.24</td></tr><tr><td></td><td>B</td><td>0.06</td><td>0.24</td><td>1 (52)</td><td>1 (147)</td><td>988</td><td>985</td><td>0.06</td><td>0.24</td></tr><tr><td></td><td>C</td><td>0.11</td><td>0.62</td><td>1 (48)</td><td>0.92 (147)</td><td>258</td><td>273</td><td>0.11</td><td>0.57</td></tr><tr><td></td><td>D</td><td>0.98</td><td>1</td><td>1 (44)</td><td>1 (146)</td><td>1500</td><td>1500</td><td>0.98</td><td>1</td></tr><tr><td></td><td>E</td><td>0.23</td><td>0.56</td><td>1 (46)</td><td>1 (147)</td><td>281</td><td>290</td><td>0.23</td><td>0.56</td></tr><tr><td>18 (269)</td><td>A</td><td>0.21</td><td>0.64</td><td>1 (28)</td><td>1 (97)</td><td>1500</td><td>1500</td><td>0.21</td><td>0.64</td></tr><tr><td></td><td>B</td><td>0.21</td><td>0.64</td><td>1 (28)</td><td>1 (97)</td><td>998</td><td>988</td><td>0.21</td><td>0.64</td></tr><tr><td></td><td>C</td><td>0.53</td><td>0.91</td><td>1 (28)</td><td>1 (96)</td><td>372</td><td>390</td><td>0.53</td><td>0.91</td></tr><tr><td></td><td>D</td><td>0.73</td><td>0.99</td><td>1 (27)</td><td>1 (95)</td><td>1500</td><td>1500</td><td>0.73</td><td>0.99</td></tr><tr><td></td><td>E</td><td>0.44</td><td>0.88</td><td>1 (27)</td><td>1 (95)</td><td>370</td><td>382</td><td>0.44</td><td>0.88</td></tr></table>
|
e0227ea55f077be4deb15311509709e0ab19a31ed373dd03a5c1f8a8b7806e5a.png
|
complex
|
<table><tr><td rowspan="2">Exp</td><td rowspan="2">Dilution of 2-butanone (‘X’), %</td><td rowspan="2">N</td><td rowspan="2">n</td><td rowspan="2">%Response</td><td colspan="2">Mean (±SE) mosquito catches</td><td rowspan="2">Exp (B)</td></tr><tr><td>Reference (MB5 + CO<sub>2</sub>)</td><td>Test treatment (MB5 + ‘X’)</td></tr><tr><td>1</td><td>99.5</td><td>4</td><td>622</td><td>77.75</td><td>122.75 ± 5.54</td><td>32.75 ± 2.86</td><td>3.748*</td></tr><tr><td>2</td><td>10</td><td>4</td><td>559</td><td>69.88</td><td>122.75 ± 5.54</td><td>17.00 ± 2.06</td><td>7.221*</td></tr><tr><td>3</td><td>1.0</td><td>4</td><td>588</td><td>73.50</td><td>118.75 ± 5.45</td><td>28.25 ± 2.66</td><td>4.204*</td></tr><tr><td>4</td><td>0.1</td><td>4</td><td>526</td><td>65.75</td><td>115.00 ± 5.36</td><td>16.50 ± 2.03</td><td>6.970*</td></tr><tr><td>5</td><td>0.01</td><td>4</td><td>415</td><td>51.88</td><td>89.75 ± 4.74</td><td>14.00 ± 1.87</td><td>6.411*</td></tr><tr><td>6</td><td>0.004</td><td>4</td><td>543</td><td>67.88</td><td>118.50 ± 5.44</td><td>17.25 ± 2.08</td><td>6.870*</td></tr><tr><td>7</td><td>0.001</td><td>4</td><td>535</td><td>66.88</td><td>118.00 ± 5.43</td><td>15.75 ± 1.98</td><td>7.492*</td></tr><tr><td>8</td><td>0.0004</td><td>4</td><td>483</td><td>60.38</td><td>106.50 ± 5.16</td><td>14.25 ± 1.89</td><td>7.474*</td></tr></table>
|
d624ca78a9d1c8e4beec5cb38369dde1f6a46d03bb2f8972cc0f736e0b51397a.png
|
complex
|
<table><tr><td rowspan="3">CS Diagnostic Kit</td><td colspan="4">Microscopy</td><td colspan="4">PCR</td></tr><tr><td colspan="2"><i>P. falciparum*</i></td><td colspan="2"><i>P. vivax</i></td><td colspan="2"><i>P. falciparum*</i></td><td colspan="2">P.<i>vivax</i></td></tr><tr><td>Positive</td><td>Negative</td><td>Positive</td><td>Negative</td><td>Positive</td><td>Negative</td><td>Positive</td><td>Negative</td></tr><tr><td>Positive</td><td>54</td><td>2</td><td>59</td><td>0</td><td>56</td><td>0</td><td>59</td><td>0</td></tr><tr><td>Negative</td><td>7</td><td>113</td><td>6</td><td>115</td><td>7</td><td>113</td><td>6</td><td>113</td></tr><tr><td>Sensitivity (95% IC)%</td><td colspan="2">88.52 (78.16, 94.33)</td><td colspan="2">90.77 (81.29, 95.7)</td><td colspan="2">88.89 (78.8, 94.51)</td><td colspan="2">90.77 (81.29, 95.7)</td></tr><tr><td>Specificity (95% IC)%</td><td colspan="2">98.26 (93.88, 99.52)</td><td colspan="2">100 (96.77, 100)</td><td colspan="2">100 (96.71, 100)</td><td colspan="2">100 (96.71, 100)</td></tr><tr><td>Positive Predictive Value (95% IC)%</td><td colspan="2">96.43 (87.88, 99.02)</td><td colspan="2">100 (93.89, 100)</td><td colspan="2">100 (93.58, 100)</td><td colspan="2">100 (93.89, 100)</td></tr><tr><td>Negative Predictive Value (95% IC)%</td><td colspan="2">94.17 (88.45, 97.15)</td><td colspan="2">95.04 (89.6, 97.71)</td><td colspan="2">94.17 (88.45, 97.15)</td><td colspan="2">94.96 (89.44, 97.67)</td></tr><tr><td>Diagnostic Accuracy (95% IC)%</td><td colspan="2">94.89 (90.57, 97.29)</td><td colspan="2">96.67 (92.92, 98.46)</td><td colspan="2">96.02 (92.02, 98.06)</td><td colspan="2">96.63 (92.84, 98.45)</td></tr><tr><td>Cohen’s kappa (Unweighted)</td><td colspan="2">0.89 (0.74, 1.03)</td><td colspan="2">0.93 (0.78,1.07)</td><td colspan="2">0.91 (0.76, 1.06)</td><td colspan="2">0.93 (0.78, 1.07)</td></tr></table>
|
9987476d829ac53db1c9545cd4e77c34fbb50415d316e5e3ff1ee2931f141aa1.png
|
complex
|
<table><tr><td rowspan="2"></td><td>Resident</td><td>Fellow</td><td>Attending</td><td>Overall</td></tr><tr><td><i>N</i> = 46</td><td><i>N</i> = 36</td><td><i>N</i> = 94</td><td><i>N</i> = 176</td></tr><tr><td>Mean theory of</td><td></td><td></td><td></td><td></td></tr><tr><td>Intelligence score (SD):</td><td>3.66 (1.22)</td><td>3.40 (1.15)</td><td>3.66 (1.29)</td><td>3.64 (1.22)</td></tr><tr><td>Fixed (1–3)</td><td>20</td><td>19</td><td>45</td><td>84</td></tr><tr><td>Growth (4–6)</td><td>23</td><td>16</td><td>47</td><td>86</td></tr><tr><td>Indeterminate (3.1-3.9)</td><td>3</td><td>1</td><td>2</td><td>6</td></tr><tr><td>Median errors</td><td></td><td></td><td></td><td></td></tr><tr><td>Reported (IQR) by:</td><td></td><td></td><td></td><td></td></tr><tr><td>Self</td><td>1 (0, 2.75)</td><td>0 (0,1)</td><td>0 (0,0)</td><td>0 (0,1)</td></tr><tr><td>Others</td><td>3 (0,3)</td><td>3.5 (0,4)</td><td>1 (0,4)</td><td>2 (0,5)</td></tr></table>
|
e4bd437832fe05d5a4d815893a6f379a9ba7aaea666b61115beea1e6a970a5e4.png
|
simple
|
<table><tr><td>SNP density (k/M)</td><td>WS</td><td>BayesC</td><td>BayesD</td></tr><tr><td>0.5</td><td>0.25</td><td>0.653 (0.223)</td><td>0.639 (0.219)</td></tr><tr><td></td><td>0.5</td><td>1.050 (0.275)</td><td>1.047 (0.245)</td></tr><tr><td></td><td>1</td><td>1.779 (0.283)</td><td>1.796 (0.259)</td></tr><tr><td>1</td><td>0.25</td><td>0.525 (0.130)</td><td>0.517 (0.095)</td></tr><tr><td></td><td>0.5</td><td>0.943 (0.138)</td><td>0.943 (0.152)</td></tr><tr><td></td><td>1</td><td>1.720 (0.215)</td><td>1.744 (0.182)</td></tr><tr><td>2</td><td>0.25</td><td>0.506 (0.138)</td><td>0.467 (0.085)</td></tr><tr><td></td><td>0.5</td><td>0.930 (0.125)</td><td>0.909 (0.121)</td></tr><tr><td></td><td>1</td><td>1.746 (0.184)</td><td>1.728 (0.157)</td></tr><tr><td>7</td><td>0.25</td><td>0.468 (0.042)</td><td>0.449 (0.046)</td></tr><tr><td></td><td>0.5</td><td>0.912 (0.074)</td><td>0.906 (0.075)</td></tr><tr><td></td><td>1</td><td>1.798 (0.120))</td><td>1.802 (0.114)</td></tr></table>
|
5770e5574a5634f9f3512d897b82da5997ee6c5c1802794e7d4344492730e414.png
|
simple
|
<table><tr><td></td><td>ALL</td><td>GIST</td><td>Melanoma</td></tr><tr><td>global-median</td><td>-0.098</td><td>0.344</td><td>-0.751</td></tr><tr><td>popLowess</td><td>-0.239</td><td>0.348</td><td>-0.760</td></tr><tr><td>Chen <i>et al</i>.</td><td>-0.228</td><td>0.315</td><td>-0.508</td></tr><tr><td>CGHnormaliter</td><td>-0.204</td><td>0.304</td><td>-0.439</td></tr></table>
|
eefd013b7e67fa09bd17dbd824a133830c200d8644a524c2ff2801d6f7a21d4c.png
|
simple
|
<table><tr><td>Characteristic</td><td></td></tr><tr><td>Age, years</td><td>69.6 ± 17.0<sup>a</sup></td></tr><tr><td>Male sex, no. (%)</td><td>187 (61.9)</td></tr><tr><td>Smoking status</td><td></td></tr><tr><td> Current smoker, no. (%)</td><td>73 (24.2)</td></tr><tr><td> Pack-years for smokers</td><td>40.1 ± 24.2<sup>a</sup></td></tr><tr><td>Antibiotic pretreatment (%)</td><td>61 (20.2)</td></tr><tr><td>Coexisting illnesses, no. (%)</td><td></td></tr><tr><td> Coronary artery disease</td><td>97 (32.1)</td></tr><tr><td> Hypertensive heart disease</td><td>78 (25.8)</td></tr><tr><td> Congestive heart failure</td><td>16 (5.3)</td></tr><tr><td> Peripheral vascular disease</td><td>20 (6.6)</td></tr><tr><td> Cerebrovascular disease</td><td>16 (5.3)</td></tr><tr><td> Renal dysfunction</td><td>81 (26.8)</td></tr><tr><td> Liver disease</td><td>31 (10.3)</td></tr><tr><td> Diabetes mellitus</td><td>61 (20.2)</td></tr><tr><td> Chronic obstructive pulmonary disease</td><td>76 (25.2)</td></tr><tr><td> Neoplastic disease</td><td>48 (15.9)</td></tr><tr><td>History, no. (%)</td><td></td></tr><tr><td> Cough</td><td>270 (89.4)</td></tr><tr><td> Sputum</td><td>221 (73.2)</td></tr><tr><td> Dyspnea</td><td>229 (75.8)</td></tr><tr><td>Examination, no. (%)</td><td></td></tr><tr><td> Rales</td><td>271 (89.7)</td></tr><tr><td>Laboratory findings</td><td></td></tr><tr><td> CRP (mg/l), median (IQ range)</td><td>129.7 [65–211]</td></tr><tr><td> Procalcitonin (μg/l), median (IQ range)</td><td>0.5 [0.2–2.2]</td></tr><tr><td> Leukocyte count (× 10<sup>9</sup>)</td><td>13.6 ± 6.7<sup>a</sup></td></tr><tr><td> proADM (pmol/l), median (IQ range)</td><td>1.1 [0.6–1.9]</td></tr><tr><td>Radiographic findings, no. (%)</td><td></td></tr><tr><td> Pleural effusion</td><td>37 (12.3)</td></tr><tr><td> Multilobar CAP</td><td>53 (17.5)</td></tr><tr><td>PSI points</td><td>99.4 ± 35.3<sup>a</sup></td></tr><tr><td>PSI class, no. (%)</td><td></td></tr><tr><td> I, II and III</td><td>120 (39.7)</td></tr><tr><td> IV</td><td>130 (43)</td></tr><tr><td> V</td><td>52 (17)</td></tr></table>
|
6bffddb1f6a4efb28ddf0dae4d21d0bca91500e29580686df4e6a26820552ecd.png
|
simple
|
<table><tr><td>Plants</td><td>Root number (mean ± SE)a</td><td>Root length (cm) (mean ± SE)b</td><td>Dry root biomass (mg) (mean ± SE)b</td><td>Shoot height (cm) (mean ± SE)b</td><td>Dry shoot biomass (mg) (mean ± SE)b</td></tr><tr><td>WT</td><td>4.4 ± 0.5</td><td>28.2 ± 0.7</td><td>543.6 ± 14.6</td><td>48.0 ± 0.9</td><td>3093.4 ± 146.1</td></tr><tr><td><i>iaaM</i></td><td>13.8 ± 1.1*</td><td>24.5 ± 0.9*</td><td>345.3 ± 23.9*</td><td>46.7 ± 1.5</td><td>2969.5 ± 73.25</td></tr><tr><td><i>iaaM</i>+<i>CKX</i></td><td>14.4 ± 1.2*</td><td>33.7 ± 1.0*</td><td>688.3 ± 57.3*</td><td>47.5 ± 1.2</td><td>3157.7 ± 55.3</td></tr></table>
|
8f7cf9b46f627452da1bb4580d5d2dc9efbfb2f8e126151f2c4df749f625da45.png
|
complex
|
<table><tr><td>Gene Symbol</td><td>Gene Name</td><td>Entrez Gene ID</td><td>Fold difference DA/Cia5a</td><td>p-value*</td></tr><tr><td> </td><td colspan="4"><i>Anti-inflammatory and regulators of immune responses</i></td></tr><tr><td><i>Scd1</i></td><td>stearoyl-Coenzyme A desaturase 1</td><td>246074</td><td>54.62</td><td>0.0001</td></tr><tr><td><i>Timp3</i></td><td>TIMP metallopeptidase inhibitor 3</td><td>25358</td><td>11.48</td><td>0.000000003</td></tr><tr><td><i>Adipoq</i></td><td>adiponectin, C1Q and collagen domain containing</td><td>246253</td><td>10.96</td><td>0.000003</td></tr><tr><td><i>Ptpn11</i></td><td>protein tyrosine phosphatase, non-receptor type 11</td><td>25622</td><td>4.18</td><td>0.00002</td></tr><tr><td><i>Cyp2j3</i></td><td>cytochrome P450, family 2, subfamily j, polypeptide 3</td><td>313375</td><td>3.38</td><td>0.002</td></tr><tr><td><i>Ptgis</i></td><td>prostaglandin I2 (prostacyclin) synthase</td><td>25527</td><td>2.63</td><td>0.0003</td></tr><tr><td><i>Cat</i></td><td>catalase</td><td>24248</td><td>1.91</td><td>0.002</td></tr><tr><td><i>Gss</i></td><td>glutathione synthetase</td><td>25458</td><td>1.56</td><td>0.001</td></tr><tr><td><i>Sod1</i></td><td>superoxide dismutase 1, soluble</td><td>24786</td><td>1.53</td><td>0.00002</td></tr><tr><td> </td><td colspan="4"><i>Nuclear receptors and an interacting protein</i></td></tr><tr><td><i>Rxrg</i></td><td>retinoid X receptor gamma, Nr2b3</td><td>83574</td><td>5.39</td><td>0.0001</td></tr><tr><td><i>Pparg</i></td><td>peroxisome proliferator-activated receptor gamma, Nr1c3</td><td>25664</td><td>5.32</td><td>0.00005</td></tr><tr><td><i>Rev-erba</i></td><td>Nr1d1</td><td>252917</td><td>3.41</td><td>0.004</td></tr><tr><td><i>Arp1</i></td><td>Nr2f2</td><td>113984</td><td>2.45</td><td>0.0002</td></tr><tr><td><i>Nrip1</i></td><td>nuclear receptor interacting protein 1</td><td>304157</td><td>2.35</td><td>0.00004</td></tr><tr><td><i>Thrb</i></td><td>thyroid hormone receptor beta, Nr1a2</td><td>24831</td><td>2.07</td><td>0.002</td></tr><tr><td><i>Thra</i></td><td>thyroid hormone receptor alpha, Nr1a1</td><td>81812</td><td>1.97</td><td>0.001</td></tr><tr><td><i>Ncor1</i></td><td>nuclear receptor co-repressor 1</td><td>54299</td><td>1.89</td><td>0.003</td></tr><tr><td><i>Rora</i></td><td>RAR-related orphan receptor alpha, Nr1f1</td><td>300807</td><td>1.88</td><td>0.0001</td></tr><tr><td><i>Lxra</i></td><td>Liver X receptor alpha, Nr1h3</td><td>58852</td><td>1.52</td><td>0.0006</td></tr></table>
|
3390399d7c5ec6201ecd48d26c81c5ad19e12b78f63765ffb2015ccf61656d90.png
|
simple
|
<table><tr><td>Variable</td><td>Frequency</td><td>Median (IQR) or percentage</td></tr><tr><td><i>Age in years</i></td><td>740</td><td>35 [27–42]</td></tr><tr><td><i>Age group</i></td><td> </td><td> </td></tr><tr><td> ≥45 years</td><td>156</td><td>21.1</td></tr><tr><td> <45 years</td><td>584</td><td>78.9</td></tr><tr><td><i>Sex</i></td><td> </td><td> </td></tr><tr><td> Male</td><td>275</td><td>37.2</td></tr><tr><td> Female</td><td>465</td><td>62.8</td></tr><tr><td><i>Marital status</i></td><td> </td><td> </td></tr><tr><td> Married</td><td>278</td><td>37.6</td></tr><tr><td> Divorced</td><td>160</td><td>21.6</td></tr><tr><td> Widow</td><td>154</td><td>20.8</td></tr><tr><td> Single</td><td>51</td><td>6.9</td></tr><tr><td><i>WHO stage</i></td><td> </td><td> </td></tr><tr><td> 3 & 4</td><td>261</td><td>35.3</td></tr><tr><td> 1 & 2</td><td>479</td><td>64.7</td></tr><tr><td><i>Baseline CD4 (cell/μl)</i></td><td>740</td><td>256 [132–469]</td></tr><tr><td><i>Baseline CD4 group</i></td><td> </td><td> </td></tr><tr><td> ≤200 cell/<i>μ</i>l</td><td>258</td><td>34.9</td></tr><tr><td> >200 cell/<i>μ</i>l</td><td>482</td><td>65.1</td></tr><tr><td><i>Hemoglobin (g/dL)</i></td><td>740</td><td>11.4 [9.7–13.1]</td></tr><tr><td>Normal HB</td><td>452</td><td>61.1</td></tr><tr><td>Anemia total</td><td>288</td><td>38.9</td></tr><tr><td> Mild anemia</td><td>147</td><td>19.9</td></tr><tr><td> Moderate anemia</td><td>88</td><td>11.9</td></tr><tr><td> Severe anemia</td><td>53</td><td>7.2</td></tr><tr><td><i>OI on diagnosis</i></td><td> </td><td> </td></tr><tr><td> Tuberculosis</td><td>197</td><td>26.6</td></tr><tr><td> Others</td><td>543</td><td>73.4</td></tr><tr><td><i>Outcome on ART</i></td><td> </td><td> </td></tr><tr><td> Median time (Mo)</td><td>740</td><td>27 [17–37]</td></tr><tr><td> Dead</td><td>86</td><td>11.6</td></tr><tr><td> Alive</td><td>654</td><td>88.4</td></tr></table>
|
7a8840cf47e0cf61ab2a0eaeb9dc8b42564905d198bd7406f5cfbd38e7a4b561.png
|
complex
|
<table><tr><td>Strain</td><td colspan="3">AltDE</td><td colspan="3">AltDE1</td></tr><tr><td>Total genes in the genome</td><td colspan="3">4389</td><td colspan="3">4748</td></tr><tr><td>Total core genes in the genome (%)<sup>a</sup></td><td colspan="3">3631 (83)</td><td colspan="3">3631 (76)</td></tr><tr><td>Total flexible genes in the genome (%)<sup>a</sup></td><td colspan="3">758 (17)</td><td colspan="3">1117 (24)</td></tr><tr><td>Comparison</td><td>Temperature (13-25°C)</td><td>Media (RM-MMG)</td><td>Media (MMG-STR)</td><td>Temperature (13-25°C)</td><td>Media (RM-MMG)</td><td>Media (MMG-STR)</td></tr><tr><td>Total genes differentially expressed (%)<sup>a</sup></td><td>985 (22)</td><td>1037 (24)</td><td>1627 (37)</td><td>1026 (22)</td><td>1362 (29)</td><td>2771 (58)</td></tr><tr><td>Total core genes differentially expressed (%)<sup>b</sup></td><td>763 (21)</td><td>809 (22)</td><td>1286 (35)</td><td>684 (19)</td><td>978 (27)</td><td>2143 (59)</td></tr><tr><td>Contribution of core genes to total genes differentially expressed</td><td>77%</td><td>78%</td><td>79%</td><td>67%</td><td>72%</td><td>77%</td></tr><tr><td>Total flexible genes differentially expressed (%)<sup>c</sup></td><td>222 (29)</td><td>230 (30)</td><td>342 (45)</td><td>342 (30)</td><td>384 (34)</td><td>629 (56)</td></tr><tr><td>Contribution of flexible genes to total genes differentially expressed</td><td>23%</td><td>22%</td><td>21%</td><td>33%</td><td>28%</td><td>23%</td></tr></table>
|
1d42ade7b14fd7ff1005057a6958852077c595c3cbb5ca84ec2f1e7855f2d9f2.png
|
simple
|
<table><tr><td>Method</td><td>Specificity</td><td>Recall</td><td>Precision</td><td>F1</td><td>ΔF1</td></tr><tr><td>Robetta</td><td>0.87</td><td>0.33</td><td>0.52</td><td>0.40</td><td>**</td></tr><tr><td>FOLDEF</td><td>0.88</td><td>0.26</td><td>0.48</td><td>0.34</td><td>-0.06</td></tr><tr><td>KFC</td><td>0.85</td><td>0.31</td><td>0.48</td><td>0.37</td><td>-0.03</td></tr><tr><td>MINERVA</td><td>0.90</td><td>0.44</td><td>0.65</td><td>0.52</td><td>+0.12</td></tr><tr><td>APIS (this work)</td><td>0.76</td><td>0.72</td><td>0.57</td><td>0.64</td><td>+0.24</td></tr></table>
|
bf24bd850b958bc10b1e912df47d8ac0fda8e7418e73a77a0a13bcfd0f1c97c9.png
|
simple
|
<table><tr><td>Food (utensil)</td><td>Accuracy</td></tr><tr><td>Meat (fork and knife)</td><td>127%</td></tr><tr><td>Sides (fork)</td><td>82.6%</td></tr><tr><td>Soup (spoon)</td><td>60.2%</td></tr><tr><td>Pizza (hands)</td><td>87.3%</td></tr><tr><td>Soda (hands)</td><td>81.7%</td></tr><tr><td>Smoothie (straw)</td><td>57.7%</td></tr><tr><td>Total</td><td>81.2%</td></tr></table>
|
780c0f74f2b73ff131db54b51a25fcdd60865a18462de763642705814cb286d1.png
|
simple
|
<table><tr><td></td><td>Unst. est.</td><td>SE</td><td>St. est.</td><td>CR</td></tr><tr><td>Harsh discipline</td><td></td><td></td><td></td><td></td></tr><tr><td> Physical discipline</td><td>1.37</td><td>0.30</td><td>.82</td><td>4.63***</td></tr><tr><td> Emotional discipline</td><td>1.00</td><td>-</td><td>.70</td><td>-</td></tr><tr><td>Internalizing problems</td><td></td><td></td><td></td><td></td></tr><tr><td> Harsh discipline</td><td>1.45</td><td>0.33</td><td>.50</td><td>4.35***</td></tr><tr><td> Emotional symptoms (SDQ)</td><td>1.00</td><td>-</td><td>.62</td><td>-</td></tr><tr><td> Peer problems (SDQ)</td><td>0.52</td><td>0.09</td><td>.45</td><td>5.64***</td></tr><tr><td> Depressive symptoms (CDI)</td><td>1.91</td><td>0.32</td><td>.61</td><td>5.99***</td></tr><tr><td>Working memory</td><td></td><td></td><td></td><td></td></tr><tr><td> Harsh discipline</td><td>−2.23</td><td>2.19</td><td>-.08</td><td>−1.02</td></tr><tr><td> Block-Tapping test forward</td><td>1.00</td><td>-</td><td>.83</td><td>-</td></tr><tr><td> Block-Tapping test backward</td><td>0.92</td><td>0.20</td><td>.71</td><td>4.59***</td></tr><tr><td>School performance</td><td></td><td></td><td></td><td></td></tr><tr><td> Harsh discipline</td><td>−0.01</td><td>0.09</td><td>-.01</td><td>−0.12</td></tr><tr><td> Working memory</td><td>0.01</td><td>0.03</td><td>.31</td><td>3.80***</td></tr><tr><td> School grades English</td><td>1.22</td><td>0.11</td><td>.74</td><td>10.97***</td></tr><tr><td> School grades Mathematics</td><td>1.14</td><td>0.11</td><td>.70</td><td>10.56***</td></tr><tr><td> School grades Swahili</td><td>1.00</td><td>-</td><td>.61</td><td>-</td></tr><tr><td> School grades Science</td><td>1.35</td><td>0.12</td><td>.83</td><td>11.51***</td></tr></table>
|
91326b9116c5cc09fa811f8c7d2ae9389b954a8f93e81ad2b9165ff623cc9567.png
|
simple
|
<table><tr><td>Factor</td><td>Chi-square</td><td>Significance</td></tr><tr><td>Female sex</td><td>255.97</td><td><i>p.</i> < 0.01</td></tr><tr><td>Family history of osteoporosis</td><td>3.11</td><td><i>p.</i> < 0.01</td></tr><tr><td>Previous fracture</td><td>1.51</td><td><i>p.</i> < 0.01</td></tr><tr><td>Underweight</td><td>20.04</td><td><i>p.</i> < 0.01</td></tr><tr><td>Steroids</td><td>7.21</td><td><i>p.</i> < 0.05</td></tr><tr><td>Rheumatoid Arthritis</td><td>2.86</td><td>ns</td></tr><tr><td>Nephrolithiasis*</td><td>3.00</td><td>ns</td></tr><tr><td>Thyroid*</td><td>3.85</td><td>ns</td></tr><tr><td>Early menopause</td><td>47.36</td><td><i>p.</i> < 0.01</td></tr><tr><td>Amenorrhea > 12 months</td><td>0.15</td><td>ns</td></tr><tr><td>Ovariectomy by age 50</td><td>44.61</td><td><i>p.</i> < 0.01</td></tr><tr><td>Alcohol consumption</td><td>0.11</td><td>ns</td></tr><tr><td>Smoking habit</td><td>6.18</td><td><i>p.</i> < 0.05</td></tr><tr><td>Exercise < 30 min/day</td><td>0.17</td><td>ns</td></tr><tr><td>Avoiding dairy products</td><td>10.50</td><td><i>p.</i> < 0.01</td></tr><tr><td>Exposure to sunlight</td><td>8.85</td><td><i>p.</i> < 0.05</td></tr><tr><td>Crohn disease*</td><td>0.74</td><td>ns</td></tr><tr><td>Celiac disease*</td><td>0.31</td><td>ns</td></tr><tr><td>Rectocolitis ulcerosa*</td><td>0.40</td><td>ns</td></tr><tr><td>Secondary osteoporosis*</td><td>15.20</td><td><i>p.</i> < 0.01</td></tr></table>
|
379b5f94db1c31e0fa8be5d4d091f227d48b9b4b9c09b98ac8ddc84702d54d78.png
|
simple
|
<table><tr><td></td><td>Telencephalon</td><td>Opctic tecta</td><td>Cerebellum</td><td>Medulla</td><td>Hypothalamus</td></tr><tr><td>Olfactory bulbs</td><td>1.06</td><td>1.02</td><td>1.23</td><td>1.15</td><td>1.04</td></tr><tr><td>Telencephalon</td><td></td><td>0.96</td><td>1.16</td><td>1.08</td><td>0.98</td></tr><tr><td>Optic tecta</td><td></td><td></td><td>1.21</td><td>1.13</td><td>1.03</td></tr><tr><td>Cerebellum</td><td></td><td></td><td></td><td>0.93</td><td>0.85</td></tr><tr><td>Medulla</td><td></td><td></td><td></td><td></td><td>0.91</td></tr></table>
|
021e1dc7b113b15d59fe03c49b03d16cc4f0962e0480874cc3fe5859518b914b.png
|
simple
|
<table><tr><td>Hospital characteristic</td><td>All hospitals (<i>n </i>= 51)</td><td>Score 0 to 6 (<i>n </i>= 17)</td><td>Score 7 to 8 (<i>n </i>= 9)</td><td>Score 9 to 14 (<i>n </i>= 16)</td><td>Score 15 to 19 (<i>n </i>= 9)</td></tr><tr><td>Number of hospital beds</td><td>107 (44 to 198)</td><td>33 (21 to 69)</td><td>143 (101 to 198)</td><td>122 (96 to 122)</td><td>250 (156 to 315)</td></tr><tr><td>Number of hospital days 2009</td><td>31,011 (6,974 to 59,696)</td><td>5,979 (4,061 to 14,265)</td><td>33,964 (19,612 to 54,391)</td><td>34,828 (24,480 to 48,239)</td><td>79,759 (34,446 to 108,542)</td></tr><tr><td>Number of ICU beds</td><td>16 (6 to 31)</td><td>6 (4 to 9)</td><td>16 (15 to 20)</td><td>20 (10 to 31)</td><td>38 (27 to 80)</td></tr><tr><td>Number of ICU days 2009</td><td>3,772 (1,284 to 8,603)</td><td>1,200 (630 to 3,772)</td><td>3,759 (3,224 to 4,784)</td><td>5,678 (2,588 to 9,040)</td><td>18,623 (8,219 to 31,715)</td></tr><tr><td>Part of a larger hospital network</td><td>25 (49.0)</td><td>4 (23.5)</td><td>2 (22.2)</td><td>10 (62.5)</td><td>9 (100)</td></tr><tr><td>Critical access hospital</td><td>8 (15.7)</td><td>7 (41.2)</td><td>0 (0)</td><td>1 (6.3)</td><td>0 (0)</td></tr><tr><td>Private, not-for-profit hospital</td><td>30 (58.8)</td><td>7 (41.2)</td><td>4 (44.4)</td><td>13 (81.2)</td><td>6 (66.7)</td></tr><tr><td>Public, not-for-profit hospital</td><td>17 (33.3)</td><td>10 (58.8)</td><td>2 (22.2)</td><td>3 (18.8)</td><td>2 (22.2)</td></tr><tr><td>Private, for-profit hospital</td><td>4 (7.8)</td><td>0 (0)</td><td>3 (33.3)</td><td>0 (0)</td><td>1 (11.1)</td></tr><tr><td>Number of ICUs</td><td>1 (1 to 1)</td><td>1 (1 to 1)</td><td>1 (1 to 1)</td><td>1 (1 to 1)</td><td>2 (2 to 2)</td></tr><tr><td>Teaching ICU</td><td>16 (31.4)</td><td>2 (11.8)</td><td>3 (33.3)</td><td>4 (25.0)</td><td>7 (77.8)</td></tr><tr><td>Open ICU</td><td>46 (90.2)</td><td>17 (100)</td><td>8 (88.9)</td><td>15 (93.8)</td><td>6 (66.7)</td></tr><tr><td>Computerized provider order entry</td><td>12 (23.5)</td><td>2 (11.8)</td><td>2 (22.2)</td><td>2 (12.5)</td><td>6 (66.7)</td></tr></table>
|
274693e8292470571eb9ff81a07016f9efe368298038c365563b5d9d7678154f.png
|
simple
|
<table><tr><td>Variable</td><td>Odds ratio</td><td>95% confidence interval</td></tr><tr><td><i>Sex</i></td><td></td><td></td></tr><tr><td> Male</td><td>1.00</td><td>—</td></tr><tr><td> Female</td><td>2.93</td><td>1.29–6.67</td></tr><tr><td><i>Posttest HIV counselling</i></td><td></td><td></td></tr><tr><td> No</td><td>1.00</td><td>—</td></tr><tr><td> Yes</td><td>2.96</td><td>1.22–7.19</td></tr><tr><td><i>Used contraception to prevent risk of transmission of HIV to partner</i></td><td></td><td></td></tr><tr><td> No</td><td>1.00</td><td>—</td></tr><tr><td> Yes</td><td>2.30</td><td>1.01–5.20</td></tr><tr><td><i>Used contraception due to partner's preference</i></td><td></td><td></td></tr><tr><td> No</td><td>1.00</td><td>—</td></tr><tr><td> Yes</td><td>2.76</td><td>1.08–7.06</td></tr><tr><td>Last CD4 cell count (per increase of 50 cells/mL)</td><td>0.73</td><td>0.62–0.87</td></tr></table>
|
ab4e0e0c343521e66246bd69fce50adf92589cb63346ff41777be84c42187d04.png
|
complex
|
<table><tr><td></td><td colspan="2">European Americans</td><td colspan="2">African Americans</td><td colspan="2">Mexican Americans</td></tr><tr><td></td><td>With noise (%)</td><td>Denoised (%)</td><td>With noise (%)</td><td>Denoised (%)</td><td>With noise (%)</td><td>Denoised (%)</td></tr><tr><td>Europe</td><td>100</td><td>100</td><td>97</td><td>94</td><td>100</td><td>98</td></tr><tr><td>Africa</td><td>1</td><td>0</td><td>99</td><td>99</td><td>91</td><td>80</td></tr><tr><td>America</td><td>29</td><td>7</td><td>32</td><td>10</td><td>100</td><td>100</td></tr><tr><td>East Asia</td><td>1</td><td>0</td><td>20</td><td>4</td><td>76</td><td>27</td></tr><tr><td>Oceania</td><td>6</td><td>0</td><td>10</td><td>3</td><td>18</td><td>0</td></tr><tr><td>Central Asia</td><td>11</td><td>1</td><td>30</td><td>3</td><td>38</td><td>7</td></tr></table>
|
c7187518d558522f9053148df4a8cd6169f5d304b0552ed0edff872fc6c2bba0.png
|
simple
|
<table><tr><td></td><td>MM mean (SD)</td><td>PA mean (SD)</td><td>Comparison mean (SD)</td><td>Statistics</td><td>Paired Comparisons*</td></tr><tr><td>MANCOVA</td><td></td><td></td><td></td><td>Multivariate Test: Wilk's λ (6, 110) = .754; <i>p </i>< 0.015</td><td></td></tr><tr><td>Composite MCMI</td><td>385.22 (136.66)</td><td>395.68 (123.02)</td><td>243.74 (63.96)</td><td>Univariate F = 5.11, df = 2, <i>p </i>< 0.009</td><td>A, B</td></tr><tr><td>Cluster A</td><td>67.89 (32.27)</td><td>71.41 (33.85)</td><td>39.52 (18.9)</td><td>Univariate F = 2.58, df = 2, <i>p </i>= 0.084</td><td></td></tr><tr><td>Cluster B</td><td>179.39 (63.7)</td><td>187.78 (55.64)</td><td>116.43 (33.42)</td><td>Univariate F = 6.19, df = 2, <i>p </i>= 0.004</td><td>A, B</td></tr><tr><td>Cluster C</td><td>137.94 (45.94)</td><td>136.50 (40.16)</td><td>87.78 (21.75)</td><td>Univariate F = 4.28, df = 2, <i>p </i>= 0.019</td><td>A, B</td></tr></table>
|
66c9690286fe97cca05cbd19ced191fe94b571a3eceec8f176a99566273cd442.png
|
simple
|
<table><tr><td><i>f</i></td><td>1/2</td><td>5/8</td><td>3/4</td><td>7/8</td><td>1</td></tr><tr><td>model A: simple</td><td>69</td><td>59</td><td>47</td><td>32</td><td>16</td></tr><tr><td>model B: treated class</td><td>62</td><td>53</td><td>42</td><td>31</td><td>19</td></tr><tr><td>model C: day care</td><td>80</td><td>73</td><td>62</td><td>43</td><td>20</td></tr><tr><td>model E: dual transmission</td><td>79</td><td>71</td><td>61</td><td>47</td><td>29</td></tr></table>
|
88bad5d44aee0a8df05b0af63ed0996cd12a4e9afdf78244061a4a2e217c8e89.png
|
simple
|
<table><tr><td></td><td>WT-NFD</td><td><i>Pr2x<sub>7</sub></i><sup>−/−</sup>-NFD</td><td>WT-HFD</td><td><i>Pr2x<sub>7</sub></i><sup>−/−</sup>-HFD</td></tr><tr><td>Body weight, g</td><td>31.8 ± 2.3</td><td>32.6 ± 1.9</td><td>41.2 ± 5.5<sup>∗</sup></td><td>40.6 ± 1.5<sup>∗</sup></td></tr><tr><td>Glucose, mmol·l<sup>−1</sup></td><td>5.56 ± 0.88</td><td>5.63 ± 0.73</td><td>9.01 ± 0.71<sup>∗</sup></td><td>8.85 ± 1.08<sup>∗</sup></td></tr><tr><td>Insulin, pmol·l<sup>−1</sup></td><td>63.9 ± 18.7</td><td>58.3 ± 11.5</td><td>158.1 ± 18.1<sup>∗</sup></td><td>151.9 ± 19.1<sup>∗</sup></td></tr><tr><td>HOMA-IR</td><td>2.21 ± 0.79</td><td>2.05 ± 0.56</td><td>8.84 ± 1.32<sup>∗</sup></td><td>8.38 ± 1.86<sup>∗</sup></td></tr><tr><td>Cholesterol, mmol·l<sup>−1</sup></td><td>2.64 ± 0.31</td><td>2.62 ± 0.54</td><td>3.93 ± 0.62<sup>∗</sup></td><td>3.82 ± 0.31<sup>∗</sup></td></tr><tr><td>Triglycerides, mmol·l<sup>−1</sup></td><td>0.56 ± 0.21</td><td>0.57 ± 0.17</td><td>1.78 ± 0.52<sup>∗</sup></td><td>1.42 ± 0.29<sup>∗</sup></td></tr><tr><td>FFA, mEq·l<sup>−1</sup></td><td>0.33 ± 0.05</td><td>0.31 ± 0.06</td><td>0.95 ± 0.11<sup>∗</sup></td><td>0.83 ± 0.09<sup>∗</sup></td></tr><tr><td>AST, UI·l<sup>−1</sup></td><td>33.6 ± 5.6</td><td>31.3 ± 4.6</td><td>87.1 ± 12.3<sup>∗</sup></td><td>55.9 ± 7.1<sup>∗</sup><sup>†</sup></td></tr><tr><td>ALT, UI·l<sup>−1</sup></td><td>22.6 ± 7.2</td><td>18.6 ± 3.6</td><td>111.4 ± 18.4<sup>∗</sup></td><td>58.3 ± 15.7<sup>∗</sup><sup>†</sup></td></tr></table>
|
218257c7644cc4f82fe59d7c5c9805240909be14fcc798798c6afc935146254d.png
|
complex
|
<table><tr><td>Treatment</td><td>Dose (mg/kg)</td><td colspan="9">Reversibility study</td></tr><tr><td> </td><td> </td><td>Liver</td><td>Kidney</td><td>Lungs</td><td>Heart</td><td>Testes</td><td>Spleen</td><td>Pancreas</td><td>Brain</td><td>Ovaries</td></tr><tr><td>Distilled water</td><td>(10 ml/kg)</td><td>2.60 ± 0.11</td><td>0.57 ± 0.01</td><td>0.73 ± 0.06</td><td>0.36 ± 0.02</td><td>1.39 ± 0.13</td><td>0.29 ± 0.01</td><td>0.25 ± 0.03</td><td>0.78 ± 0.03</td><td>0.12 ± 0.00</td></tr><tr><td>DAS-77</td><td>80</td><td>2.53 ± 0.12</td><td>0.55 ± 0.03</td><td>0.68 ± 0.03</td><td>0.35 ± 0.02</td><td>1.21 ± 0.05</td><td>0.25 ± 0.01</td><td>0.24 ± 0.02</td><td>0.82 ± 0.04</td><td>0.10 ± 0.01</td></tr><tr><td>DAS-77</td><td>400</td><td>2.74 ± 0.12</td><td>0.62 ± 0.01</td><td>0.88 ± 0.0<sup>*</sup></td><td>0.42 ± 0.03</td><td>0.95 ± 0.27</td><td>0.25 ± 0.01</td><td>0.26 ± 0.02</td><td>0.71 ± 0.04</td><td>0.12 ± 0.01</td></tr><tr><td>DAS-77</td><td>2000</td><td>2.79 ± 0.10</td><td>0.63 ± 0.05</td><td>0.83 ± 0.02</td><td>0.38 ± 0.03</td><td>1.35 ± 0.28</td><td>0.27 ± 0.02</td><td>0.34 ± 0.02</td><td>0.82 ± 0.04</td><td>0.14 ± 0.01</td></tr></table>
|
64f21d32d774243c1f2b72d529b76b6dc3e98afe4369ae310c2021e3a3d8ff41.png
|
simple
|
<table><tr><td></td><td>Baseline</td><td>Week 12</td><td>Percentage change (%)#</td><td>Baseline vs. week 12 p-value</td></tr><tr><td>hsCRP [mg/dL]</td><td></td><td></td><td></td><td></td></tr><tr><td>PTV</td><td>0.17 ± 0.2</td><td>0.14 ± 0.21</td><td>−28.6 ± 157.4</td><td>0.08</td></tr><tr><td>ATV</td><td>0.33 ± 1.1</td><td>0.19 ± 0.38</td><td>−10.8 ± 124.9</td><td>0.38</td></tr><tr><td>CPK [U/L]</td><td></td><td></td><td></td><td></td></tr><tr><td>PTV</td><td>125.4 ± 64.6</td><td>153.2 ± 252.7</td><td>22.3 ± 140.6</td><td>0.13</td></tr><tr><td>ATV</td><td>130.9 ± 81.1</td><td>142.7 ± 90.8</td><td>17.8 ± 45.8</td><td>0.0001</td></tr><tr><td>AST [U/L]</td><td></td><td></td><td></td><td></td></tr><tr><td>PTV</td><td>27.5 ± 10.7</td><td>28.3 ± 13.6</td><td>5.9 ± 29.3</td><td>0.05</td></tr><tr><td>ATV</td><td>26.8 ± 7.1</td><td>27.4 ± 8.5</td><td>4.5 ± 24.9</td><td>0.07</td></tr><tr><td>ALT [U/L]</td><td></td><td></td><td></td><td></td></tr><tr><td>PTV</td><td>31.5 ± 17.9</td><td>32.1 ± 19.5</td><td>6.7 ± 33.8</td><td>0.06</td></tr><tr><td>ATV</td><td>30.6 ± 15.1</td><td>31.1 ± 14.3</td><td>10.5 ± 39.9</td><td>0.008</td></tr><tr><td>Gamma GT [U/L]</td><td></td><td></td><td></td><td></td></tr><tr><td>PTV</td><td>37.6 ± 37</td><td>34.8 ± 25.6</td><td>−5.6 ± 29.9</td><td>0.07</td></tr><tr><td>ATV</td><td>36.8 ± 27.5</td><td>37. ± 27.1</td><td>6.2 ± 32.3</td><td>0.05</td></tr><tr><td>Total bilirubin [mg/dL]**</td><td></td><td></td><td></td><td></td></tr><tr><td>PTV</td><td>0.8 ± 0.3</td><td>0.7 ± 0.3</td><td>−0.9 ± 31.8</td><td>0.77</td></tr><tr><td>ATV</td><td>0.8 ± 0.3</td><td>0.9 ± 0.4</td><td>14.0 ± 43.0</td><td>0.001</td></tr><tr><td>BUN [mg/dL]</td><td></td><td></td><td></td><td></td></tr><tr><td>PTV</td><td>15.7 ± 3.6</td><td>16.4 ± 4.0</td><td>5.2 ± 22.0</td><td>0.02</td></tr><tr><td>ATV</td><td>15.7 ± 3.9</td><td>16.1 ± 4.5</td><td>4.2 ± 19.8</td><td>0.03</td></tr><tr><td>Serum creatinine [mg/dL]</td><td></td><td></td><td></td><td></td></tr><tr><td>PTV</td><td>0.8 ± 0.2</td><td>0.8 ± 0.2</td><td>−1.2 ± 9.9</td><td>0.24</td></tr><tr><td>ATV</td><td>0.8 ± 0.2</td><td>0.8 ± 0.2</td><td>−0.7 ± 10.7</td><td>0.54</td></tr><tr><td>LDH [U/L]</td><td></td><td></td><td></td><td></td></tr><tr><td>PTV</td><td>192.0 ± 31.7</td><td>189.7 ± 33.8</td><td>−0.3 ± 14.6</td><td>0.84</td></tr><tr><td>ATV</td><td>193.8 ± 38.4</td><td>195.3 ± 47.7</td><td>1.3 ± 17.9</td><td>0.45</td></tr></table>
|
e3638c1cc3311358c2d4390f6a29d13d4e9b72a6c9b474024e8c1f3b1d01ffa6.png
|
complex
|
<table><tr><td rowspan="2">Variables</td><td colspan="3">PITC acceptance status</td></tr><tr><td>Yes (%)</td><td>No (%)</td><td>Total (%)</td></tr><tr><td colspan="4"><i>Age</i></td></tr><tr><td>≤19</td><td>85 (81.7)</td><td>19 (18.3)</td><td>104 (26.9)</td></tr><tr><td>20–29</td><td>181 (81.9)</td><td>40 (18.1)</td><td>221 (57.3)</td></tr><tr><td>30–45</td><td>46 (75.4)</td><td>15 (24.6)</td><td>61 (15.8)</td></tr><tr><td colspan="4"><i>Residence</i></td></tr><tr><td>Urban</td><td>235 (78.9)</td><td>63 (21.1)</td><td>298 (74.6)</td></tr><tr><td>Rural</td><td>77 (87.5)</td><td>11 (12.5)</td><td>88 (25.4)</td></tr><tr><td colspan="4"><i>Religion</i></td></tr><tr><td>Orthodox christians</td><td>130 (78.8)</td><td>35 (21.2)</td><td>165 (42.7)</td></tr><tr><td>Muslim</td><td>137 (82.0)</td><td>30 (18.0)</td><td>167 (43.3)</td></tr><tr><td>Protestant</td><td>40 (81.6)</td><td>9 (18.4)</td><td>49 (12.7)</td></tr><tr><td>Catholic</td><td>5 (100)</td><td>0 (0.0)</td><td>5 (1.3)</td></tr><tr><td colspan="4"><i>Ethnicity</i></td></tr><tr><td>Berta</td><td>78 (87.6)</td><td>11 (12.4)</td><td>89 (23.1)</td></tr><tr><td>Amhara</td><td>133 (76.0)</td><td>42 (24.0)</td><td>175 (45.3)</td></tr><tr><td>Oromo</td><td>53 (81.5)</td><td>12 (18.5)</td><td>65 (16.8)</td></tr><tr><td>Others<sup>a</sup></td><td>48 (84.2)</td><td>9 (15.8)</td><td>57 (14.7)</td></tr><tr><td colspan="4"><i>Educational status</i></td></tr><tr><td>Not able to read and write</td><td>37 (78.7)</td><td>10 (21.3)</td><td>47 (12. 2)</td></tr><tr><td>Able to read and write</td><td>31 (77.5)</td><td>9 (22.5)</td><td>40 (10.4)</td></tr><tr><td>Grade 1–8</td><td>70 (79.5)</td><td>18 (20.5)</td><td>88 (22.8)</td></tr><tr><td>Grade 9–12</td><td>72 (76.6)</td><td>22 (23.4)</td><td>94 (24.4)</td></tr><tr><td>Above 12</td><td>102 (87.2)</td><td>15 (12.8)</td><td>117 (30.3)</td></tr><tr><td colspan="4"><i>Occupation</i></td></tr><tr><td>Merchant</td><td>29 (90.6)</td><td>3 (9.4)</td><td>32 (8.3)</td></tr><tr><td>Farmer</td><td>49 (84.5)</td><td>9 (15.5)</td><td>58 (15.0)</td></tr><tr><td>Employed<sup>b</sup></td><td>105 (85.4)</td><td>18 (14.6)</td><td>123 (31.9)</td></tr><tr><td>Student</td><td>25 (89.3)</td><td>3 (10.7)</td><td>28 (7.3)</td></tr><tr><td>Housewife</td><td>104 (71.7)</td><td>41 (28.3)</td><td>145 (37.6)</td></tr><tr><td colspan="4"><i>Marital status</i></td></tr><tr><td>Unmarried</td><td>8 (66.7)</td><td>4 (33.3)</td><td>12 (3.1)</td></tr><tr><td>Married/living together</td><td>303 (83.2)</td><td>68 (16.8)</td><td>364 (96.1)</td></tr><tr><td>Divorced</td><td>1 (33.3)</td><td>2 (66.7)</td><td>3 (0.8)</td></tr><tr><td colspan="4"><i>Household expenditur</i> (Birr/month)</td></tr><tr><td>No response</td><td>78 (81.2)</td><td>18 (18.8)</td><td>96 (24.9)</td></tr><tr><td><1000</td><td>70 (83.7)</td><td>24 (16.3)</td><td>94 (24.4)</td></tr><tr><td>≥1000</td><td>164 (74.5)</td><td>32 (24.4)</td><td>196 (50.8)</td></tr></table>
|
4a7a4b94daf7d1ae874dfbe928d8199d1969ada52ebaf0368494d9794069908a.png
|
simple
|
<table><tr><td>Week</td><td>Direct heritability</td><td>Indirect heritability</td><td>Total heritability</td></tr><tr><td>1</td><td>0.17 (0.03)</td><td>0.44 (0.13)</td><td>0.19 (0.10)</td></tr><tr><td>2</td><td>0.24 (0.03)</td><td>0.23 (0.07)</td><td>0.09 (0.06)</td></tr><tr><td>3</td><td>0.22 (0.02)</td><td>0.18 (0.06)</td><td>0.05 (0.04)</td></tr><tr><td>4</td><td>0.15 (0.02)</td><td>0.16 (0.06)</td><td>0.06 (0.04)</td></tr><tr><td>5</td><td>0.08 (0.02)</td><td>0.18 (0.11)</td><td>0.12 (0.10)</td></tr></table>
|
bda3d96d1ee86f0be6de2a803ba7cc883404a299cae1701e1aef27ebc326f7c6.png
|
complex
|
<table><tr><td rowspan="2">Principle parameter</td><td> </td><td colspan="3">EACM</td><td colspan="3">EAC</td></tr><tr><td> </td><td>Case number</td><td>Eradication rate (%)</td><td><i>P</i> value</td><td>Case number</td><td>Eradication rate (%)</td><td><i>P</i> value</td></tr><tr><td rowspan="2">Age</td><td><60 years</td><td>75/78</td><td>96.1</td><td rowspan="2">0.578</td><td>52/64</td><td>81.2</td><td rowspan="2">0.496</td></tr><tr><td>≥60 years</td><td>13/14</td><td>92.8</td><td>21/28</td><td>75.0</td></tr><tr><td rowspan="2">Sex</td><td>Female</td><td>44/47</td><td>93.6</td><td rowspan="2">0.328</td><td>33/46</td><td>71.1</td><td rowspan="2">0.071</td></tr><tr><td>Male</td><td>44/45</td><td>97.8</td><td>40/46</td><td>86.9</td></tr><tr><td rowspan="2">Smoking</td><td>(−)</td><td>74/78</td><td>94.9</td><td rowspan="2">0.386</td><td>61/78</td><td>78.2</td><td rowspan="2">0.523</td></tr><tr><td>(+)</td><td>14/14</td><td>100.0</td><td>12/14</td><td>85.7</td></tr><tr><td rowspan="2">Alcohol consumption</td><td>(−)</td><td>69/72</td><td>95.8</td><td rowspan="2">0.872</td><td>61/78</td><td>78.2</td><td rowspan="2">0.523</td></tr><tr><td>(+)</td><td>19/20</td><td>95.0</td><td>12/14</td><td>85.7</td></tr><tr><td rowspan="2">Previous history of peptic ulcer </td><td>(−)</td><td>74/78</td><td>94.9</td><td rowspan="2">0.386</td><td>57/73</td><td>78.1</td><td rowspan="2">0.557</td></tr><tr><td>(+)</td><td>14/14</td><td>100.0</td><td>16/19</td><td>84.2</td></tr><tr><td rowspan="2">Compliance</td><td>Good</td><td>92/92</td><td>100.0</td><td rowspan="2">—</td><td>92/92</td><td>100.0</td><td rowspan="2">—</td></tr><tr><td>Poor</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td colspan="8"><i>H. pylori</i> culture (<i>n</i> = 68)</td></tr><tr><td rowspan="2">Amoxicillin</td><td>Susceptible</td><td>31/34</td><td>91.2</td><td rowspan="2">—</td><td>15/33</td><td>45.4</td><td rowspan="2">0.367</td></tr><tr><td>Resistance</td><td>0</td><td>—</td><td>0/1</td><td>0</td></tr><tr><td rowspan="2">Clarithromycin </td><td>Susceptible</td><td>29/30</td><td>96.7</td><td rowspan="2">0.002</td><td>15/15</td><td>100</td><td rowspan="2"><0.001</td></tr><tr><td>Resistance</td><td>2/4</td><td>50.0</td><td>0/19</td><td>0</td></tr><tr><td rowspan="2">Metronidazole</td><td>Susceptible</td><td>23/23</td><td>100</td><td rowspan="2">0.009</td><td>11/24</td><td>45.8</td><td rowspan="2">0.755</td></tr><tr><td>Resistance</td><td>8/11</td><td>72.7</td><td>4/10</td><td>40.0</td></tr><tr><td rowspan="2">Dual resistance</td><td>Absent </td><td>30/31</td><td>96.8</td><td rowspan="2"><0.001</td><td>15/28</td><td>53.6</td><td rowspan="2"><0.001</td></tr><tr><td>Present</td><td>1/3</td><td>33.3</td><td>0/6</td><td>0</td></tr></table>
|
dcabe4a54b77db44dd88712608d1a79410d4c0d427738621d39909f677241d59.png
|
simple
|
<table><tr><td>Amino acid</td><td>No. residues/100 residues</td></tr><tr><td>Arginine</td><td>7.12</td></tr><tr><td>Histidine</td><td>3.39</td></tr><tr><td>Isoleucine</td><td>3.76</td></tr><tr><td>Leucine</td><td>7.71</td></tr><tr><td>Lysine</td><td>9.18</td></tr><tr><td>Methionine</td><td>3.52</td></tr><tr><td>Phenylalanine</td><td>4.46</td></tr><tr><td>Threonine</td><td>4.67</td></tr><tr><td>Tryptophan</td><td>0.19</td></tr><tr><td>Valine</td><td>5.17</td></tr><tr><td>Indispensable AA (IAA)</td><td>49.16</td></tr><tr><td>Alanine</td><td>5.70</td></tr><tr><td>Aspartic acid</td><td>10.45</td></tr><tr><td>Cystine</td><td>1.05</td></tr><tr><td>Glutamic acid</td><td>15.72</td></tr><tr><td>Glycine</td><td>6.56</td></tr><tr><td>Proline</td><td>3.61</td></tr><tr><td>Serine</td><td>4.10</td></tr><tr><td>Tyrosine</td><td>3.65</td></tr><tr><td>Dispensable AA (DAA)</td><td>50.84</td></tr></table>
|
9aba2cc0b39dd5bb0e2f748d9c4176882b4e514257b891fb0fe251e736b75cf9.png
|
simple
|
<table><tr><td>Anatomical region</td><td>BA</td><td><i>x</i></td><td><i>y</i></td><td><i>z</i></td><td><i>Z</i>-value</td><td>Extent</td></tr><tr><td>R lingual/paraH gyrus</td><td>19/30</td><td>18</td><td>−51</td><td>−3</td><td>5.03</td><td>109</td></tr><tr><td><i>R lingual gyrus</i></td><td><i>19</i></td><td><i>18</i></td><td><i>−59</i></td><td><i>−5</i></td><td><i>3.54</i></td><td></td></tr><tr><td>L lingual/paraH gyrus</td><td>19/30</td><td>−16</td><td>−47</td><td>−3</td><td>4.91</td><td>227</td></tr><tr><td></td><td></td><td><i>−8</i></td><td><i>−62</i></td><td><i>0</i></td><td><i>3.50</i></td><td></td></tr><tr><td><i>L post. cingulate gyrus</i></td><td><i>23/31</i></td><td><i>−12</i></td><td><i>−56</i></td><td><i>12</i></td><td><i>3.50</i></td><td></td></tr><tr><td>Lingual gyrus</td><td>19/18</td><td>4</td><td>−58</td><td>1</td><td>3.63</td><td>16</td></tr><tr><td>R posterior insula/TTG</td><td>41</td><td>38</td><td>−17</td><td>16</td><td>4.49</td><td>45</td></tr><tr><td>L superior temporal gyrus</td><td>22</td><td>−50</td><td>−24</td><td>16</td><td>4.07</td><td>38</td></tr><tr><td>L MidFG/frontal pole</td><td>10</td><td>−34</td><td>51</td><td>16</td><td>4.00</td><td>21</td></tr><tr><td>L mPFC/ACC</td><td>10</td><td>−8</td><td>43</td><td>14</td><td>3.97</td><td>17</td></tr><tr><td>L anterior cingulate cortex</td><td>32</td><td>−14</td><td>34</td><td>19</td><td>3.87</td><td>20</td></tr><tr><td></td><td></td><td><i>−22</i></td><td><i>36</i></td><td><i>15</i></td><td><i>3.18</i></td><td></td></tr><tr><td>Anterior cingulate cortex</td><td>32/24</td><td>0</td><td>47</td><td>0</td><td>3.39</td><td>14</td></tr><tr><td>L inferior frontal gyrus</td><td>44/45</td><td>−34</td><td>11</td><td>16</td><td>3.85</td><td>16</td></tr><tr><td>mPFC/frontal pole</td><td>10</td><td>−4</td><td>65</td><td>12</td><td>3.85</td><td>11</td></tr><tr><td>R MidFG/frontal pole</td><td>10</td><td>40</td><td>47</td><td>12</td><td>3.63</td><td>15</td></tr><tr><td>L precuneus</td><td>7</td><td>−16</td><td>−76</td><td>42</td><td>4.42</td><td>78</td></tr><tr><td>L posterior cingulate</td><td>31</td><td>−12</td><td>−33</td><td>31</td><td>4.19</td><td>13</td></tr><tr><td>R precuneus</td><td>7</td><td>12</td><td>−72</td><td>40</td><td>3.76</td><td>44</td></tr><tr><td></td><td></td><td><i>14</i></td><td><i>−62</i></td><td><i>42</i></td><td><i>3.60</i></td><td></td></tr><tr><td></td><td></td><td><i>12</i></td><td><i>−68</i></td><td><i>48</i></td><td><i>3.35</i></td><td></td></tr><tr><td>Cuneus</td><td>17/31</td><td>0</td><td>−71</td><td>11</td><td>3.44</td><td>10</td></tr><tr><td>Precuneus/post. cingulate</td><td>31/23</td><td>−2</td><td>−63</td><td>25</td><td>3.37</td><td>41</td></tr><tr><td></td><td>31/23</td><td><i>−2</i></td><td><i>−68</i></td><td><i>33</i></td><td><i>3.35</i></td><td></td></tr><tr><td>R IPL/angular g./TPJ</td><td>40/39</td><td>40</td><td>−62</td><td>38</td><td>3.71</td><td>25</td></tr><tr><td></td><td></td><td><i>34</i></td><td><i>−68</i></td><td><i>42</i></td><td><i>3.33</i></td><td></td></tr><tr><td>L MTG/angular g./TPJ</td><td>39</td><td>−34</td><td>−65</td><td>29</td><td>3.71</td><td>22</td></tr><tr><td>L IPL/angular g./TPJ</td><td>40/39</td><td>−51</td><td>−60</td><td>40</td><td>3.65</td><td>17</td></tr><tr><td>R hippocampus/ParaH g.</td><td>30/19</td><td>24</td><td>−39</td><td>−6</td><td>3.65</td><td>26</td></tr><tr><td>L superior temporal gyrus</td><td>22/42</td><td>−61</td><td>−26</td><td>16</td><td>3.59</td><td>15</td></tr></table>
|
4de968997c5b657d8107a6441c33742876f131a8f197c2d684afb82369dc2160.png
|
simple
|
<table><tr><td>Dataset</td><td>Number of sequences</td></tr><tr><td>GATA1</td><td>14,351</td></tr><tr><td>SOX2</td><td>4526</td></tr><tr><td>OCT4</td><td>3761</td></tr><tr><td>STAT3</td><td>2546</td></tr><tr><td>KLF1</td><td>945</td></tr></table>
|
d586b84a8fd2beb5e0fbc7a5dc725136fdbd9aaaefb954f8c1a2a42afba47a8b.png
|
simple
|
<table><tr><td>Locations of lesion</td><td>Group 1</td><td>Group 2</td><td><i>p</i> value</td></tr><tr><td>RIV</td><td>(1/1) 100.00%</td><td>(2/2) 100.00%</td><td>-</td></tr><tr><td>RSCV</td><td>(0/0) 0.00%</td><td>(2/2) 100.00%</td><td>-</td></tr><tr><td>SVC</td><td>(1/1) 100.00%</td><td>(3/3) 100.00%</td><td>-</td></tr><tr><td>IJV+ SVC</td><td>(1/1) 100.00%</td><td>(0/1) 0.00%</td><td>-</td></tr><tr><td>RIV + SVC</td><td>(0/2) 0.00%</td><td>(3/4) 75.00%</td><td>0.350</td></tr><tr><td>RSCV + RIV</td><td>(0/2) 0.00%</td><td>(2/3) 66.67%</td><td>0.361</td></tr><tr><td>RSCV + RIV + SVC</td><td>(1/2) 50.00%</td><td>(2/3) 66.67%</td><td>0.709</td></tr><tr><td>LIV</td><td>(1/2) 50.00%</td><td>(2/2) 100.00%</td><td>0.171</td></tr><tr><td>LSCV</td><td>(1/1) 100.00%</td><td>(2/2) 100.00%</td><td>-</td></tr><tr><td>LIV + SVC</td><td>(1/2) 50.00%</td><td>(3/3) 100.00%</td><td>0.171</td></tr><tr><td>LSCV + LIV</td><td>(2/3) 66.67%</td><td>(2/3) 66.67%</td><td>-</td></tr><tr><td>LSCV + LIV + SVC</td><td>(0/1) 0.00%</td><td>(1/2) 50.00%</td><td>-</td></tr><tr><td>Total</td><td>(9/19) 47.36%</td><td>(25/30) 83.33%</td><td>0.012</td></tr></table>
|
72bba1eb0b19251bab71fe06a7b3dae5c6c6e7cc45c5ea4069889c10c25c832e.png
|
simple
|
<table><tr><td>Variables</td><td>Group 1 ISH positive<i>N</i> = 10</td><td>Group 2 ISH negative <i>N</i> = 15</td><td><i>P</i></td></tr><tr><td>Patient age at LT</td><td>49 ±11</td><td>52 ±11</td><td>.66</td></tr><tr><td>Female gender (patient)</td><td>40%</td><td>13%</td><td>.13</td></tr><tr><td>Caucasian (patient)</td><td>90%</td><td>87%</td><td>.69</td></tr><tr><td>Recipient body mass index</td><td>31 ±7</td><td>29 ±6</td><td>.51</td></tr><tr><td>MELD at LT</td><td>14 ±5</td><td>18 ±9</td><td>.42</td></tr><tr><td>Genotype 1 (unknown in 1 patient per group)</td><td>56%</td><td>86%</td><td>.11</td></tr><tr><td>Donor age</td><td>47 ±13</td><td>43 ±14</td><td>.82</td></tr><tr><td>Female gender (donor)</td><td>40%</td><td>53%</td><td>.51</td></tr><tr><td>Caucasian (Donor)</td><td>90%</td><td>67%</td><td>.34</td></tr><tr><td>Cold ischemia time, hours</td><td>7 ±2</td><td>7 ±2</td><td>.74</td></tr><tr><td>Warm ischemia time, minutes</td><td>39 ±9</td><td>34 ±10</td><td>.28</td></tr><tr><td>Tacrolimus as primary immune suppressant</td><td>100%</td><td>83%</td><td>.23</td></tr><tr><td>Steroid bolus treated ACR</td><td>30%</td><td>40%</td><td>.61</td></tr><tr><td>LT to ISH biopsy interval, months</td><td>23 ±10</td><td>24 ±12</td><td>.91</td></tr></table>
|
cc720abf801c4ad19a97890155910db8f73c3cf3b72d8cf23cfdd4d8686aabb6.png
|
simple
|
<table><tr><td>S1</td><td>S2</td><td>S3</td><td>S4</td><td>Id</td><td>Neuro-Fuzzy output</td></tr><tr><td>6752</td><td>6664</td><td>6577</td><td>6490</td><td>0</td><td>0.7655</td></tr><tr><td>6664</td><td>6577</td><td>6490</td><td>6404</td><td>0</td><td>0.7383</td></tr><tr><td>6577</td><td>6490</td><td>6404</td><td>6320</td><td>0</td><td>0.7004</td></tr><tr><td>6490</td><td>6404</td><td>6320</td><td>6236</td><td>0</td><td>0.6653</td></tr><tr><td>6404</td><td>6320</td><td>6236</td><td>6153</td><td>0</td><td>0.6348</td></tr><tr><td>6320</td><td>6236</td><td>6153</td><td>6072</td><td>0</td><td>0.5904</td></tr><tr><td>6236</td><td>6153</td><td>6072</td><td>5992</td><td>0</td><td>0.5428</td></tr></table>
|
ab5dc640cc291606a1ea5079c86a2eb8b8d2139e022ff75c75aa474fceb0a020.png
|
simple
|
<table><tr><td>Experiment</td><td>∆6</td><td>REG19</td><td>TS01</td></tr><tr><td>1</td><td>0</td><td>11</td><td>120</td></tr><tr><td>2</td><td>0</td><td>64</td><td>714</td></tr><tr><td>3</td><td>4</td><td>111</td><td>445</td></tr><tr><td>4</td><td>no data</td><td>no data</td><td>599</td></tr><tr><td>average</td><td>133</td><td>6200</td><td>42,633</td></tr></table>
|
7a305957c237f40b9d474a21d6326946e8b40014c0be569fbe56108cf1fa393f.png
|
complex
|
<table><tr><td></td><td colspan="5">Males</td><td colspan="5">Females</td></tr><tr><td></td><td>% (n/N)</td><td>PR<sup>b</sup></td><td>95% CI</td><td>PR<sup>c</sup></td><td>95% CI</td><td>% (n/N)</td><td>PR<sup>c</sup></td><td>95% CI</td><td>PR<sup>b</sup></td><td>95% CI</td></tr><tr><td>Baseline</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td><i>Overweight/Obese</i></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Primary School</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Low PA School</td><td>14 (51/371)</td><td>1.0</td><td>Ref</td><td>1.0</td><td>Ref</td><td>12 (48/417)</td><td>1.0</td><td>Ref</td><td>1.0</td><td>Ref</td></tr><tr><td> Med PA School</td><td>10 (48/460)</td><td>0.76</td><td>(0.52–1.11)</td><td>0.80</td><td>(0.57–1.12)</td><td>13 (60/455)</td><td>1.15</td><td>(0.81–1.61)</td><td>1.14</td><td>(0.80–1.62)</td></tr><tr><td> High PA School</td><td>11 (53/503)</td><td>0.77</td><td>(0.55–1.06)</td><td>0.77</td><td>(0.56–1.07)</td><td>13 (59/472)</td><td>1.09</td><td>(0.80–1.48)</td><td>1.10</td><td>(0.83–1.47)</td></tr><tr><td colspan="2"><i>p</i><sub><i>trend</i></sub></td><td></td><td>0.13</td><td></td><td>0.14</td><td></td><td></td><td>0.62</td><td></td><td>0.51</td></tr><tr><td>Secondary School</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Low PA School</td><td>9 (40/440)</td><td>1.0</td><td>Ref</td><td>1.0</td><td>Ref</td><td>12 (51/442)</td><td>1.0</td><td>Ref</td><td>1.0</td><td>Ref</td></tr><tr><td> Med PA School</td><td>11 (55/485)</td><td>1.25</td><td>(0.78–1.99)</td><td>1.27</td><td>(0.86–1.88)</td><td>13 (57/456)</td><td>1.08</td><td>(0.72–1.63)</td><td>1.15</td><td>(0.80–1.65)</td></tr><tr><td> High PA School</td><td>11 (68/622)</td><td>1.20</td><td>(0.82–1.76)</td><td>1.14</td><td>(0.79–1.64)</td><td>13 (69/532)</td><td>1.12</td><td>(0.80–1.59)</td><td>1.15</td><td>(0.81–1.64)</td></tr><tr><td colspan="2"><i>p</i><sub><i>trend</i></sub></td><td></td><td>0.39</td><td></td><td>0.59</td><td></td><td></td><td>0.50</td><td></td><td>0.44</td></tr><tr><td>Follow-Up</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td><i>Overweight/Obese</i></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Low PA School</td><td>59 (123/208)</td><td>1.0</td><td>Ref</td><td>1.0</td><td>Ref</td><td>39 (92/239)</td><td>1.0</td><td>Ref</td><td>1.0</td><td>Ref</td></tr><tr><td> Med PA School</td><td>66 (169/254)</td><td>1.13</td><td>(0.97–1.30)</td><td>1.10</td><td>(0.97–1.25)</td><td>38 (96/250)</td><td>1.00</td><td>(0.78–1.28)</td><td>0.98</td><td>(0.79–1.22)</td></tr><tr><td> High PA School</td><td>63 (182/288)</td><td>1.07</td><td>(0.93–1.23)</td><td>1.08</td><td>(0.95–1.23)</td><td>41 (110/270)</td><td>1.06</td><td>(0.83–1.34)</td><td>1.04</td><td>(0.84–1.28)</td></tr><tr><td colspan="2"><i>p</i><sub><i>trend</i></sub></td><td></td><td>0.46</td><td></td><td>0.33</td><td></td><td></td><td>0.63</td><td></td><td>0.63</td></tr></table>
|
b501ebdef2767bed84269a60bb87ec1e6305435b9e044001023380998e6a777e.png
|
complex
|
<table><tr><td>Pin</td><td>I/O Attached</td><td>Action</td><td>States</td></tr><tr><td>L0</td><td>Red LED</td><td>move</td><td rowspan="2"></td></tr><tr><td>L1</td><td>Green LED</td><td>turn</td></tr><tr><td>L2</td><td>Orange LED</td><td rowspan="6"></td><td>gripper is open</td></tr><tr><td>L4</td><td>Yellow LED</td><td>bottle is collected</td></tr><tr><td>L3</td><td>Switch A</td><td>touching </td></tr><tr><td>L5</td><td>Switch B</td><td>see drop </td></tr><tr><td>L6</td><td>Switch C</td><td>see bottle</td></tr><tr><td>L7</td><td>Switch D</td><td>over drop</td></tr></table>
|
a4a3adb75523e8ff18384e4b3647b2397bb82afe83357bc77ba320f05b56457b.png
|
complex
|
<table><tr><td></td><td>12-15 weeks old</td><td colspan="2">Symptomatic</td></tr><tr><td></td><td>WT</td><td>SOD1a</td><td>SOD1b</td></tr><tr><td>n (fiber, mice)</td><td>30, 11</td><td>19, 8</td><td>20, 10</td></tr><tr><td>Males</td><td>17, 5</td><td>11, 4</td><td>10, 5</td></tr><tr><td>Females</td><td>13, 6</td><td>8, 4</td><td>10,5</td></tr><tr><td>Age range (days)</td><td>89-108</td><td>94-107</td><td>94-102</td></tr><tr><td>RMP (mV)</td><td>-64.8 ± 2.50</td><td>-64.4 ± 2.05</td><td>-67.1 ± 2.67</td></tr><tr><td>EPPs amplitude (mV)</td><td>21.0 ± 2.45</td><td>11.4 ± 2.00 <sup>#WT</sup></td><td>24.9 ± 2.33 <sup>#SOD1a</sup></td></tr><tr><td>EPPs amplitude <sub>NOR</sub> (mV)</td><td>23.6 ± 2.21</td><td>12.8 ± 2.06 <sup>#WT</sup></td><td>28.1 ± 2.41</td></tr><tr><td><i>Quantal content</i><sub>NOR</sub></td><td>41.3 ± 3.79</td><td>32.7 ± 4.40</td><td>38.8 ± 3.30</td></tr><tr><td>MEPPs amplitude (mV)</td><td>0.50 ± 0.03</td><td>0.32 ± 0.02 <sup>#WT</sup></td><td>0.64 ± 0.02 <sup>#WT #SOD1a</sup></td></tr><tr><td>MEPPs rise-time (ms)</td><td>0.98 ± 0.07</td><td>1.39 ± 0.12 <sup>#WT</sup></td><td>0.93 ± 0.06 <sup>#SOD1a</sup></td></tr><tr><td>MEPPs decay-time(ms)</td><td>3.12 ± 0.14</td><td>3.12 ± 0.17</td><td>3.28 ± 0.20</td></tr><tr><td>MEPPs frequency (s<sup>-1</sup>)</td><td>0.76 ± 0.11</td><td>0.61 ± 0.11</td><td>1.26 ± 0.33</td></tr><tr><td>N<sup>°</sup> of NMJs with GMEPPs</td><td>16</td><td>3</td><td>17</td></tr><tr><td>GMEPPs frequency (s<sup>-1</sup>)</td><td>0.44 ± 0.12</td><td>0.07 ± 0.03 <sup>+</sup><sup>WT</sup></td><td>0.38 ± 0.12 <sup>+</sup><sup>SOD1a</sup></td></tr><tr><td>Fr(GMEPPs)/Fr(MEPPs)</td><td>1.58 ± 0.49</td><td>0.11 ± 0.07 <sup>+</sup><sup>WT</sup></td><td>1.40 ± 0.80</td></tr></table>
|
8c874982ccec090933f3a88061cfc4ee3c49c2a1549f321e0ae5629eca3a87ec.png
|
simple
|
<table><tr><td></td><td>age (median, IQR)</td><td>Female sex (n)</td><td>FEV1 % predicted (median, IQR)</td><td>ICS dose, mcg/day (median, IQR)</td><td>Current smoker (n)</td></tr><tr><td>AKL1 – Placebo (n = 16)</td><td>41.00, 33.50 – 55.75</td><td>13</td><td>90.00, 79.75 – 115.50</td><td>1000, 400 – 2000</td><td>1</td></tr><tr><td>Placebo – AKL1 (n = 16)</td><td>35.50, 29.50 – 55.50</td><td>12</td><td>85.50, 56.50 – 110.00</td><td>800, 400 – 1150</td><td>1</td></tr><tr><td>P value</td><td>0.67</td><td>0.67</td><td>0.25</td><td>0.51</td><td>1.00</td></tr></table>
|
b6453d8303b875d376e3a69462464e67cacda1d154dfb7024ef0fceacee19eb0.png
|
complex
|
<table><tr><td>Ancestry</td><td>Parent</td><td colspan="3">Count</td><td colspan="3">Mean age</td></tr><tr><td></td><td></td><td>Alive</td><td>Dead</td><td>Total</td><td>Alive</td><td>Dead</td><td>All</td></tr><tr><td>African</td><td>Father</td><td>2435</td><td>6924</td><td>9359</td><td>72.4</td><td>70.4</td><td>70.9</td></tr><tr><td>African</td><td>Mother</td><td>4185</td><td>5889</td><td>10,074</td><td>73.1</td><td>70.7</td><td>71.7</td></tr><tr><td>European</td><td>Father</td><td>113,611</td><td>178,017</td><td>291,628</td><td>62.9</td><td>71.2</td><td>68</td></tr><tr><td>European</td><td>Mother</td><td>150,854</td><td>144,144</td><td>294,998</td><td>66.2</td><td>75.1</td><td>70.5</td></tr><tr><td></td><td>ALL</td><td>271,085</td><td>334,974</td><td>606,059</td><td></td><td></td><td></td></tr></table>
|
ea0891e23289dcad8c8de4caed56a934aecffa1986150c4b968d2f2391f2dee1.png
|
simple
|
<table><tr><td>Pathway</td><td>miRNAs</td><td>Genes</td></tr><tr><td>MAPK signaling pathway</td><td>10</td><td>95</td></tr><tr><td>PI3K-Akt signaling pathway</td><td>9</td><td>106</td></tr><tr><td>Endocytosis</td><td>10</td><td>72</td></tr><tr><td>TGF-β signaling pathway</td><td>6</td><td>35</td></tr><tr><td>Wnt signaling pathway</td><td>9</td><td>58</td></tr><tr><td>Ubiquitin mediated proteolysis</td><td>8</td><td>49</td></tr><tr><td>Regulation of actin cytoskeleton</td><td>8</td><td>74</td></tr></table>
|
7861b35586050ca1ee3d1a7688495f559bc840e667e773328a2c4828782c6b65.png
|
simple
|
<table><tr><td>Gene</td><td>GeneBank accession number</td><td>Specific primer sequences (5’ to 3’)</td><td>Product size (bp)</td></tr><tr><td>αA-crystallin (<i>CRYAA</i>)</td><td>U05569</td><td>F: CGGGACAAGTTCGTCATCTT</td><td>203</td></tr><tr><td> </td><td> </td><td>R: GCAGACAGGGAGCAAGAGAG</td><td> </td></tr><tr><td>Heat-shock protein 70 (<i>Hsp70</i>)</td><td>NM05345</td><td>1F: AAGTACAAAGCGGAGGACG</td><td>249</td></tr><tr><td> </td><td> </td><td>1R: GATGGGGTTACACACCTGC</td><td> </td></tr><tr><td> </td><td> </td><td>2F: TGCTGATCCAGGTGTACGAG</td><td>185</td></tr><tr><td> </td><td> </td><td>2R: CGTTGGTGATGGTGATCTTG</td><td> </td></tr><tr><td>Heat-shock protein 90α (<i>Hsp90α</i>))</td><td>NM005348.3</td><td>F: ACCCAGACCCAAGACCAACCG</td><td>141</td></tr><tr><td> </td><td> </td><td>R: ATTTGAAATGAGCTCTCTCAG</td><td> </td></tr><tr><td>Superoxide dismutase (<i>SOD</i>)</td><td>NM000454.4</td><td>F: AGGGCATCATCAATTTCGAGC</td><td>430</td></tr><tr><td> </td><td> </td><td>R: CAAGGGAATGTTTATTGGGCG</td><td> </td></tr><tr><td>αB-crystallin (<i>CRYAB</i>)</td><td>NM001885.1</td><td>F: TCACCTAGCCACCATGGACATCGCCA</td><td>541</td></tr><tr><td> </td><td> </td><td>R: CAAAAGCTTATTACTATTTCTTGGGGG</td><td> </td></tr><tr><td>Metallothionein 1M (<i>MT</i>)</td><td>NM176870.2</td><td>F: GCAAAGAGTGCAAATGCACCTC</td><td>125</td></tr><tr><td> </td><td> </td><td>R: TCAGGCACAGCAGCTGCACT</td><td> </td></tr><tr><td>Interleukin-6 (<i>IL-6</i>)</td><td>NM000600.2</td><td>F: CTGGTCTTTTGGAGTTTGAGGTATACC</td><td>295</td></tr><tr><td> </td><td> </td><td>R: CCATGCTACATTTGCCGAAGA</td><td> </td></tr><tr><td>Glyceraldehyde 3-phosphate dehydrogenase (<i>GAPDH</i>)</td><td>BC014085</td><td>F: GAAGGTGAAGGTCGGAGT</td><td>225</td></tr><tr><td> </td><td> </td><td>R: GAAGATGGTGATGGGATTTC</td><td> </td></tr></table>
|
db962b0d3961fa409205e8265399120f7a2f519dc9fecba0b755a3e15374d9dd.png
|
complex
|
<table><tr><td>Neuropsychological test</td><td colspan="2">Schizophrenics high SANS-score (S1)</td><td colspan="2">Schizophrenics low SANS-score (S2)</td><td colspan="2">Controls (C)</td><td></td><td colspan="3">Post-hoc analyses</td></tr><tr><td></td><td>Mean</td><td>SD</td><td>Mean</td><td>SD</td><td>Mean</td><td>SD</td><td>F-value<sup>1</sup></td><td>S1 vs. S2*</td><td>S2 vs. C*</td><td>S1 vs. C*</td></tr><tr><td>WMS-R, logical memory I</td><td>22,80</td><td>5,73</td><td>29,40</td><td>6,15</td><td>33,28</td><td>6,97</td><td>6,58**</td><td>n.s.</td><td>n.s.</td><td>p ≤0,01</td></tr><tr><td>WMS-R, logical memory II</td><td>15,70</td><td>5,98</td><td>25,10</td><td>5,61</td><td>29,63</td><td>8,54</td><td>8,34**</td><td>p ≤0,05</td><td>n.s.</td><td>p ≤0,01</td></tr><tr><td>NAI, wordlist trial I</td><td>6,20</td><td>1,03</td><td>7,90</td><td>1,97</td><td>8,22</td><td>2,79</td><td>1,97</td><td>n.s.</td><td>n.s.</td><td>n.s.</td></tr><tr><td>NAI, wordlist trial II</td><td>8,80</td><td>1,93</td><td>10,40</td><td>2,07</td><td>11,84</td><td>2,48</td><td>4,97**</td><td>n.s.</td><td>n.s.</td><td>p ≤0,01</td></tr><tr><td>NAI, wordlist trial III</td><td>11,00</td><td>1,76</td><td>12,80</td><td>1,55</td><td>13,22</td><td>1,75</td><td>4,22**</td><td>n.s.</td><td>n.s.</td><td>p ≤0,01</td></tr><tr><td>NAI, wordlist delayed</td><td>7,90</td><td>3,76</td><td>11,40</td><td>2,41</td><td>11,91</td><td>3,38</td><td>3,7**</td><td>n.s.</td><td>n.s.</td><td>p ≤0,01</td></tr><tr><td>HAWIE-R, information</td><td>14,80</td><td>4,42</td><td>16,50</td><td>3,17</td><td>18,94</td><td>3,63</td><td>5,5**</td><td>n.s.</td><td>n.s.</td><td>p ≤0,01</td></tr><tr><td>WMS-R, visual reproduction I</td><td>37,90</td><td>2,96</td><td>37,60</td><td>2,01</td><td>39,47</td><td>1,68</td><td>3,27*</td><td>n.s.</td><td>p ≤0,05</td><td>n.s.</td></tr><tr><td>WMS-R, visual reproduction II</td><td>34,60</td><td>6,29</td><td>37,50</td><td>1,90</td><td>39,13</td><td>2,20</td><td>5,36**</td><td>n.s.</td><td>n.s.</td><td>p ≤0,01</td></tr><tr><td>HAWIE-R, digit span</td><td>15,60</td><td>3,17</td><td>14,50</td><td>2,80</td><td>17,25</td><td>4,53</td><td>1,89</td><td>n.s.</td><td>n.s.</td><td>n.s.</td></tr><tr><td>HAWIE-R, digit span forward</td><td>8,20</td><td>2,04</td><td>8,20</td><td>1,69</td><td>8,78</td><td>2,09</td><td>1,27</td><td>n.s.</td><td>n.s.</td><td>n.s.</td></tr><tr><td>HAWIE-R, digit span backward</td><td>7,40</td><td>1,84</td><td>6,30</td><td>1,49</td><td>8,47</td><td>2,85</td><td>2,34</td><td>n.s.</td><td>n.s.</td><td>n.s.</td></tr><tr><td>Stroop interference</td><td>84,00</td><td>23,08</td><td>90,70</td><td>24,22</td><td>63,56</td><td>11,97</td><td>7,85**</td><td>n.s.</td><td>p ≤0,01</td><td>p ≤0,01</td></tr><tr><td>Verbal fluency</td><td>30,10</td><td>9,83</td><td>30,70</td><td>7,76</td><td>41,34</td><td>15,51</td><td>2,75</td><td>n.s.</td><td>n.s.</td><td>n.s.</td></tr><tr><td>WCST, ntcc1</td><td>19,60</td><td>11,65</td><td>12,13</td><td>6,36</td><td>12,26</td><td>3,82</td><td>7,07**</td><td>n.s.</td><td>n.s.</td><td>p ≤0,01</td></tr><tr><td>WCST, perseverative reactions</td><td>14,40</td><td>10,16</td><td>25,88</td><td>23,01</td><td>12,39</td><td>12,60</td><td>2,46</td><td>n.s.</td><td>n.s.</td><td>n.s.</td></tr><tr><td>WCST, perseverative errors</td><td>13,10</td><td>8,50</td><td>22,63</td><td>18,94</td><td>10,88</td><td>10,17</td><td>2,77*</td><td>n.s.</td><td>p ≤0,05</td><td>n.s.</td></tr></table>
|
3d1358f85c4b2a1e0c34846813280003ac697eb5983f6c290d8422966203386d.png
|
complex
|
<table><tr><td></td><td colspan="4">Patients with diabetes</td><td colspan="4">Diabetes-free comparison group</td><td></td><td></td></tr><tr><td></td><td>Person-years</td><td>Cases</td><td>IR per 1000 person-years</td><td>95% CI</td><td>Person-years</td><td>Cases</td><td>IR per 1000 person-years</td><td>95% CI</td><td>IRR</td><td>95% CI</td></tr><tr><td>All</td><td>284887.4</td><td>5802</td><td>20.4</td><td>19.8–20.9</td><td>284953.5</td><td>3087</td><td>10.8</td><td>10.5–11.2</td><td>1.9</td><td>1.8–2.0</td></tr><tr><td>Men</td><td>153029.5</td><td>2524</td><td>16.5</td><td>15.9–17.1</td><td>148846.7</td><td>1267</td><td>8.5</td><td>8.0–9.0</td><td>1.9</td><td>1.8–2.1</td></tr><tr><td>Women</td><td>131857.9</td><td>3278</td><td>24.9</td><td>24.0–25.7</td><td>136106.8</td><td>1820</td><td>13.4</td><td>12.8–14.0</td><td>1.9</td><td>1.8–2.0</td></tr><tr><td>Age 40–44</td><td>9224.9</td><td>22</td><td>2.4</td><td>1.4–3.4</td><td>8675.2</td><td>6</td><td>0.7</td><td>0.1–1.2</td><td>3.4</td><td>1.4–8.5</td></tr><tr><td>Age 45–49</td><td>25840.3</td><td>70</td><td>2.7</td><td>2.1–3.3</td><td>24085.6</td><td>10</td><td>0.4</td><td>0.2–0.7</td><td>6.5</td><td>3.3–12.5</td></tr><tr><td>Age 50–54</td><td>37674.4</td><td>193</td><td>5.1</td><td>4.4–5.8</td><td>35173.7</td><td>31</td><td>0.9</td><td>0.6–1.2</td><td>5.8</td><td>4.0–8.5</td></tr><tr><td>Age 55–59</td><td>44047.4</td><td>324</td><td>7.4</td><td>6.6–8.2</td><td>42089.5</td><td>118</td><td>2.8</td><td>2.3–3.3</td><td>2.6</td><td>2.1–3.2</td></tr><tr><td>Age 60–64</td><td>46713.6</td><td>526</td><td>11.3</td><td>10.3–12.2</td><td>45310.4</td><td>199</td><td>4.4</td><td>3.8–5.0</td><td>2.6</td><td>2.2–3.0</td></tr><tr><td>Age 65–69</td><td>43022.1</td><td>860</td><td>20.0</td><td>18.7–21.3</td><td>43263.2</td><td>369</td><td>8.5</td><td>7.7–9.4</td><td>2.3</td><td>2.1–2.6</td></tr><tr><td>Age 70–74</td><td>34468.6</td><td>1111</td><td>32.2</td><td>30.3–34.1</td><td>36143.3</td><td>611</td><td>16.9</td><td>15.6–18.2</td><td>1.9</td><td>1.7–2.1</td></tr><tr><td>Age 75–79</td><td>24776.3</td><td>1295</td><td>52.3</td><td>49.4–55.1</td><td>27036.8</td><td>782</td><td>28.9</td><td>26.9–31.0</td><td>1.8</td><td>1.7–2.0</td></tr><tr><td>Age 80–84</td><td>12867.7</td><td>911</td><td>70.8</td><td>66.2–75.4</td><td>15319.3</td><td>601</td><td>39.2</td><td>36.1–42.4</td><td>1.8</td><td>1.6–2.0</td></tr><tr><td>Age 85–89</td><td>4836.9</td><td>403</td><td>83.3</td><td>75.2–91.5</td><td>5989.4</td><td>290</td><td>48.4</td><td>42.8–54.0</td><td>1.7</td><td>1.5–2.0</td></tr><tr><td>Age ≥90</td><td>1415.1</td><td>87</td><td>61.5</td><td>48.6–74.4</td><td>1867.0</td><td>70</td><td>37.5</td><td>28.7–46.3</td><td>1.6</td><td>1.2–2.2</td></tr></table>
|
b20686f22edc8566254ac5636e6bd4ee8a6a1438ab6479aa0209430c77481cd7.png
|
complex
|
<table><tr><td rowspan="2">Microstructure analysis</td><td rowspan="2">Vehicle</td><td colspan="3">SB-742457</td></tr><tr><td>3.0 mg/kg</td><td>10 mg/kg</td><td>30 mg/kg</td></tr><tr><td>Number of licks</td><td>1456.7 (199.9)</td><td>992.8* (255.2)</td><td>1130.7 (249.9)</td><td>1238.9 (278.4)</td></tr><tr><td>Bout duration (s)</td><td>2.7 (0.5)</td><td>1.9 (0.1)</td><td>2.1 (0.3)</td><td>2.0 (0.3)</td></tr><tr><td>Bout number</td><td>97.2 (12.8)</td><td>73.5* (17.2)</td><td>80.1 (13.9)</td><td>114.5 (27.3)</td></tr><tr><td>Intra-bout lick rate(licks/s)</td><td>6.4 (0.1)</td><td>6.4 (0.2)</td><td>6.3 (0.2)</td><td>5.9* (0.1)</td></tr><tr><td>Latency (s)</td><td>84.7 (46.9)</td><td>66.1 (28.0)</td><td>76.1 (20.7)</td><td>62.7 (23.9)</td></tr></table>
|
54b904f9bde9ba6ba282921f84e14405c74a0adeafd2e7d4a3b9123350a45e0a.png
|
complex
|
<table><tr><td>Characteristic</td><td>Doctors</td><td>Nurses</td></tr><tr><td colspan="3">Sex</td></tr><tr><td>Female</td><td>7</td><td>5</td></tr><tr><td>Male</td><td>8</td><td>0</td></tr><tr><td colspan="3">Age (years)</td></tr><tr><td>Mean</td><td>37</td><td>45</td></tr><tr><td>Range</td><td>26–53</td><td>38–53</td></tr><tr><td colspan="3">Years of practice in total</td></tr><tr><td>Mean</td><td>13</td><td>24</td></tr><tr><td>Range</td><td>1.75–29</td><td>16–33</td></tr><tr><td colspan="3">Years of practice in nephrology</td></tr><tr><td>Mean</td><td>9</td><td>20</td></tr><tr><td>Range</td><td>0.3–26</td><td>15–26</td></tr></table>
|
561d7f0fece6a967766a6cfaf3484a2c71a6f424b4dbc115454f2f3ed592a0ce.png
|
simple
|
<table><tr><td></td><td>Pre-Delphi questionnaire</td><td>Round 1</td><td>Round 2</td><td>Round 3</td></tr><tr><td>Consumers</td><td>16</td><td>13</td><td>13</td><td>9</td></tr><tr><td>Carers</td><td>3</td><td>2</td><td>0</td><td>0</td></tr><tr><td>Professionals</td><td>26</td><td>21</td><td>17</td><td>16</td></tr></table>
|
91bf8d054e990a503398a2b2ea1912e031960eeebdfbfa64bd5152adf944f5f3.png
|
simple
|
<table><tr><td>Exposure</td><td>Cases (<i>n</i> = 2634)</td><td>Controls (<i>n</i> = 5074)</td><td>Crude OR (95%CI)</td><td>Adjusted OR† (95%CI)</td></tr><tr><td>Current use, <i>n</i> (%)</td><td></td><td></td><td></td><td></td></tr><tr><td>Conventional NSAIDs − PPIs</td><td>1599 (60.7)</td><td>3013 (59.4)</td><td>1</td><td>1</td></tr><tr><td>Conventional NSAIDs + PPIs</td><td>775 (29.4)</td><td>1356 (26.7)</td><td>1.08 (0.97–1.20)</td><td>0.79 (0.68–0.92)*</td></tr><tr><td>Selective COX‐2 inhibitors − PPIs</td><td>179 (6.8)</td><td>487 (9.6)</td><td>0.69 (0.58–0.83)*</td><td>0.66 (0.48–0.89)*</td></tr><tr><td>Selective COX‐2 inhibitors + PPIs</td><td>81 (3.1)</td><td>218 (4.3)</td><td>0.70 (0.54–0.91)*</td><td>0.51 (0.35–0.73)*</td></tr></table>
|
4d2c89d896cb1ab70dfd461bf2a41d1c711e1a30ae839efb9d4045d0808f725b.png
|
complex
|
<table><tr><td rowspan="2">Time</td><td colspan="2">50 Units, <i>n</i> = 9</td><td colspan="2">100 Units, <i>n</i> = 10</td><td colspan="2">200 Units, <i>n</i> = 10</td><td rowspan="2"><i>F</i> Statistic (d.f.) <sup>a</sup></td><td rowspan="2"><i>p</i>-Value</td></tr><tr><td>Mean, g</td><td>(SD)</td><td>Mean, g</td><td>(SD)</td><td>Mean, g</td><td>(SD)</td></tr><tr><td>Baseline</td><td>0.54</td><td>(0.419)</td><td>0.58</td><td>(0.305)</td><td>0.53</td><td>(0.703)</td><td rowspan="5">0.58 (4)</td><td rowspan="5">0.687</td></tr><tr><td>2 weeks</td><td>0.27</td><td>(0.185)</td><td>0.28</td><td>(0.098)</td><td>0.34</td><td>(0.502)</td></tr><tr><td>6 weeks</td><td>0.30</td><td>(0.260)</td><td>0.33</td><td>(0.229)</td><td>0.23</td><td>(0.257)</td></tr><tr><td>12 weeks</td><td>0.33</td><td>(0.287)</td><td>0.30</td><td>(0.237)</td><td>0.28</td><td>(0.403)</td></tr><tr><td>24 weeks</td><td>0.34</td><td>(0.231)</td><td>0.34</td><td>(0.271)</td><td>0.22</td><td>(0.237)</td></tr></table>
|
56af3c3630ce634c56b6762f0b67f47955b303bd97307890f2b5555374f4b7bc.png
|
complex
|
<table><tr><td></td><td>Compound</td><td>Content (mg/g)</td></tr><tr><td rowspan="3"><i>Panax ginseng</i></td><td>Rb1</td><td>2.24</td></tr><tr><td>Re</td><td>1.13</td></tr><tr><td>Rg1</td><td>1.47</td></tr><tr><td rowspan="2"><i>Salvia miltiorrhiza</i></td><td>Salvianolia acid B</td><td>28.2</td></tr><tr><td>Tanshinone IIA</td><td>0.6</td></tr></table>
|
a6490925a18905142c28e3eceb0c4b6af2c1198a988ad4ad95e4d95aaba41bc2.png
|
complex
|
<table><tr><td rowspan="2"> Age group</td><td rowspan="2">Sex</td><td colspan="4">Testosterone concentration (ng/mL)</td><td rowspan="2">Sex* group mean</td><td rowspan="2">Group mean</td><td rowspan="2">Sex mean</td></tr><tr><td>0.10</td><td>1</td><td>10</td><td>100</td></tr><tr><td rowspan="2">Group-I</td><td>Male</td><td>1.27 ± 0.06</td><td>1.04 ± 0.04</td><td>1.18 ± 0.04</td><td>1.02 ± 0.04</td><td>1.13 ± 0.03</td><td rowspan="2">1.04 ± 0.017</td><td rowspan="3">1.03 ± 0.01 (Male)</td></tr><tr><td>Female</td><td>0.97 ± 0.03</td><td>0.94 ± 0.02</td><td>0.94 ± 0.02</td><td>0.98 ± 0.03</td><td>0.96 ± 0.01</td></tr><tr><td rowspan="2">Group-II</td><td>Male</td><td>0.95 ± 0.03</td><td>1.05 ± 0.03</td><td>0.93 ± 0.04</td><td>0.91 ± 0.03</td><td>0.96 ± 0.02</td><td rowspan="2">1.03 ± 0.017</td></tr><tr><td>Female</td><td>1.11 ± 0.05</td><td>1.140 ± 0.04</td><td>1.08 ± 0.05</td><td>1.07 ± 0.03</td><td>1.10 ± 0.02</td><td rowspan="3">1.05 ± 0.01 (Female)</td></tr><tr><td rowspan="2">Group-III</td><td>Male</td><td>0.94 ± 0.05</td><td>1.05 ± 0.05</td><td>1.06 ± 0.03</td><td>0.90 ± 0.03</td><td>0.99 ± 0.02</td><td rowspan="2">1.04 ± 0.017</td></tr><tr><td>Female</td><td>1.06 ± 0.06</td><td>1.08 ± 0.05</td><td>1.12 ± 0.05</td><td>1.14 ± 0.09</td><td>1.10 ± 0.03</td></tr><tr><td colspan="2">Treatment mean</td><td>1.05 ± 0.02</td><td>1.05 ± 0.02</td><td>1.05 ± 0.02</td><td>1.00 ± 0.02</td><td></td></tr></table>
|
74e8d687a77ff3a894517b6eb511246ea7d1dec2e7de96dffdea93b96bc4d19d.png
|
complex
|
<table><tr><td rowspan="2"></td><td>Entire cohort</td><td>PODXL neg</td><td>PODXL pos</td><td></td></tr><tr><td>n (%)</td><td>n (%)</td><td>n (%)</td><td><i>p-</i>value</td></tr><tr><td></td><td>171 (100.0)</td><td>29 (17.0)</td><td>142 (83.0)</td><td></td></tr><tr><td colspan="5">Age</td></tr><tr><td> ≤70</td><td>85 (49.7)</td><td>12 (41.4)</td><td>73 (51.4)</td><td rowspan="2">0.416</td></tr><tr><td> >70</td><td>86 (50.3)</td><td>17 (58.6)</td><td>69 (48.6)</td></tr><tr><td colspan="5">Sex</td></tr><tr><td> Female</td><td>39 (22.8)</td><td>9 (31.0)</td><td>30 (21.1)</td><td rowspan="2">0.330</td></tr><tr><td> Male</td><td>132 (77.2)</td><td>20 (69.0)</td><td>112 (78.9)</td></tr><tr><td colspan="5">T stage</td></tr><tr><td> T1</td><td>18 (10.5)</td><td>2 (6.9)</td><td>16 (11.3)</td><td rowspan="4">0.637</td></tr><tr><td> T2</td><td>32 (18.7)</td><td>6 (20.7)</td><td>26 (18.3)</td></tr><tr><td> T3</td><td>94 (55.0)</td><td>16 (55.2)</td><td>78 (54.9)</td></tr><tr><td> T4</td><td>27 (15.8)</td><td>5 (17.2)</td><td>22 (15.5)</td></tr><tr><td colspan="5">N stage</td></tr><tr><td> N0</td><td>57 (33.3)</td><td>16 (55.2)</td><td>41 (28.9)</td><td rowspan="4">0.006</td></tr><tr><td> N1</td><td>29 (17.0)</td><td>4 (13.8)</td><td>25 (17.6)</td></tr><tr><td> N2</td><td>41 (24.0)</td><td>6 (20.7)</td><td>35 (24.6)</td></tr><tr><td> N3</td><td>44 (25.7)</td><td>3 (10.3)</td><td>41 (28.9)</td></tr><tr><td colspan="5">M stage</td></tr><tr><td> M0</td><td>152 (88.9)</td><td>25 (86.2)</td><td>127 (89.4)</td><td rowspan="2">0.535</td></tr><tr><td> M1</td><td>19 (11.1)</td><td>4 (13.8)</td><td>15 (10.6)</td></tr><tr><td colspan="5">R classification</td></tr><tr><td> R0</td><td>117 (68.4)</td><td>22 (75.9)</td><td>95 (66.9)</td><td rowspan="3">0.556</td></tr><tr><td> R1</td><td>45 (26.3)</td><td>5 (17.2)</td><td>40 (28.2)</td></tr><tr><td> R2</td><td>9 (5.3)</td><td>2 (6.9)</td><td>7 (4.9)</td></tr><tr><td colspan="5">Differentiation grade</td></tr><tr><td> Low grade</td><td>8 (4.7)</td><td>4 (13.8)</td><td>4 (2.8)</td><td rowspan="3">0.023</td></tr><tr><td> Intermediate grade</td><td>52 (30.4)</td><td>10 (34.5)</td><td>42 (29.6)</td></tr><tr><td> High grade</td><td>111 (64.9)</td><td>15 (51.7)</td><td>96 (67.6)</td></tr><tr><td colspan="5">Lauren classification</td></tr><tr><td> Intestinal</td><td>119 (69.6)</td><td>23 (79.3)</td><td>96 (67.6)</td><td rowspan="3">0.335</td></tr><tr><td> Mixed</td><td>9 (5.3)</td><td>0 (0.0)</td><td>9 (6.3)</td></tr><tr><td> Diffuse</td><td>43 (25.1)</td><td>6 (20.7)</td><td>37 (26.1)</td></tr><tr><td colspan="5">Location</td></tr><tr><td> Esophagus + EG junction</td><td>106 (62.0)</td><td>15 (51.7)</td><td>91 (64.1)</td><td rowspan="2">0.217</td></tr><tr><td> Stomach</td><td>65 (38.0)</td><td>14 (48.3)</td><td>51 (35.9)</td></tr></table>
|
1286252ff86f8b66923b2b9d28756b53bfc31c582ad97f25ee4f607518562722.png
|
complex
|
<table><tr><td>Characteristic</td><td>Non-IRABC</td><td>IRABC</td><td><i>P</i><sup>a</sup></td><td>OR<sup>b</sup></td><td>95% CI<sup>b</sup></td><td><i>P</i><sup>b</sup></td></tr><tr><td>Number</td><td>1060</td><td>580</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Mean age ± SD<sup>c</sup></td><td>65.0 ± 20.2</td><td>70.0 ± 18.8</td><td><0.001</td><td> </td><td> </td><td> </td></tr><tr><td> Age 65 and older<sup>c</sup></td><td>629 (61.1)</td><td>401 (71.9)</td><td><0.001</td><td>1.464</td><td>1.122-1.912</td><td>0.005</td></tr><tr><td colspan="7">Specimen types</td></tr><tr><td> Respiratory tracts</td><td>481 (45.4)</td><td>341 (58.8)</td><td><0.001</td><td>2.597</td><td>1.888-3.570</td><td><0.001</td></tr><tr><td> Blood</td><td>192 (18.1)</td><td>52 (9.0)</td><td><0.001</td><td> </td><td> </td><td>Reference</td></tr><tr><td> Pus/discharge</td><td>160 (15.1)</td><td>59 (10.2)</td><td>0.005</td><td>1.934</td><td>1.240-3.018</td><td>0.004</td></tr><tr><td> Urine</td><td>140 (13.2)</td><td>76 (13.1)</td><td>>0.99</td><td>2.138</td><td>1.401-3.263</td><td><0.001</td></tr><tr><td colspan="7">Healthcare settings</td></tr><tr><td> Medical centers</td><td>507 (47.8)</td><td>228 (39.3)</td><td>0.001</td><td>0.814</td><td>0.631-1.049</td><td>0.112</td></tr><tr><td> ICU Settings</td><td>328 (30.9)</td><td>272 (46.9)</td><td><0.001</td><td>1.919</td><td>1.482-2.486</td><td><0.001</td></tr><tr><td colspan="7">Geographic regions</td></tr><tr><td> Northern</td><td>336 (31.7)</td><td>136 (23.4)</td><td><0.001</td><td> </td><td> </td><td>Reference</td></tr><tr><td> Central</td><td>341 (32.2)</td><td>286 (49.3)</td><td><0.001</td><td>2.43</td><td>1.791-3.296</td><td><0.001</td></tr><tr><td> Southern</td><td>258 (24.3)</td><td>85 (14.7)</td><td><0.001</td><td>1.178</td><td>0.812-1.710</td><td>0.388</td></tr><tr><td> Eastern</td><td>125 (11.8)</td><td>73 (12.6)</td><td>0.635</td><td>2.24</td><td>1.489-3.370</td><td><0.001</td></tr><tr><td>TSAR period<sup>d</sup></td><td> </td><td> </td><td> </td><td>2.277</td><td>2.054-2.523</td><td><0.001</td></tr></table>
|
8113eb9ec8467397d1db33859cc544ba77ee967e03f87bfc8c2ce54cbb070e18.png
|
simple
|
<table><tr><td>Group</td><td>Mean fluorescence recovery rate(%,<i>x</i>±s) (t=4min)</td></tr><tr><td>BGC-823Cx43</td><td>35.6±0.9*</td></tr><tr><td>BGC-823Cx43T154A</td><td>12.1±0.6</td></tr><tr><td>BGC-823v</td><td>13.4±0.7</td></tr><tr><td>SGC-7901Cx43</td><td>39.4±0.8†</td></tr><tr><td>SGC-7901Cx43T154A</td><td>15.3±0.4</td></tr><tr><td>SGC-7901v</td><td>14.7±0.6</td></tr></table>
|
1bd546dd39063e9fc729ae91860511bc7dd87a3974fb771b14e7243d2477fb62.png
|
complex
|
<table><tr><td></td><td>b</td><td>l-95 %</td><td>u-95 %</td><td>N<sub>eff</sub></td></tr><tr><td colspan="5">Dominance</td></tr><tr><td> Intercept</td><td>−0.30</td><td>−0.75</td><td>0.16</td><td>4000.00</td></tr><tr><td> <i>SS</i> vs. <i>LL</i> + <i>LS</i></td><td>0.05</td><td>−0.48</td><td>0.60</td><td>4000.00</td></tr><tr><td> Sex</td><td>0.70</td><td>−0.05</td><td>1.45</td><td>3812.24</td></tr><tr><td> <i>SS</i> vs. <i>LL</i> + <i>LS</i> × sex</td><td>−0.15</td><td>−0.96</td><td>0.77</td><td>4000.00</td></tr><tr><td colspan="5">Conscientiousness</td></tr><tr><td> Intercept</td><td>0.55</td><td>0.10</td><td>1.00</td><td>4000.00</td></tr><tr><td> <i>SS</i> vs. <i>LL</i> + <i>LS</i></td><td>−0.46</td><td>−1.01</td><td>0.10</td><td>4000.00</td></tr><tr><td> Sex</td><td>−0.62</td><td>−1.38</td><td>0.15</td><td>4000.00</td></tr><tr><td> <i>SS</i> vs. <i>LL</i> + <i>LS</i> × sex</td><td>0.22</td><td>−0.65</td><td>1.04</td><td>4000.00</td></tr><tr><td colspan="5">Low alpha</td></tr><tr><td> Intercept</td><td>−0.47</td><td>−0.93</td><td>−0.03</td><td>4000.00</td></tr><tr><td> <i>SS</i> vs. <i>LL</i> + <i>LS</i></td><td>0.31</td><td>−0.27</td><td>0.83</td><td>3822.28</td></tr><tr><td> Sex</td><td>0.77</td><td>0.08</td><td>1.56</td><td>4287.68</td></tr><tr><td> <i>SS</i> vs. <i>LL</i> + <i>LS</i> × sex</td><td>−0.30</td><td>−1.12</td><td>0.54</td><td>4090.68</td></tr><tr><td colspan="5">Disinhibition</td></tr><tr><td> Intercept</td><td>−0.47</td><td>−0.90</td><td>−0.00</td><td>4000.00</td></tr><tr><td> <i>SS</i> vs. <i>LL</i> + <i>LS</i></td><td>0.41</td><td>−0.11</td><td>0.99</td><td>4000.00</td></tr><tr><td> Sex</td><td>0.65</td><td>−0.07</td><td>1.43</td><td>3578.12</td></tr><tr><td> <i>SS</i> vs. <i>LL</i> + <i>LS</i> × sex</td><td>−0.33</td><td>−1.18</td><td>0.54</td><td>3419.31</td></tr><tr><td colspan="5">Negative emotionality/low dominance</td></tr><tr><td> Intercept</td><td>0.21</td><td>−0.24</td><td>0.65</td><td>3945.26</td></tr><tr><td> <i>SS</i> vs. <i>LL</i> + <i>LS</i></td><td>0.03</td><td>−0.49</td><td>0.58</td><td>4105.81</td></tr><tr><td> Sex</td><td>−0.62</td><td>−1.35</td><td>0.13</td><td>4000.00</td></tr><tr><td> <i>SS</i> vs. <i>LL</i> + <i>LS</i> × sex</td><td>0.12</td><td>−0.72</td><td>0.98</td><td>3875.40</td></tr></table>
|
027a112a5cdbae7f5e93c2cc9f16532bc0b88d3000d94949fffece41765f8138.png
|
complex
|
<table><tr><td>Age (Years)</td><td>Gender</td><td>0</td><td>1</td><td>2</td><td>≥3</td><td>χ<sup>2</sup></td><td><i>p</i></td></tr><tr><td rowspan="2">60–69</td><td>Male</td><td> 30 (2.5)</td><td>1128 (62.1)</td><td>298 (61.6)</td><td>56 (45.5)</td><td rowspan="2">2933.719</td><td rowspan="2"><0.001 </td></tr><tr><td>Female</td><td>1590 (54.2)</td><td> 5 (0.6)</td><td> 6 (2.8)</td><td> 7 (14.9)</td></tr><tr><td rowspan="2">70–79</td><td>Male</td><td> 819 (68.3)</td><td> 475 (26.2)</td><td>118 (24.4)</td><td>48 (39.0)</td><td rowspan="2">5.898</td><td rowspan="2">0.117 </td></tr><tr><td>Female</td><td> 846 (28.8)</td><td> 497 (55.9)</td><td>122 (56.2)</td><td>28 (59.6)</td></tr><tr><td rowspan="2">80–89</td><td>Male</td><td> 321 (26.8)</td><td> 192 (10.6)</td><td> 63 (13.0)</td><td>13 (10.6)</td><td>10.156</td><td>0.017 </td></tr><tr><td>Female</td><td> 417 (14.2)</td><td> 328 (36.9)</td><td> 71 (32.7)</td><td> 9 (19.1)</td><td></td><td></td></tr><tr><td rowspan="2">≥90</td><td>Male</td><td> 30 (2.5)</td><td> 21 (1.1)</td><td> 5 (1.0)</td><td> 6 (4.9)</td><td>1.318</td><td>0.251 </td></tr><tr><td>Female</td><td> 80 (2.7)</td><td> 59 (6.6)</td><td> 18 (8.3)</td><td> 3 (6.4)</td><td></td><td></td></tr></table>
|
62083e9d3416888c2a3c8194b76a66b2664e7666db0b4f58597308d7cc05d15b.png
|
complex
|
<table><tr><td rowspan="2"></td><td colspan="3">Categories of Infant Feeding Index</td><td rowspan="2"><i>p<sub>trend</sub></i></td></tr><tr><td>Poor</td><td>Medium</td><td>Good</td></tr><tr><td colspan="5">Acute upper respiratory infection</td></tr><tr><td>Two weeks prevalence (%)</td><td>31.7</td><td>25.5</td><td>20.6</td><td>0.16 <sup>a</sup></td></tr><tr><td>Unadjusted OR (95% CI)</td><td>1.00 (reference)</td><td>0.74 (0.40–1.36)</td><td>0.56 (0.25–1.28)</td><td>0.16</td></tr><tr><td>Adjusted OR (95% CI) <sup>b</sup></td><td>1.00 (reference)</td><td>0.78 (0.42–1.47)</td><td>0.46 (0.16–1.28)</td><td>0.16</td></tr><tr><td>Prevalence (%)</td><td>65.0</td><td>71.9</td><td>36.5</td><td>0.0007 <sup>a</sup></td></tr><tr><td>Unadjusted OR (95% CI)</td><td>1.00 (reference)</td><td>1.38 (0.76–2.49)</td><td>0.31 (0.15–0.65)</td><td><0.001</td></tr><tr><td>Adjusted OR (95% CI) <sup>b</sup></td><td>1.00 (reference)</td><td>1.45 (0.79–2.67)</td><td>0.60 (0.24–1.53)</td><td>0.57</td></tr><tr><td colspan="5">Diarrhea</td></tr><tr><td>Two weeks prevalence (%)</td><td>13.3</td><td>19.0</td><td>22.2</td><td>0.21 <sup>a</sup></td></tr><tr><td>Unadjusted OR (95% CI)</td><td>1.00 (reference)</td><td>1.53 (0.68–3.42)</td><td>1.86 (0.72–4.81)</td><td>0.21</td></tr><tr><td>Adjusted OR (95% CI) <sup>b</sup></td><td>1.00 (reference)</td><td>1.49 (0.66–3.38)</td><td>1.77 (0.54–5.81)</td><td>0.31</td></tr><tr><td>Prevalence (%)</td><td>55.0</td><td>64.6</td><td>36.7</td><td>0.11 <sup>a</sup></td></tr><tr><td>Unadjusted OR (95% CI)</td><td>1.00 (reference)</td><td>1.50 (0.85–2.64)</td><td>0.56 (0.28–1.18)</td><td>0.11</td></tr><tr><td>Adjusted OR (95% CI) <sup>b</sup></td><td>1.00 (reference)</td><td>1.42 (0.79–2.55)</td><td>1.00 (0.40–2.48)</td><td>0.73</td></tr></table>
|
b9c4231ce8dde689e55b0491ec82a83c16e5001803d564d515f782b2c5a61220.png
|
complex
|
<table><tr><td></td><td></td><td colspan="3">Factor solution OLQ-13</td><td colspan="3">Factor solution OLQ-11</td></tr><tr><td>item</td><td>dim</td><td>1</td><td>2</td><td>3</td><td>1</td><td>2</td><td>3</td></tr><tr><td>A</td><td>Me</td><td>-</td><td>-</td><td>.408</td><td>-</td><td>-</td><td>.405</td></tr><tr><td>B</td><td>Co</td><td>-</td><td>.753</td><td>-</td><td></td><td></td><td></td></tr><tr><td>C</td><td>Ma</td><td>-</td><td>.880</td><td>-</td><td>-.150</td><td>.669</td><td>-</td></tr><tr><td>D</td><td>Me</td><td>.128</td><td>-.223</td><td>.348</td><td></td><td></td><td></td></tr><tr><td>E</td><td>Ma</td><td>.285</td><td>.198</td><td>.102</td><td>.160</td><td>.368</td><td>-</td></tr><tr><td>F</td><td>Co</td><td>.512</td><td>-</td><td>.163</td><td>.455</td><td>.165</td><td>.120</td></tr><tr><td>G</td><td>Me</td><td>.142</td><td>-</td><td>.409</td><td>.117</td><td>.126</td><td>.374</td></tr><tr><td>H</td><td>Co</td><td>.818</td><td>-</td><td>-</td><td>.850</td><td>-</td><td>-</td></tr><tr><td>I</td><td>Co</td><td>.787</td><td>-</td><td>-</td><td>.714</td><td>.101</td><td>-</td></tr><tr><td>J</td><td>Ma</td><td>.363</td><td>.299</td><td>-</td><td>.139</td><td>.576</td><td></td></tr><tr><td>K</td><td>Co</td><td>.259</td><td>-</td><td>.327</td><td>.283</td><td>-</td><td>.266</td></tr><tr><td>L</td><td>Me</td><td>.109</td><td>-</td><td>.699</td><td>.167</td><td>-</td><td>.728</td></tr><tr><td>M</td><td>Ma</td><td>.627</td><td>-</td><td>.182</td><td>.624</td><td>-</td><td>.206</td></tr><tr><td colspan="2">Explained variance</td><td colspan="3">32% one factor/42% three factor</td><td colspan="3">35% one factor/40% three factor</td></tr></table>
|
cf94e4b25ba9400708a41bb5883708fe7e92c9dda2bc9d69d33c66de031a490c.png
|
complex
|
<table><tr><td>Parameter</td><td>Total (<i>N</i> = 193)</td></tr><tr><td colspan="2">Reason for last admission</td></tr><tr><td> Palliative procedure or surgery</td><td>28 (14.5)</td></tr><tr><td> Gastrointestinal symptoms</td><td>52 (26.9)</td></tr><tr><td> Cardiovascular or pulmonary symptoms</td><td>39 (20.2)</td></tr><tr><td> Infectious state</td><td>31 (16.2)</td></tr><tr><td> Uncontrolled pain</td><td>11 (5.7)</td></tr><tr><td> Hematologic instability</td><td>12 (6.2)</td></tr><tr><td> Neurologic symptom</td><td>7 (3.6)</td></tr><tr><td> Others</td><td>13 (6.7)</td></tr><tr><td>ICU admission in the last month</td><td>23 (11.9)</td></tr><tr><td colspan="2">Imaging examination conducted in the last month</td></tr><tr><td> No examination</td><td>56 (29.0)</td></tr><tr><td> Examination</td><td>137 (71.0)</td></tr><tr><td>CT</td><td>101 (73.7)</td></tr><tr><td>MRI</td><td>8 (5.8)</td></tr><tr><td>PET-CT</td><td>1 (0.7)</td></tr><tr><td>Combined imaging (>2)</td><td>27 (19.7)</td></tr><tr><td colspan="2">Type of treatment administered during the last 6 mo</td></tr><tr><td> Chemotherapy alone</td><td>155 (80.3)</td></tr><tr><td> Chemotherapy with radiation</td><td>26 (13.5)</td></tr><tr><td> Chemotherapy with surgery</td><td>12 (6.2)</td></tr><tr><td>Gastrointestinal surgery</td><td>9</td></tr><tr><td>Pelvic exenteration</td><td>2</td></tr><tr><td>Neuro-surgery</td><td>1</td></tr><tr><td colspan="2">Type of chemotherapy-agent administered during the last 6 mo</td></tr><tr><td> IV only</td><td>177 (91.7)</td></tr><tr><td> IV with PO</td><td>16 (8.3)</td></tr></table>
|
506fa1bd09eedff08385cf1e7e4e4448c8dd1516faf36211118a8279de0267c8.png
|
complex
|
<table><tr><td></td><td>DFS, <i>P</i> value</td><td>OS, <i>P</i> value</td></tr><tr><td></td><td>[HR (95 % CI)]</td><td>[HR (95 % CI)]</td></tr><tr><td colspan="3">Age (years)</td></tr><tr><td> <50</td><td>0.251</td><td>0.885</td></tr><tr><td> ≥50</td><td>0.678 (0.349–1.316)</td><td>0.938 (0.395–2.228)</td></tr><tr><td colspan="3">Sex</td></tr><tr><td> Female</td><td>0.776</td><td>0.164</td></tr><tr><td> Male</td><td>1.163 (0.411–3.297)</td><td>0.490 (0.179–1.337)</td></tr><tr><td colspan="3">Nodal status</td></tr><tr><td> (−) metastasis, (−) ECS</td><td><i>0.001</i></td><td><i>0.008</i></td></tr><tr><td> (+) metastasis, (−) ECS</td><td>1.193 (0.384–3.705)</td><td>1.858 (0.463–7.447)</td></tr><tr><td> (+) metastasis, (+) ECS</td><td>3.586 (1.733–7.420)</td><td>4.618 (1.729–12.338)</td></tr><tr><td colspan="3">Differentiation</td></tr><tr><td> Well/moderate</td><td><i>0.027</i></td><td><i>0.041</i></td></tr><tr><td> Poor</td><td>2.437 (1.105–5.372)</td><td>2.868 (1.043–7.886)</td></tr><tr><td colspan="3">Pathologic tumor status</td></tr><tr><td> Early<sup>a</sup></td><td><i>0.023</i></td><td><i>0.096</i></td></tr><tr><td> Advanced<sup>b</sup></td><td>2.172 (1.111–4.247)</td><td>2.084 (0.877–4.949)</td></tr><tr><td colspan="3">CRP</td></tr><tr><td> <5 mg/mL</td><td><i>0.016</i></td><td><i>0.027</i></td></tr><tr><td> ≥5 mg/mL</td><td>2.274 (1.163–4.448)</td><td>2.636 (1.118–6.217)</td></tr><tr><td colspan="3">Cyfra 21-1</td></tr><tr><td> <3.3 ng/mL</td><td>0.135</td><td>0.667</td></tr><tr><td> ≥3.3 ng/mL</td><td>1.885 (0.821–4.328)</td><td>0.726 (0.169–3.120)</td></tr><tr><td colspan="3">Tumor depth</td></tr><tr><td> <10 mm</td><td><i>0.030</i></td><td><i>0.052</i></td></tr><tr><td> ≥10 mm</td><td>2.207 (1.080–4.510)</td><td>2.560 (0.991–6.613)</td></tr><tr><td>Cyfra 21-1 and CRP</td><td><i>0.019</i></td><td>0.235</td></tr><tr><td> Cyfra 21-1 < 3.3 ng/mL, CRP < 5 mg/L</td><td>1</td><td>1</td></tr><tr><td> Cyfra 21-1 ≥ 3.3 ng/mL, CRP < 5 mg/L</td><td>0.575 (0.077–4.300)</td><td>0.000 (0.000)</td></tr><tr><td> Cyfra 21-1 < 3.3 ng/mL, CRP ≥ 5 mg/L</td><td>1.683 (0.761–3.722)</td><td>2.578 (1.036–6.414)</td></tr><tr><td> Cyfra 21-1 ≥ 3.3 ng/mL, CRP ≥ 5 mg/L</td><td>4.065 (1.610–10.261)</td><td>1.928 (0.426–8.726)</td></tr></table>
|
aa333dd96d6cd25d6ccf0bc9129f0ec9040d831dfa06d20da8758df623e3fa85.png
|
complex
|
<table><tr><td></td><td>Period Prevalence Per 100 000 (95% CI)</td><td>Incidence Per 100 000 (95% CI)</td></tr><tr><td>Overall</td><td>140.2 (100.1–179.2)</td><td>72.7 (52.5–91.8)</td></tr><tr><td colspan="3">Age, y</td></tr><tr><td>18–24</td><td>23.3 (16.7–29.8)</td><td>14.8 (10.6–18.8)</td></tr><tr><td>25–44</td><td>59.1 (42.9–74.4)</td><td>34.1 (25.2–42.2)</td></tr><tr><td>45–64</td><td>177.5 (127.2–225.9)</td><td>96.7 (70.2–121.4)</td></tr><tr><td>≥65</td><td>479.6 (338.3–618.9)</td><td>231.9 (164.7–297.6)</td></tr><tr><td colspan="3">Sex</td></tr><tr><td>Men</td><td>110.1 (78.1–141.4)</td><td>61.9 (44.3–78.7)</td></tr><tr><td>Women</td><td>169.1 (121.0–215.4)</td><td>83.1 (60.4–104.3)</td></tr><tr><td colspan="3">Race</td></tr><tr><td>White</td><td>192.3 (136.7–246.6)</td><td>99.75 (71.64–126.6)</td></tr><tr><td>Black</td><td>219.9 (157.7–279.2)</td><td>106.8 (77.72–133.4)</td></tr><tr><td>Asian/Pacific Islander</td><td>92.7 (66.6–117.9)</td><td>51.48 (37.62–64.45)</td></tr><tr><td colspan="3">Chronic kidney disease</td></tr><tr><td>Yes</td><td>573.3 (405.6–736.2)</td><td>266.4 (189.1–341.2)</td></tr><tr><td>No</td><td>124.9 (89.2–159.5)</td><td>66.5 (48.1–83.8)</td></tr><tr><td colspan="3">Diabetes mellitus</td></tr><tr><td>Yes</td><td>373.9 (265.9–478.2)</td><td>183.4 (131.6–232.5)</td></tr><tr><td>No</td><td>123.6 (88.2–158.0)</td><td>66.4 (48.0–83.9)</td></tr><tr><td colspan="3">Hypertension</td></tr><tr><td>Yes</td><td>415.9 (294.2–534.9)</td><td>193.7 (138.6–46.5)</td></tr><tr><td>No</td><td>94.9 (68.1–120.7)</td><td>53.9 (39.1–67.8)</td></tr><tr><td colspan="3">Coronary heart disease</td></tr><tr><td>Yes</td><td>697.0 (494.4–891.5)</td><td>298.7 (212.5–381.3)</td></tr><tr><td>No</td><td>157.3 (112.2–201.0)</td><td>71.3 (51.5–90.0)</td></tr><tr><td colspan="3">Heart failure</td></tr><tr><td>Yes</td><td>825.0 (579.4–1064.7)</td><td>365.9 (256.3–473.6)</td></tr><tr><td>No</td><td>154.4 (110.3–197.3)</td><td>70.5 (51.0–89.0)</td></tr></table>
|
d0b8b556c90729722eca59c0dccd975807e001db08377c79878289fab1b7acc9.png
|
complex
|
<table><tr><td rowspan="2">Assembler</td><td colspan="5">Species assembled</td></tr><tr><td><i>A.hydrophila</i></td><td><i>B</i>.<i>cereus</i></td><td><i>B</i>.<i>fragilis</i></td><td><i>S</i>.<i>aureus</i></td><td><i>X</i>.<i>axonopodis</i></td></tr><tr><td>ABySS</td><td>237.5</td><td>48.3</td><td>146.2</td><td>73.9</td><td>89.9</td></tr><tr><td>CABOG</td><td>278.4</td><td>61.6</td><td>94.2</td><td>102.8</td><td>105.8</td></tr><tr><td>MIRA</td><td>246.2</td><td>47.4</td><td>134.3</td><td>132.4</td><td>105.6</td></tr><tr><td>MaSuRCA</td><td>828.6</td><td>103.6</td><td>158.7</td><td>221.8</td><td>117.9</td></tr><tr><td>SGA</td><td>68.8</td><td>23.4</td><td>41.2</td><td>38.1</td><td>47.8</td></tr><tr><td>SOAPdenovo</td><td>243.9</td><td>57.9</td><td>116.1</td><td>146.3</td><td>74.2</td></tr><tr><td>SPAdes</td><td>379.7</td><td>97.2</td><td>157.7</td><td>187.1</td><td>117.5</td></tr><tr><td>Velvet</td><td>184.4</td><td>38.9</td><td>125.2</td><td>122.5</td><td>83.0</td></tr></table>
|
7f2957e935079ac795da76636ea13389e77ef9a1121f58e7926600946847e026.png
|
complex
|
<table><tr><td>Groups</td><td>No smoker (n: 6742)</td><td>Ex-smoker (n: 976)</td><td>Cigarette smoking (n: 864)</td><td>Hookah smoking (n: 1067)</td><td>Cigarette and hookah (n: 41)</td><td><i>p</i> value</td></tr><tr><td>FBG<sup>1</sup> (mg/dl)</td><td>92.65 ± 38.71</td><td>96.78 ± 43.26</td><td>87.59 ± 33.86<sup>ab</sup></td><td>93.60 ± 42.43<sup>c</sup></td><td>94.85 ± 47.02</td><td>0.013</td></tr><tr><td>TG<sup>2</sup> (mg/dl)</td><td>117 (83–170)</td><td>128 (90.5–177.5)</td><td>122 (86–180)</td><td>121 (88–171)</td><td>122 (96–186)</td><td>0.125</td></tr><tr><td>Cholesterol<sup>1</sup> (mg/dl)</td><td>192.41 ± 39.36</td><td>191.10 ± 38.76</td><td>184.18 ± 39.4<sup>a</sup></td><td>190.53 ± 37.6<sup>a</sup></td><td>189.27 ± 37.25</td><td>0.045</td></tr><tr><td>LDL<sup>1</sup> (mg/dl)</td><td>116.77 ± 35.53</td><td>117.18 ± 35.45</td><td>112.42 ± 34.93</td><td>117.48 ± 33.63</td><td>109.03 ± 35.39</td><td>0.9</td></tr><tr><td>HDL<sup>1</sup> (mg/dl)</td><td>43.63 ± 10</td><td>41.96 ± 10.18</td><td>38.77 ± 9.22<sup>ab</sup></td><td>42.53 ± 9.04<sup>ab</sup></td><td>41.11 ± 9.65</td><td>< 0.001</td></tr><tr><td>Uric acid<sup>1</sup> (mg/dl)</td><td>4.62 ± 1.4</td><td>4.91 ± 1.45</td><td>5 ± 1.34<sup>ab</sup></td><td>4.36 ± 1.32<sup>c</sup></td><td>5.37 ± 1.6<sup>c</sup></td><td>< 0.001</td></tr><tr><td>Serum urea<sup>1</sup> (mg/dl)</td><td>12.93 ± 4.28</td><td>13.54 ± 4.2</td><td>13.48 ± 4.22</td><td>12.52 ± 4.05</td><td>13.8 ± 5.57</td><td>0.63</td></tr><tr><td>Cr<sup>1</sup> (mg/dl)</td><td>0.85 ± 0.25</td><td>0.90 ± 0.24</td><td>0.93 ± 0.25</td><td>0.84 ± 0.27</td><td>0.93 ± 0.21</td><td>0.65</td></tr><tr><td colspan="7">GFR<sup>3</sup> ml/min</td></tr><tr><td> < 60</td><td>119 (2.7%)</td><td>28 (4.4%)</td><td>33 (5.7%)</td><td>10 (1.5%)</td><td>1 (3.3%)</td><td rowspan="2">< 0.001</td></tr><tr><td> > 60</td><td>4364 (97.3%)</td><td>605 (95.6%)</td><td>546 (94.3%)</td><td>646 (98.5%)</td><td>29 (96.7%)</td></tr><tr><td>hsCRP<sup>2</sup> (mg/l)</td><td>1.62 (0.98–3.51)</td><td>1.55 (1–3.35)</td><td>1.71 (1.06–3.89)</td><td>1.63 (1.04–3.46)</td><td>2.02 (1.1–4.65)</td><td>< 0.001</td></tr></table>
|
603223f0380bd6e30f2e263ba4a1e394275184bfc72a8e4370ec3a71f60aa3c5.png
|
simple
|
<table><tr><td>Element</td><td>Measurement</td></tr><tr><td>Ulna (NMMNH P-19460), length of semilunar notch</td><td>24.5*</td></tr><tr><td>Ulna (NMMNH P-19460), depth of semilunar notch</td><td>6.2*</td></tr><tr><td>Ulna (NMMNH P-19460), maximum mediolateral breadth</td><td>21.5</td></tr><tr><td>Radius (NMMNH P-19460), length</td><td>93.0</td></tr><tr><td>Radius (NMMNH P-19460), anteroposterior midshaft diameter</td><td>11.0</td></tr><tr><td>Radius (NMMNH P-19460), midshaft mediolateral diameter</td><td>11.5</td></tr><tr><td>Metacarpal II (NMMNH P-19460), length</td><td>25.0</td></tr><tr><td>Metacarpal II (NMMNH P-19460), proximal breadth</td><td>9.8</td></tr><tr><td>Metacarpal II (NMMNH P-19460), midshaft mediolateral diameter</td><td>8.7</td></tr><tr><td>Metacarpal II (NMMNH P-19460), distal breadth</td><td>12.4</td></tr><tr><td>Metacarpal III (NMMNH P-19640), length</td><td>29.3</td></tr><tr><td>Metacarpal III (NMMNH P-19640), proximal breadth</td><td>13.9</td></tr><tr><td>Metacarpal III (NMMNH P-19640), midshaft mediolateral diameter</td><td>9.8</td></tr><tr><td>Metacarpal III (NMMNH P-19640), distal breadth</td><td>13.5</td></tr><tr><td>Metacarpal IV (NMMNH P-19640), length</td><td>23.9</td></tr><tr><td>Metacarpal IV (NMMNH P-19640), proximal breadth</td><td>10.9</td></tr><tr><td>Metacarpal IV (NMMNH P-19640), midshaft mediolateral diameter</td><td>6.8</td></tr><tr><td>Metacarpal IV (NMMNH P-19640), distal breadth</td><td>9.9</td></tr><tr><td>Ungual (NMMNH P-19640), proximal breadth of most complete</td><td>8.6</td></tr></table>
|
1e294ee02a36b2a266d54fa6adf11920e0622016a55582570719f3e00c498ad7.png
|
simple
|
<table><tr><td> </td><td>Media surveillance</td><td>Active surveillance</td><td>Total casualties</td></tr><tr><td> </td><td>Jan 08 –Sep 09</td><td>Oct 09 – Dec 11</td><td>N (% total)</td></tr><tr><td> </td><td>N (% total)</td><td>N (% total)</td><td> </td></tr><tr><td>Sex</td><td> </td><td> </td><td> </td></tr><tr><td>Male</td><td>255 (78.0)</td><td>86 (78.2)</td><td>341 (78.0)</td></tr><tr><td>Female</td><td>60 (18.3)</td><td>24 (21.8)</td><td>84 (19.2)</td></tr><tr><td>Unknown</td><td>12 (3.7)</td><td>0 (0)</td><td>12 (2.7)</td></tr><tr><td>Age group</td><td> </td><td> </td><td> </td></tr><tr><td>Child (< 18 years)</td><td>25 (7.6)</td><td>15 (13.6)</td><td>40 (9.2)</td></tr><tr><td>Adult</td><td>192 (58.7)</td><td>94 (85.5)</td><td>286 (65.4)</td></tr><tr><td>Unknown</td><td>110 (33.6)</td><td>1 (0.9)</td><td>111 (25.4)</td></tr><tr><td>Outcome</td><td> </td><td> </td><td> </td></tr><tr><td>Non-fatal injury</td><td>298 (91.1)</td><td>105 (95.5)</td><td>403 (92.2)</td></tr><tr><td>Fatal injury</td><td>29 (8.9)</td><td>5 (4.5)</td><td>34 (7.8)</td></tr><tr><td>Type of explosive device</td><td> </td><td> </td><td> </td></tr><tr><td>Socket bomb</td><td>50 (15.3)</td><td>48 (43.6)</td><td>98 (22.4)</td></tr><tr><td>Sutali bomb</td><td>47 (14.4)</td><td>7 (6.4)</td><td>54 (12.4)</td></tr><tr><td>Pressure cooker bomb</td><td>16 (4.9)</td><td>6 (5.5)</td><td>22 (5.0)</td></tr><tr><td>Other improvised explosive device</td><td>87 (26.6)</td><td>41 (37.3)</td><td>128 (29.3)</td></tr><tr><td>Unknown</td><td>127 (38.8)</td><td>8 (7.3)</td><td>135 (30.9)</td></tr><tr><td>Place of incident</td><td> </td><td> </td><td> </td></tr><tr><td>Busy street or crossroads</td><td>69 (21.1)</td><td>15 (13.6)</td><td>84 (19.2)</td></tr><tr><td>Shop or market</td><td>26 (8.0)</td><td>18 (16.4)</td><td>44 (10.1)</td></tr><tr><td>Place of worship</td><td>26 (8.0)</td><td>0 (0)</td><td>26 (5.9)</td></tr><tr><td>Near government or police office</td><td>28 (8.6)</td><td>1 (0.9)</td><td>29 (6.6)</td></tr><tr><td>Near school or hospital</td><td>5 (1.5)</td><td>0 (0)</td><td>5 (1.1)</td></tr><tr><td>Near stadium</td><td>44 (13.5)</td><td>0 (0)</td><td>44 (10.1)</td></tr><tr><td>Factory or industry</td><td>7 (2.1)</td><td>2 (1.8)</td><td>9 (2.1)</td></tr><tr><td>On the bus</td><td>9 (2.8)</td><td>52 (47.3)</td><td>61 (14.0)</td></tr><tr><td>Near bus station</td><td>18 (5.5)</td><td>0 (0)</td><td>18 (4.1)</td></tr><tr><td>Home</td><td>43 (13.1)</td><td>16 (14.5)</td><td>59 (13.5)</td></tr><tr><td>Other</td><td>50 (15.3)</td><td>6 (5.5)</td><td>56 (12.8)</td></tr><tr><td>Unknown</td><td>2 (0.6)</td><td>0 (0)</td><td>2 (0.5)</td></tr><tr><td>Total</td><td>327</td><td>110</td><td>437</td></tr></table>
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.